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Abstract	  
Due	  to	  the	  success	  of	  antiretroviral	  (ART)	  medications,	  youth	  perinatally	  infected	  
with	  HIV	  (PHIV+)	  are	  surviving	  into	  adolescence	  and	  young	  adulthood	  –	  the	  first	  
generation	  to	  do	  so.	  Factors	  which	  influence	  non-­‐adherence	  to	  ART	  in	  this	  group	  are	  
of	  particular	  importance	  to	  the	  development	  of	  effective	  assessments	  and	  
interventions.	  Within-­‐participant	  research	  is	  important	  given	  the	  significant	  
prevalence	  of	  inconsistent	  ART	  adherence	  reported	  in	  the	  literature.	  Previous	  
studies	  have	  focused	  on	  between-­‐participants	  differences	  and	  tended	  to	  ask	  
participants	  to	  estimate	  their	  adherence	  over	  a	  period	  of	  time.	  No	  quantitative	  
episodic	  (or	  event-­‐level)	  investigations,	  related	  to	  specific	  incidences	  of	  adherence	  or	  
non-­‐adherence,	  have	  been	  conducted	  previously	  in	  this	  area.	  	  
	  
The	  present	  study	  aimed	  to	  address	  these	  gaps	  in	  the	  literature	  by	  investigating	  
within-­‐participant	  variation	  in	  episodic	  antiretroviral	  adherence	  informed	  by	  the	  
Information-­‐Motivation-­‐Behavioural	  Skills	  (IMB)	  Model.	  The	  study	  explored	  
situational	  variation	  between	  adherent	  and	  non-­‐adherent	  events	  in	  information,	  
personal	  motivation,	  social	  motivation,	  and	  	  behavioural	  skills.	  	  A	  secondary	  aim	  was	  
to	  investigate	  whether	  situational	  	  differences	  in	  affect,	  or	  behavioural	  context	  were	  
associated	  with	  episodic	  adherence.	  	  	  
	  
Twenty-­‐nine	  PHIV+	  young	  people	  recruited	  from	  the	  Adolescents	  and	  Adults	  Living	  
with	  Perinatal	  HIV	  (AALPHI)	  cohort	  completed	  questionnaires	  measuring	  
psychological	  and	  behavioural	  variables.	  	  Paired	  t-­‐tests	  and	  McNemar’s	  chi-­‐square	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tests	  were	  used	  to	  analyse	  associations	  between	  behavioural	  and	  psychological	  
factors	  related	  to	  adherent	  and	  non-­‐adherent	  events.	  	  
	  
Weekend	  days,	  being	  away	  from	  home	  and	  a	  disrupted	  daily	  routine	  were	  associated	  
with	  episodes	  of	  non-­‐adherence.	  Lower	  reported	  behavioural	  skills	  and	  lower	  
positive	  affect	  were	  associated	  with	  non-­‐adherent	  episodes.	  There	  were	  no	  
significant	  effects	  of	  negative	  affect,	  information,	  personal	  or	  social	  motivation.	  	  A	  
conditional	  logistic	  regression	  model	  including	  behavioural	  skills	  and	  positive	  affect	  
was	  significantly	  predictive	  of	  non-­‐adherent	  episodes,	  although	  each	  predictor	  was	  
not	  statistically	  significant	  independently.	  	  	  
	  
These	  findings	  are	  discussed	  in	  relation	  to	  previous	  antiretroviral	  adherence	  studies.	  	  
Clinical	  and	  theoretical	  implications	  are	  discussed.	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Introduction	  
Adolescents	  and	  young	  adults	  with	  perinatally-­‐infected	  HIV	  (PHIV+)	  require	  
antiretroviral	  treatment	  (ART)	  to	  manage	  the	  virus.	  This	  medication	  has	  a	  high	  
adherence	  requirement	  to	  be	  optimally	  effective	  and	  non-­‐adherence	  can	  be	  
problematic.	  	  	  
This	  chapter	  reviews	  the	  evolution	  of	  PHIV+	  and	  discusses	  the	  challenges	  faced	  by	  
adolescents	  in	  growing	  up	  with	  this	  newly	  chronic	  condition,	  particularly	  in	  reference	  
to	  ART	  adherence.	  Methods	  of	  measuring	  adherence	  and	  theoretical	  models	  used	  to	  
explain	  adherence	  behaviour	  are	  discussed.	  	  An	  outline	  of	  the	  research	  questions	  
concludes	  this	  chapter.	  
HIV:	  general	  overview	  
Disease	  
The	  Human	  Immunodeficiency	  Virus	  (HIV),	  a	  type	  of	  retrovirus,	  was	  identified	  as	  the	  
causative	  agent	  of	  Acquired	  Immune	  Deficiency	  Syndrome	  (AIDS)	  in	  1983	  after	  the	  
first	  cases	  of	  AIDS	  were	  recognised	  in	  the	  USA	  two	  years	  earlier	  (Sharp	  &	  Hahn,	  
2011).	  	  HIV	  targets	  multiple	  cells	  of	  the	  human	  immune	  system,	  interacting	  with	  
macrophages	  and	  dendritic	  cells	  and	  transferring	  to	  CD4	  T	  cells	  in	  regional	  lymph	  
nodes	  where	  the	  virus	  then	  replicates	  rapidly	  (Adler,	  Edwards,	  Miller,	  Williams,	  
2012).	  	  Infection	  with	  HIV	  causes	  a	  number	  of	  associated	  conditions	  varying	  from	  
symptoms	  of	  primary	  infection	  (such	  as	  rash,	  fever,	  malaise,	  night	  sweats,	  sore	  
throat),	  to	  serious	  diseases	  associated	  with	  a	  suppressed	  immune	  system,	  including:	  
tumours,	  hepatitis,	  liver,	  lung,	  gut,	  skin,	  eye	  and	  kidney	  disease,	  and	  significant	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neurological	  manifestations	  (Adler,	  Edwards,	  Miller,	  Williams,	  2012).	  	  Following	  a	  
progressive	  loss	  of	  CD4	  cells,	  patients	  develop	  AIDS-­‐defining	  conditions	  which,	  when	  
left	  untreated,	  are	  likely	  to	  result	  in	  death.	  	  	  
Transmission	  
The	  HIV	  infection	  is	  transmitted	  via	  four	  main	  routes:	  
1. sexual	  intercourse	  (anal,	  oral,	  vaginal)	  
2. contaminated	  needles	  (intravenous	  drug	  users,	  needlestick	  injuries)	  
3. tissue	  donation	  (blood	  transfusion,	  organ	  transplants)	  
4. mother-­‐to-­‐child	  (in	  utero,	  at	  birth,	  via	  breastfeeding).	  
The	  most	  common	  route	  of	  infection	  globally	  is	  unprotected	  sexual	  intercourse.	  	  
Transmission	  via	  sexual	  intercourse,	  or	  contamination	  of	  needles	  or	  tissue	  products,	  
can	  be	  grouped	  as	  means	  of	  ‘behavioural’	  transmission.	  	  ‘Perinatal’	  transmission	  is	  a	  
term	  also	  used	  for	  mother-­‐to-­‐child,	  or	  vertical	  transmission.	  	  	  
	  
Left	  untreated	  and	  at	  high	  concentrations	  in	  the	  blood	  (measured	  by	  viral	  load;	  VL),	  
HIV	  can	  be	  easily	  transmitted,	  causing	  considerable	  public	  health	  threat	  in	  some	  
countries	  where	  treatments	  are	  not	  widely	  available.	  	  With	  successful	  suppression	  of	  
the	  virus	  such	  that	  viral	  load	  is	  “undetectable”,	  or	  under	  75	  copies	  (virus	  particles)	  in	  
one	  millilitre	  of	  blood,	  the	  risk	  of	  transmission	  of	  HIV	  is	  very	  low	  (“What	  is	  viral	  load”,	  
2015).	  	  	  
	  
Prevention	  of	  mother-­‐to-­‐child,	  or	  perinatal,	  transmission	  is	  a	  World	  Health	  
Organisation	  priority	  and	  subject	  of	  a	  ‘Strategic	  Vision’	  report	  to	  reduce	  rates	  of	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perinatal	  HIV	  infection	  (WHO,	  2010).	  	  The	  WHO	  advocates	  a	  four-­‐tiered	  approach	  to	  
this:	  preventing	  primary	  infection	  of	  HIV	  among	  women	  of	  childbearing	  age,	  
preventing	  unwanted	  pregnancy	  in	  women	  of	  childbearing	  age,	  preventing	  
transmission	  of	  HIV	  from	  a	  woman	  to	  her	  child	  and	  providing	  appropriate	  care,	  
support	  and	  treatment	  to	  mothers	  and	  their	  children	  living	  with	  HIV.	  	  Across	  Europe,	  
this	  strategy	  has	  been	  operationalized	  via	  offers	  of	  effective	  medications	  to	  all	  HIV+	  
mothers	  and	  babies	  born	  to	  HIV+	  mothers,	  relating	  to	  the	  third	  and	  fourth	  parts	  of	  
the	  WHO	  strategy.	  	  Breastfeeding	  is	  also	  not	  recommended	  (Bamford	  et	  al.,	  2015;	  
British	  HIV	  Association	  (BHIVA),	  2009).	  
	  
Population:	  UK	  &	  Global	  
Since	  the	  identification	  of	  HIV	  in	  the	  1980s,	  approximately	  60million	  people	  have	  
been	  infected,	  resulting	  in	  over	  25million	  deaths	  from	  AIDS,	  becoming	  one	  of	  the	  
most	  lethal	  pandemics	  in	  recent	  history	  (Merson,	  O’Malley,	  Serwadda,	  &	  Apisuk,	  
2008).	  	  Although	  there	  are	  reports	  of	  HIV	  in	  every	  country	  in	  the	  world,	  the	  highest	  
prevalence	  rates	  are	  among	  young	  adults	  in	  Sub-­‐Saharan	  Africa.	  	  Across	  this	  region,	  
on	  average,	  3	  in	  every	  100	  people	  between	  15-­‐24	  have	  HIV;	  this	  figure	  is	  even	  
greater	  in	  Malawi,	  Zambia,	  Lesotho,	  Mozambique,	  Zimbabwe,	  Swaziland,	  Uganda	  
and	  South	  Africa	  (WHO,	  2010).	  	  The	  most	  recent	  data	  from	  the	  Joint	  United	  Nations	  
Programme	  on	  HIV/AIDS	  (UNAIDS)	  estimates	  35million	  adults	  and	  children	  are	  living	  
with	  HIV	  globally	  (UNAIDS,	  2014).	  	  Of	  these,	  24.7	  million	  are	  living	  in	  Sub-­‐Saharan	  
Africa	  (UNAIDS,	  2014).	  	  An	  estimated	  108,000	  adults	  and	  children	  in	  the	  United	  
Kingdom	  live	  with	  HIV	  (Public	  Health	  England	  Report,	  2014).	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Paediatric	  Population	  
The	  most	  recent	  prevalence	  estimates	  from	  UNAIDS	  report	  3.4	  million	  infected	  
children	  under	  15	  years	  (UNAIDS,	  2013)	  and	  2	  million	  adolescents	  between	  10	  and	  
19	  years	  worldwide	  (World	  Health	  Organization,	  2013).	  	  The	  population	  prevalence	  
data	  seldom	  distinguish	  routes	  of	  transmission,	  a	  methodological	  flaw	  often	  
repeated	  in	  the	  research	  literature,	  making	  it	  problematic	  for	  drawing	  conclusions	  
about	  particular	  populations	  (discussed	  further	  below)	  (Mofenson	  &	  Cotton,	  2013).	  	  
It	  is	  reasonable	  to	  assume	  most,	  but	  not	  all,	  children	  with	  HIV	  acquired	  the	  infection	  
perinatally	  (PHIV+).	  Global	  HIV	  incidence	  of	  older	  children	  and	  teenagers	  is	  likely	  to	  
include	  some	  behavioural	  means	  of	  infections	  (BHIV+),	  i.e.	  unprotected	  sex	  and	  
injected	  drug	  use	  (Sohn	  &	  Hazra,	  2013).	  	  	  	  	  
UK	  Paediatric	  Population	  
Fifty-­‐nine	  clinics	  across	  the	  UK	  report	  data	  on	  all	  HIV-­‐infected	  children	  known	  to	  
follow-­‐up	  as	  part	  of	  the	  Collaborative	  HIV	  Paediatric	  Study	  (CHIPS).	  This	  has	  given	  
researchers	  a	  comprehensive	  indication	  of	  how	  many	  PHIV+	  young	  people	  are	  
currently	  living	  in	  the	  UK.	  	  The	  most	  recent	  data,	  in	  March	  2014,	  indicate	  a	  total	  of	  
1873	  children	  receiving	  HIV	  care,	  from	  2006	  onwards.	  	  Of	  these,	  108	  children	  had	  
died	  and	  595	  young	  people	  transitioned	  to	  adult	  clinics.	  	  Fifty-­‐five	  percent	  of	  these	  
young	  people	  were	  born	  outside	  the	  UK	  or	  Ireland.	  	  As	  of	  March	  2014,	  a	  total	  of	  
1037	  HIV-­‐positive	  young	  people	  (median	  age	  13)	  were	  alive	  and	  actively	  followed	  by	  
paediatric	  clinics,	  of	  whom	  96%	  were	  perinatally-­‐infected.	  	  Seventy-­‐nine	  percent	  are	  
of	  Black	  African	  ethnicity.	  	  Half	  of	  the	  young	  people	  are	  seen	  at	  London	  clinics	  
(Collaborative	  HIV	  Paediatric	  Study	  (CHIPS),	  2014).	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Treatment:	  Antiretroviral	  Therapy	  (ART)	  
The	  first	  antiretroviral	  treatment	  for	  HIV,	  a	  single	  nucleoside	  analogue	  reverse	  
transcriptase	  inhibitor	  (NRTI)	  called	  azidothymidine	  (AZT),	  was	  not	  introduced	  until	  
four	  years	  after	  the	  virus	  was	  discovered	  (Ruprecht,	  et	  al,	  1986).	  	  Until	  this	  time,	  
patients	  with	  HIV	  were	  treated	  by	  managing	  complications	  and	  opportunistic	  
infections	  only.	  	  
	  
In	  1996,	  trial	  data	  of	  combination	  (cART)	  or	  highly	  active	  antiretroviral	  therapy	  
(HAART)	  (hereafter	  referred	  to	  as	  antiretroviral	  therapy,	  ART)	  were	  presented	  at	  the	  
11th	  International	  Conference	  on	  AIDS	  (1996).	  	  These	  drugs	  were	  introduced	  to	  
combat	  the	  virus	  at	  various	  stages	  of	  its	  lifecycle.	  	  ART	  became	  available	  in	  the	  USA	  
and	  UK	  between	  1997-­‐8	  and	  has	  significantly	  improved	  mortality	  and	  morbidity	  rates	  
(Mellins	  &	  Malee,	  2013;	  Judd,	  Doerholt,	  et	  al,	  2007).	  	  	  The	  availability	  of	  medication	  
varies	  according	  to	  country:	  access	  is	  growing	  but	  remains	  limited	  in	  resource-­‐limited	  
countries,	  including	  some	  Sub-­‐Saharan	  African	  nations	  (UNAIDS,	  2014).	  	  
	  
Since	  the	  introduction	  of	  ART,	  there	  have	  been	  several	  pharmacological	  
developments.	  To	  date,	  there	  are	  over	  25	  antiretroviral	  agents	  falling	  into	  six	  classes	  
of	  treatment:	  NRTIs,	  non-­‐nucleoside	  reverse	  transcriptase	  inhibitors,	  protease	  
inhibitors,	  integrase	  inhibitors	  and	  fusion	  or	  entry	  inhibitors	  (BHIVA,	  2014).	  	  ART	  is	  
available	  in	  the	  form	  of:	  dispersible	  tablets,	  tablets,	  granules,	  powders,	  capsules,	  and	  
dispersible	  tablets	  for	  suspension.	  	  Combinations	  of	  these	  drugs	  are	  now	  available	  in	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fixed	  dose	  pill	  combinations	  to	  help	  to	  reduce	  pill	  burden,	  which	  has	  an	  impact	  on	  
adherence	  (BHIVA,	  2009).	  	  The	  side	  effects	  of	  newer	  ARTs	  are	  fewer	  than	  older	  drug	  
formulations,	  but	  long-­‐term	  toxicity	  data	  are	  limited	  (Bamford	  et	  al.,	  2015).	  	  	  
	  
Paediatric	  ART	  
Paediatric	  ART	  regimens	  were	  developed	  much	  later	  than	  adult	  formulations,	  with	  
antiretroviral	  therapy	  not	  approved	  for	  children	  at	  all	  until	  the	  1990s	  (“Guidelines	  
and	  recommendations”,	  2015).	  	  Children	  born	  in	  the	  1980s	  and	  early	  1990s	  were	  
either	  untreated	  or	  treated	  with	  suboptimal	  regimens	  (Chandawani,	  et	  al,	  2012).	  	  
There	  is	  paucity	  of	  child-­‐	  and	  adolescent-­‐specific	  ART	  trials.	  	  Instead,	  guidelines	  for	  
prescribing	  in	  this	  population	  are	  drawn	  from	  cohort	  studies,	  extrapolating	  from	  
adult	  data	  and	  expert	  opinion	  (Bamford,	  et	  al,	  2015).	  	  The	  lack	  of	  specific	  data	  for	  
children	  and	  adolescents	  increases	  the	  risk	  of	  ineffective	  ART	  regimens.	  	  
Perinatally	  Infected	  HIV+	  Adolescents	  and	  Young	  Adults	  
Today’s	  adolescents	  and	  young	  adults	  with	  perinatally	  infected	  HIV	  (PHIV+)	  are	  a	  
unique	  group	  of	  young	  people:	  they	  are	  the	  first	  generation	  to	  have	  acquired	  the	  
infection	  through	  vertical	  transmission	  and	  live	  into	  their	  teenage	  years	  and	  beyond.	  	  
Children	  born	  with	  HIV	  infection	  before	  1995	  were	  expected	  to	  experience	  
catastrophic	  consequences	  of	  their	  illness.	  	  Pre-­‐1995	  births	  carried	  twice	  the	  risk	  of	  
the	  HIV-­‐infected	  child	  developing	  AIDS-­‐defining	  conditions	  or	  dying	  before	  age	  5,	  
compared	  to	  HIV+	  children	  born	  after	  this	  time	  (Small	  et	  al.,	  2014).	  	  Data	  from	  1996	  
report	  over	  60%	  of	  children	  diagnosed	  with	  HIV	  and	  living	  in	  New	  York	  City,	  USA,	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died	  before	  reaching	  adolescence	  (New	  York	  City	  Department	  of	  Health	  and	  Mental	  
Hygiene,	  2013).	  	  	  
	  
The	  risks	  of	  disease	  progression	  are	  similar	  between	  adults	  and	  PHIV+	  youth	  from	  
the	  age	  of	  5	  and	  older	  	  (Bamford	  et	  al.,	  2015).	  	  However,	  there	  are	  key	  differences	  
between	  these	  two	  populations,	  outlined	  below.	  	  	  
Developmental	  Issues	  	  
Adolescence	  is	  a	  time	  of	  psychosocial,	  biological	  and	  neurocognitive	  maturation	  
(Suris,	  et	  al,	  2004)	  during	  which	  young	  people	  experience	  significant	  growth	  and	  
pubertal	  changes.	  	  Development	  of	  social	  identity,	  intimate	  relationships	  and	  
occupational	  life	  skills	  occur	  during	  this	  time,	  as	  well	  as	  sexual	  experimentation	  and	  
risk-­‐taking	  behaviours	  (Taddeo,	  Egedy,	  &	  Frappier,	  2008).	  	  
	  	  
There	  may	  be	  a	  reciprocal	  and	  complex	  interaction	  between	  chronic	  illness	  (including	  
PHIV+)	  and	  adolescent	  development.	  	  That	  is,	  the	  condition	  can	  impact	  on	  particular	  
biological,	  psychological	  or	  social	  developmental	  processes,	  but	  psychosocial	  
changes	  and	  adjustments	  can	  also	  impact	  on	  the	  illness:	  the	  timing	  of	  development	  
in	  one	  area	  may	  affect	  the	  other(s)	  (Suris,	  Michaud,	  &	  Viner,	  2004).	  	  In	  the	  case	  of	  
PHIV+,	  the	  virus	  can	  affect	  bone	  mass	  density	  and	  bone	  mineral	  concentration	  
(Pitukcheewanont,	  Safani,	  Church,	  &	  Gilsanz,	  2005),	  even	  if	  the	  young	  person	  is	  
taking	  ART	  	  (de	  Lima	  et	  al.,	  2013).	  	  PHIV+	  young	  people	  are	  more	  likely	  than	  
perinatally-­‐exposed	  but	  not	  infected	  (PHIV-­‐)	  controls	  to	  have	  abnormal	  body	  fat	  
distribution	  related	  to	  cardiovascular	  disease	  risk	  as	  a	  result	  of	  both	  primary	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infection	  with	  HIV	  and	  side	  effects	  of	  ART	  	  (Jacobson	  et	  al.,	  2011).	  	  The	  increased	  
calorific	  requirement	  for	  growth	  during	  puberty	  may	  compound	  these	  issues	  	  (Suris	  
et	  al.,	  2004;	  Suris	  &	  Parera,	  2005)	  
	  
Puberty	  may	  be	  impaired	  or	  delayed	  as	  a	  result	  of	  PHIV+,	  compared	  to	  age-­‐matched	  
PHIV-­‐	  and	  HIV	  unexposed	  controls	  	  (de	  Martino,	  Tovo,	  Galli,	  Gabiano,	  &	  Chiarelli,	  
2001;	  Williams	  et	  al.,	  2013).	  	  ART	  has	  brought	  forward	  pubertal	  onset	  in	  adolescents	  
depending	  on	  birth	  cohort:	  youth	  born	  after	  1997	  may	  have	  better	  outcomes	  due	  to	  
the	  availability	  of	  optimal	  treatments	  since	  birth,	  although	  the	  mechanisms	  of	  and	  
interactions	  between	  PHIV+	  exposure,	  ART	  medications	  and	  the	  processes	  of	  
puberty	  remain	  poorly	  understood	  	  (Adler,	  et	  al,	  2012;	  Williams	  et	  al.,	  2013).	  	  For	  
those	  PHIV+	  young	  people	  who	  may	  experience	  disturbance	  in	  normative	  puberty,	  
this	  may	  have	  a	  subsequent	  impact	  on	  delayed	  sexual	  maturity,	  formation	  of	  
intimate	  relationships	  and	  self-­‐esteem,	  which	  may	  all,	  in	  turn,	  increase	  the	  risk	  of	  
mental	  health	  problems	  (discussed	  further	  in	  ‘Psychosocial	  issues’	  below)	  	  (Mellins	  &	  
Malee,	  2013).	  
	  
During	  adolescence,	  executive	  control	  functions	  are	  refined,	  leading	  to	  a	  more	  self-­‐
directed	  and	  self-­‐regulating	  mind	  	  (Laughton,	  Cornell,	  Boivin,	  &	  Van	  Rie,	  2013).	  	  
Although	  the	  adolescent	  brain	  does	  not	  grow	  larger,	  there	  is	  reorganisation	  and	  
maturation	  of	  the	  neural	  pathways,	  which	  is	  evident	  in	  changing	  cognitive	  
performance	  and	  observable	  behaviour,	  such	  as	  risk-­‐taking	  and	  impulsive	  action	  	  
(Steinberg,	  2005).	  	  Key	  components	  of	  these	  changes	  are	  developments	  in:	  working	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memory,	  processing	  speed,	  voluntary	  response	  inhibition,	  cognitive	  flexibility,	  rule-­‐
guided	  behaviour,	  abstract	  thinking	  and	  response	  planning	  	  (Luna,	  2009).	  	  All	  of	  
these	  processes	  are	  central	  to	  health	  behaviours	  and	  crucial	  as	  adolescents	  take	  over	  
control	  of	  their	  own	  healthcare	  from	  their	  caregivers	  during	  transition	  to	  adulthood.	  	  	  
	  
There	  is	  a	  paucity	  of	  research	  in	  the	  area	  of	  cognitive	  capacities	  of	  PHIV+	  young	  
people	  during	  adolescence,	  however,	  with	  a	  larger	  focus	  on	  younger	  (age	  6-­‐12)	  or	  
older	  (age	  7-­‐16)	  children	  to	  the	  neglect	  of	  older	  teenagers	  and	  young	  adults	  	  
(Puthanakit	  et	  al.,	  2013;	  Smith	  &	  Wilkins,	  2014;	  Smith	  et	  al.,	  2008).	  	  There	  is	  
considerable	  heterogeneity	  in	  testing	  and	  measurement	  of	  the	  neurocognitive	  
correlates	  of	  PHIV+	  infection	  in	  adolescents,	  particularly	  in	  resource-­‐limited	  
countries	  	  (Laughton	  et	  al.,	  2013).	  	  	  	  
	  
The	  effect	  of	  HIV	  on	  cognitive	  functioning	  may	  not	  be	  reversed	  despite	  initiation	  of	  
ART.	  	  In	  one	  cohort	  of	  PHIV+	  Thai	  children,	  there	  was	  no	  improvement	  in	  cognitive	  
function	  following	  commencement	  of	  ART,	  even	  when	  virological	  suppression	  and	  
immunological	  recovery	  was	  achieved	  (Puthanakit,	  Aurpibul,	  Yoksan,	  Sirisanthana,	  &	  
Sirisanthana,	  2010;	  Puthanakit,	  Aurpibul,	  Louthrenoo,	  et	  al.,	  2010).	  	  There	  may	  also	  
be	  neuropsychological	  sequelae	  associated	  with	  ART	  toxicity	  (or	  adverse	  drug	  
reactions)	  in	  children	  and	  young	  people,	  including	  bad	  dreams,	  mood	  swings,	  
drowsiness,	  dizziness,	  impaired	  learning	  and	  depression	  	  (Bamford	  et	  al.,	  2015;	  
Welch	  et	  al.,	  2009).	  Studies	  in	  the	  USA	  and	  Europe	  have	  demonstrated	  significantly	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poorer	  overall	  cognitive	  development	  for	  adolescents	  on	  ART	  compared	  to	  national	  
norms	  (Laughton	  et	  al.,	  2013).	  	  	  
	  
PHIV+	  may	  impact	  on	  the	  normative	  development	  of	  independence	  during	  
adolescence,	  characterised	  by	  poor	  mastery	  of	  activities	  of	  daily	  living.	  	  A	  single	  
investigation	  into	  differences	  between	  age-­‐matched	  PHIV+	  and	  PHIV-­‐	  young	  people	  
found	  lower	  mastery	  of	  daily	  living	  and	  self-­‐care	  skills	  as	  measured	  be	  self-­‐	  and	  
caregiver	  report	  	  (Pearlstein	  et	  al.,	  2014).	  	  However,	  these	  effects	  were	  not	  
significant	  when	  controlling	  for	  age,	  gender,	  verbal	  ability	  and	  psychiatric	  functioning	  
and	  have	  not	  been	  replicated,	  so	  must	  be	  interpreted	  with	  caution.	  
	  
Long-­‐term	  exposure	  to	  the	  HIV	  virus	  is	  likely	  to	  result	  in	  underlying	  inflammation	  and	  
suboptimal	  immune	  system	  function,	  even	  with	  effective	  treatment	  	  (Bamford	  et	  al.,	  
2015;	  Siberry	  et	  al.,	  2011).	  	  Therefore,	  PHIV+	  adolescents	  may	  have	  experienced	  an	  
increased	  number	  of	  common	  infections	  or	  illnesses	  throughout	  childhood	  and	  may	  
have	  a	  number	  of	  experiences	  in	  common	  with	  other	  young	  people	  with	  chronic	  
illnesses	  such	  as	  continuing	  contact	  with	  medical	  professionals,	  pain	  and	  missed	  
school	  (Persson	  et	  al.,	  2014).	  	  	  There	  may	  also	  be	  unique	  implications	  of	  growing	  up	  
with	  PHIV+	  that	  set	  apart	  these	  young	  people	  from	  other	  adolescents	  with	  chronic	  
illness.	  
Psychosocial	  Issues	  
PHIV+	  young	  people	  are	  put	  at	  risk	  for	  poor	  psychological	  and	  behavioural	  outcomes	  
globally	  by	  financial	  hardship,	  poor	  health	  care	  and	  limited	  access	  to	  education	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(UNAIDS,	  2014).	  	  Furthermore,	  they	  are	  more	  likely	  to	  have	  experienced	  the	  death	  or	  
serious	  illness	  of	  one	  or	  both	  parents	  	  (Kang	  et	  al.,	  2008;	  Kang	  et	  al.,	  2008).	  	  PHIV+	  
youth	  may	  have	  increased	  genetic	  vulnerability	  for	  mental	  health	  and	  substance	  
abuse	  problems,	  indicated	  by	  high	  rates	  of	  both	  in	  HIV+	  parents.	  	  Cohort	  studies	  
across	  cultures	  consistently	  suggest	  high	  rates	  of	  behavioural	  and	  emotional	  health	  
problems	  in	  PHIV+	  youth	  	  (Bomba	  et	  al.,	  2010;	  Mellins	  et	  al.,	  2012;	  Mellins	  et	  al.,	  
2011;	  Menon	  et	  al.,	  2007;	  Puthanakit	  et	  al.,	  2013).	  
	  
PHIV+	  young	  people	  are	  set	  apart	  from	  HIV+	  adults	  and	  BHIV+	  youth	  in	  that	  they	  are	  
born	  into	  families	  with	  prior	  experience	  of	  HIV	  	  (Cluver,	  Gardner,	  &	  Operario,	  2008).	  	  
Families	  may	  have	  experienced	  prolonged	  discrimination	  and	  stigma	  	  (Nyblade,	  
Stangl,	  Weiss,	  &	  Ashburn,	  2009).	  	  	  
ART	  Adherence	  
Adherence	  is	  defined	  by	  the	  World	  Health	  Organisation	  as,	  “the	  extent	  to	  which	  a	  
person’s	  behaviour	  –	  taking	  medication,	  following	  a	  diet,	  and/or	  executing	  lifestyle	  
changes,	  corresponds	  with	  agreed	  recommendations	  from	  a	  health	  care	  provider”	  
(WHO,	  2003).	  	  Exact	  optimal	  adherence	  figures	  vary	  according	  to	  specific	  
requirements	  of	  a	  particular	  regimen.	  ART	  adherence	  of	  greater	  than	  90-­‐95%	  is	  
generally	  considered	  necessary	  to	  maximise	  effectiveness	  and	  prevent	  resistance	  
(BHIVA,	  2014).	  	  Adherence	  to	  ART	  is	  a	  good	  predictor	  of	  clinical	  outcome	  and	  has	  led	  
to	  reductions	  in	  morbidity	  and	  mortality	  from	  AIDS	  globally.	  	  However,	  in	  young	  
people	  age	  10-­‐19,	  mortality	  rates	  are	  increasing,	  in	  part	  due	  to	  lack	  of	  support	  for	  
ART	  adherence,	  as	  well	  as	  poor	  prioritisation	  of	  adolescents	  in	  public	  health	  planning	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and	  a	  lack	  of	  acceptable	  healthcare	  services	  for	  this	  age	  group,	  according	  to	  the	  
World	  Health	  Organisation	  	  (WHO,	  2013).	  	  
	  
Suboptimal	  Adherence	  
The	  speed	  at	  which	  the	  HIV	  virus	  replicates	  necessitates	  near-­‐perfect	  adherence	  to	  
antiretroviral	  medication	  at	  all	  times	  to	  prevent	  progression	  of	  the	  disease	  and	  
destruction	  of	  the	  immune	  system	  	  (Adefolalu	  &	  Nkosi,	  2013).	  	  The	  likelihood	  of	  
developing	  antiretroviral	  resistance	  increases	  with	  suboptimal	  medication	  
adherence.	  	  This	  has	  implications	  not	  only	  for	  the	  individual	  in	  narrowing	  the	  
available	  treatment	  options,	  but	  also	  for	  transmission	  risk	  to	  others.	  	  Medication-­‐
resistant	  strains	  of	  HIV	  can	  develop	  and,	  without	  adequate	  precautions,	  be	  
transmitted	  easily	  and	  unknowingly,	  causing	  an	  increasingly	  virulent	  epidemic	  	  
(Murphy,	  Marelich,	  Rappaport,	  Hoffman,	  &	  Farthing,	  2007).	  	  Adherence	  rates	  for	  the	  
PHIV+	  population	  are	  presented	  later	  in	  this	  chapter.	  
Adherence	  Guidelines	  
With	  changing	  ART	  formulations,	  there	  have	  been	  numerous	  iterations	  of	  ART	  
prescribing	  guidelines	  for	  adults,	  young	  people	  and	  children.	  	  The	  number	  of	  CD4	  
cells	  in	  a	  blood	  sample	  is	  often	  used	  to	  determine	  if	  and	  when	  ART	  should	  be	  
initiated.	  	  A	  normal	  range	  in	  adolescents	  and	  adults	  is	  between	  of	  500-­‐1200	  cells/μl	  
and	  indicates	  good	  function	  of	  the	  immune	  system;	  a	  low	  or	  falling	  CD4	  count	  may	  
indicate	  damage	  to	  the	  immune	  system	  and	  progression	  of	  HIV	  (“What	  is	  a	  CD4	  cell”,	  
2014).	  At	  present,	  the	  European	  recommendation	  is	  to	  commence	  ART	  in	  children	  
over	  age	  5	  and	  adults	  when	  CD4	  approaches	  <350cells/	  μl;	  the	  WHO	  and	  US	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guidelines	  recommend	  starting	  at	  <500cells/	  μl	  	  (Bamford	  et	  al.,	  2015;	  WHO,	  2014)	  	  
Initiation	  is	  also	  recommended	  in	  children	  where	  there	  is	  delay	  in	  growth	  or	  onset	  of	  
puberty,	  neurocognitive	  delay,	  at	  the	  request	  of	  the	  child	  or	  family,	  when	  
adolescents	  become	  sexually	  active	  and	  during	  pregnancy	  	  (Bamford	  et	  al.,	  2015).	  
Prior	  to	  commencing	  ART	  in	  both	  adults	  and	  children,	  a	  thorough	  assessment	  of	  
readiness	  and	  preparedness	  to	  adhere	  to	  the	  regimen	  is	  recommended	  in	  most	  
national	  guidelines	  (Bamford,	  et	  al,	  2015;	  BHIVA,	  2014;	  Children’s	  HIV	  Association,	  
2013).	  	  If	  barriers	  to	  adherence	  are	  identified,	  prescribers	  are	  encouraged	  to	  delay	  
initiation	  of	  ART	  and	  endeavour	  to	  address	  such	  barriers.	  	  The	  British	  HIV	  Association	  
recommend	  a	  thorough	  assessment	  of	  individual	  barriers	  and	  formulation	  of	  
strategies	  to	  manage,	  although	  there	  are	  no	  clear	  guidelines	  for	  how	  to	  assess	  
barriers	  or	  what	  specific	  strategies	  may	  be	  most	  useful.	  	  
PHIV+	  ART	  Adherence	  
Following	  the	  pivotal	  development	  in	  HIV	  treatment,	  introduction	  of	  ART,	  the	  
epidemic	  has	  “changed	  face”	  from	  a	  terminal	  prognosis	  to	  a	  chronic,	  life-­‐long	  
condition	  in	  resource	  rich	  countries	  with	  effective	  treatment	  	  (Mofenson	  &	  Cotton,	  
2013).	  	  	  
	  
The	  purpose	  of	  treatment	  for	  HIV	  infection	  has	  evolved	  from	  short-­‐term	  
management	  of	  co-­‐morbid	  illnesses	  and	  limiting	  mortality	  to	  promotion	  of	  quality	  of	  
life	  and	  minimising	  symptoms	  to	  a	  near-­‐normal	  life	  expectancy	  	  (Nakagawa	  et	  al.,	  
2012).	  	  Although	  risk	  of	  death	  of	  PHIV+	  children	  has	  reduced,	  the	  virus	  remains	  life	  
threatening	  without	  adequate	  treatment	  management.	  	  As	  the	  first	  generation	  to	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grow	  up	  with	  ART,	  predicted	  life	  expectancy	  and	  rates	  of	  mortality	  in	  perinatally	  
infected	  young	  adults	  are	  unknown.	  	  A	  recent	  mortality	  audit	  of	  248	  PHIV+	  young	  
people	  who	  have	  transitioned	  to	  fourteen	  adult	  clinics	  in	  the	  UK	  found	  eleven	  
deaths,	  with	  nine	  out	  of	  these	  associated	  with	  poor	  adherence	  to	  medication	  and	  
concomitant	  advanced	  disease	  	  (Fish,	  Judd,	  Jungmann,	  O’Leary,	  &	  Foster,	  2014).	  	  This	  
highlights	  the	  great	  importance	  of	  investigating	  barriers	  to	  adherence	  in	  the	  PHIV+	  
population	  so	  that	  these	  young	  people	  can	  be	  supported	  to	  maintain	  optimal	  
adherence	  to	  their	  ART	  regimens.	  	  Indeed,	  PENTA	  recommend	  adherence	  is	  explicitly	  
discussed	  between	  patient	  and	  professional	  at	  every	  clinic	  visit	  (Bamford,	  et	  al,	  
2015).	  
Rates	  Of	  ART	  Adherence	  
A	  recent	  systematic	  review	  and	  meta-­‐analysis	  was	  conducted	  of	  51	  studies	  reporting	  
adherence	  for	  10725	  patients	  between	  12-­‐24	  years	  old.	  This	  study	  found	  that	  only	  
62.3%	  were	  over	  85%	  adherent	  to	  ART	  	  (Kim,	  Gerver,	  Fidler,	  &	  Ward,	  2014).	  	  
Measures	  of	  adherence	  included	  self-­‐report	  in	  13	  studies	  or	  viral	  suppression	  
(measured	  by	  undetectable	  viral	  load)	  in	  36	  studies,	  however	  there	  was	  little	  effect	  
on	  the	  adherence	  estimates	  of	  different	  means	  of	  measurement.	  	  There	  were	  some	  
differences	  between	  geographical	  regions	  with	  adherence	  in	  Africa	  and	  Asia	  higher	  
than	  Europe,	  South	  America	  and	  North	  America.	  	  The	  authors	  suggest	  differences	  in	  
the	  epidemic	  of	  HIV	  (generalised	  across	  the	  nation	  versus	  focused	  in	  particular	  sub-­‐
populations)	  as	  one	  possible	  explanation	  for	  this	  finding:	  HIV-­‐infected	  adolescents	  in	  
more	  developed	  countries	  may	  belong	  to	  more	  vulnerable,	  at-­‐risk,	  marginalised	  
groups	  with	  poorer	  access	  to	  adequate	  services	  in	  spite	  of	  greater	  national	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resources.	  	  Kim	  and	  colleagues	  compare	  their	  findings	  of	  adolescent	  adherence	  to	  
adult	  data.	  One	  cohort	  study	  across	  17	  European	  countries	  and	  a	  Brazilian	  study	  with	  
almost	  2000	  participants	  demonstrated	  adult	  adherence	  was	  significantly	  greater	  
than	  adolescent	  adherence	  in	  Europe	  and	  South	  America.	  	  These	  results	  reiterate	  the	  
importance	  of	  adherence	  research	  in	  an	  adolescent	  group.	  	  	  
	  
One	  problem	  with	  the	  findings	  in	  this	  review	  is	  the	  threshold	  for	  “adherence”,	  set	  at	  
85%	  or	  over	  in	  a	  given	  time	  period,	  without	  a	  clear	  rationale.	  	  Optimal	  adherence	  is	  
generally	  considered	  to	  be	  >90-­‐95%	  to	  achieve	  effective	  virological	  suppression.	  	  The	  
clinical	  implications	  for	  taking	  medication	  85%	  of	  the	  time	  versus	  95%	  could	  be	  
argued	  to	  be	  significant.	  	  This	  highlights	  a	  methodological	  issue	  when	  measuring	  
medication	  adherence:	  there	  is	  not	  a	  consistent	  or	  standardised	  means	  to	  classify	  
good	  adherence	  or	  non-­‐adherence.	  	  Measurement	  issues	  are	  discussed	  in	  greater	  
detail	  below.	  	  
Adolescents	  are	  consistently	  found	  to	  be	  significantly	  less	  adherent	  to	  ART	  than	  
younger	  children	  	  (Arrivillaga,	  Martucci,	  Hoyos,	  &	  Arango,	  2013;	  Malee	  et	  al.,	  2011;	  
Merzel,	  VanDevanter,	  &	  Irvine,	  2008)	  and	  adults	  	  (Nachega,	  Hislop,	  &	  Nguyen…,	  
2009).	  	  In	  an	  observational	  cohort	  study	  of	  nearly	  8000	  adolescents	  (age	  11-­‐19)	  and	  
adults	  (age	  >19)	  in	  Southern	  Africa,	  the	  young	  patients	  were	  less	  likely	  to	  be	  100%	  
adherent	  or	  achieve	  immunological	  recovery	  as	  measured	  by	  CD4+	  count	  	  (Barclay	  et	  
al.,	  2007).	  	  Given	  the	  numerous	  developments	  that	  occur	  during	  adolescence,	  it	  may	  
follow	  that	  a	  young	  person’s	  adherence	  at	  this	  time	  is	  not	  necessarily	  stable.	  Rather	  
it	  may	  be	  a	  dynamic	  function	  of	  developing	  cognitive	  and	  psychosocial	  capacities	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(Hanghøj	  &	  Boisen,	  2014;	  Simoni	  et	  al.,	  2007).	  	  However,	  PHIV+	  adolescents	  may	  
have	  lower	  rates	  of	  virological	  suppression	  and	  higher	  rates	  of	  ART	  resistance	  than	  
HIV+	  adults	  (Tassiopoulos	  	  et	  	  al.	  2013),	  therefore	  understanding	  barriers	  to	  and	  
promotion	  of	  adherence	  to	  first-­‐line	  regimens	  is	  key	  to	  managing	  health	  outcomes	  in	  
this	  population.	  
	  
Of	  the	  UK	  PHIV+	  population,	  according	  to	  the	  CHIPS	  project,	  in	  2014:	  40%	  were	  
taking	  their	  first	  ART	  regimen,	  37%	  were	  on	  a	  subsequent	  ART	  regimen,	  7%	  were	  on	  
mono-­‐	  or	  dual-­‐ART	  treatment,	  11%	  were	  treatment	  naïve	  and	  5%	  were	  not	  taking	  
any	  antiretroviral	  drugs	  having	  taken	  them	  at	  some	  point	  previously	  (CHIPS,	  2014).	  	  A	  
change	  from	  first	  to	  subsequent	  regimen,	  or	  mono-­‐	  or	  dual-­‐	  therapy	  may	  implicate	  
problems	  with	  resistance	  to	  a	  first-­‐line	  treatment	  or	  ineffectiveness	  of	  a	  previous	  
medication.	  It	  is	  not	  possible	  to	  ascertain	  for	  what	  reason	  the	  medication	  was	  
changed	  from	  these	  data.	  	  However,	  it	  is	  possible	  that	  adherence	  problems	  could	  be	  
linked	  with	  both	  medication	  resistance	  and	  ineffectiveness,	  which	  would	  both	  
necessitate	  a	  change	  to	  an	  alternative	  regimen.	  
Measurement	  of	  adherence	  
A	  key	  difficulty	  in	  medication	  adherence	  research	  is	  a	  lack	  of	  standardised	  methods	  
of	  measurement.	  	  As	  a	  result,	  many	  approaches	  are	  used,	  including:	  self-­‐report,	  pill-­‐
count,	  biological	  markers	  (such	  as	  viral	  load),	  electronic	  monitoring,	  pharmacy-­‐based	  
records,	  provider	  estimation	  and	  therapeutic	  drug	  monitoring	  	  (Kim	  et	  al.,	  2014).	  	  
The	  most	  common	  of	  these	  are	  discussed	  below.	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Pill-­‐count	  
Recording	  the	  number	  of	  pills	  prescribed	  at	  the	  start	  of	  the	  month	  minus	  the	  number	  
remaining	  at	  the	  end	  is	  known	  as	  the	  pill-­‐count	  method	  of	  adherence	  measurement	  	  
(e.g.	  Murphy,	  Marelich,	  Rappaport,	  Hoffman,	  &	  Farthing,	  2007).	  	  It	  is	  a	  robust	  
method	  of	  adherence	  measurement	  that	  is	  significantly	  correlated	  with	  viral	  load	  
across	  studies	  	  (Farley	  et	  al.,	  2008).	  	  	  
	  
Pill	  count	  data	  is	  not	  as	  easy	  to	  collect	  as	  self-­‐report	  as	  participants	  may	  neglect	  to	  
bring	  in	  their	  medicine	  bottles	  to	  clinic	  or	  research	  appointments,	  which	  may	  lead	  to	  
incomplete	  or	  missing	  information	  and	  an	  inaccurate	  overall	  adherence	  value.	  	  
Furthermore,	  in	  paediatric	  populations	  in	  particular,	  some	  ART	  is	  prescribed	  in	  liquid	  
form,	  which	  is	  much	  more	  challenging	  to	  measure	  accurately	  by	  a	  ‘counting’	  method.	  
Biological	  markers	  
Another	  objective	  method	  of	  measuring	  non-­‐adherence	  is	  by	  taking	  blood	  serum	  
assays	  to	  measure	  CD4	  count	  and	  HIV	  RNA	  viral	  load	  	  (Sherr	  et	  al.,	  2010).	  	  A	  lower	  
CD4	  count	  and	  a	  higher	  viral	  load	  are	  biological	  markers	  of	  non-­‐adherence	  or	  
resistance	  to	  ART.	  	  It	  may	  be	  impractical	  and	  costly	  for	  researchers	  to	  use	  blood	  tests	  
to	  measure	  adherence,	  especially	  as	  one	  cannot	  be	  certain	  of	  the	  exact	  time	  frame	  
of	  the	  non-­‐adherence	  (particularly	  without	  a	  baseline	  blood	  result	  to	  compare	  to).	  	  	  
Real-­‐time	  monitoring	  and	  prospective	  methods	  
There	  is	  a	  general	  reliance	  on	  global	  (over	  a	  specified	  period	  of	  time)	  and	  
retrospective	  reports	  of	  adherence	  in	  the	  literature.	  	  Continuous,	  real-­‐time	  
monitoring	  is	  possible	  through	  the	  use	  of	  electronic,	  cellular	  or	  wireless	  internet	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enabled	  devices,	  examples	  of	  which	  are	  the	  Medication	  Events	  Monitoring	  System	  	  
(Barclay	  et	  al.,	  2007;	  Hardy	  et	  al.,	  2011)	  and	  Wisepill	  (Haberer	  et	  al.,	  2010).	  	  Each	  of	  
these	  systems	  monitors	  when	  a	  medicines	  bottle	  or	  dosing	  box	  is	  opened	  and	  
transmits	  a	  signal	  to	  record	  as	  such.	  	  	  
Advocates	  of	  these	  systems	  of	  measurement	  argue	  that	  they	  enable	  suboptimal	  
adherence	  to	  be	  detected	  quickly	  and	  before	  any	  adverse	  effects	  of	  resistance	  or	  
increased	  viral	  load	  progress	  	  (Haberer	  et	  al.,	  2010).	  	  However,	  the	  systems	  are	  
costly,	  require	  training	  to	  use,	  may	  overestimate	  non-­‐adherence	  and	  are,	  overall,	  not	  
routinely	  practical	  	  (Usitalo	  et	  al.,	  2014).	  
Self-­‐report	  
Adherence	  measurement	  by	  self-­‐report	  is	  common,	  in	  spite	  of	  generally	  accepted	  
flaws,	  because	  it	  is	  an	  inexpensive	  method	  with	  is	  feasible	  across	  settings	  	  (Chesney	  
et	  al.,	  2000).	  	  There	  is	  a	  tendency	  for	  data	  collected	  in	  this	  way	  to	  overestimate	  
adherence,	  possibly	  due	  to	  social	  desirability	  and	  ceiling	  effects	  	  (Usitalo	  et	  al.,	  2014).	  	  	  
	  
In	  paediatric	  research,	  it	  is	  necessary	  to	  select	  between	  actual	  self-­‐report	  and	  
caregiver	  report.	  	  However,	  it	  has	  been	  found	  that	  adolescents	  are	  willing	  to	  openly	  
disclose	  non-­‐adherence	  through	  self-­‐report	  	  (Hanghøj	  &	  Boisen,	  2014;	  Staples	  &	  
Bravender,	  2002).	  	  When	  these	  data	  are	  checked	  against	  more	  objective	  measures	  of	  
plasma	  HIV	  concentrations	  or	  detectable	  viraemia,	  there	  is	  a	  significant	  correlation,	  
providing	  evidence	  of	  validity	  for	  self-­‐reported	  adherence/non-­‐adherence	  	  (Kahana,	  
Rohan,	  Allison,	  Frazier,	  &	  Drotar,	  2013)	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One	  of	  the	  inherent	  biases	  in	  self-­‐report	  is	  an	  individual’s	  ability	  to	  recall	  past	  events.	  	  
Conway’s	  (1996)	  model	  of	  autobiographical	  memory	  asserts	  that	  such	  memories	  are	  
organised	  hierarchically:	  remembering	  specific	  episodes	  elicits	  the	  most	  detail.	  
Nevertheless,	  all	  remembering	  can	  be	  unreliable	  and	  must	  be	  scaffolded,	  or	  
supported	  with	  temporal	  or	  thematic	  cues	  to	  promote	  an	  accurate	  account	  	  (Belli,	  
1998).	  These	  cues	  enhance	  the	  quality	  of	  retrospective	  report	  by	  triggering	  a	  similar	  
perceptual	  context	  and	  a	  sense	  of	  ‘re-­‐living’	  the	  event.	  	  Therefore,	  more	  details	  
about	  the	  event	  can	  be	  recalled	  (Conway,	  1996;	  Brewer,	  1996).	  	  	  These	  principles	  are	  
relied	  upon	  in	  the	  Cognitive	  Interview,	  used	  by	  the	  criminal	  justice	  system	  to	  
enhance	  the	  reliability	  of	  witness	  memory	  	  (Schwarz,	  2007).	  
Research	  designs	  using	  the	  Day	  Reconstruction	  Method	  (DRM)	  aim	  to	  promote	  
accurate	  remembering	  of	  episodic	  memories.	  DRM	  involves	  remembering	  the	  
context	  of	  a	  daily	  event	  to	  reconstruct	  the	  subjective	  experience	  and	  minimise	  recall	  
bias	  	  (Kahneman,	  Krueger,	  Schkade,	  Schwarz,	  &	  Stone,	  2004).	  	  In	  the	  original	  
description	  of	  this	  method,	  participants	  were	  asked	  to	  reconstruct	  the	  previous	  day.	  	  
This	  is	  particularly	  important	  in	  the	  recall	  of	  affective	  states,	  due	  to	  the	  confounding	  
influence	  of	  post-­‐hoc	  decontextualized	  beliefs	  about	  emotion	  	  (Robinson	  &	  Clore,	  
2002).	  	  By	  invoking	  the	  contextual	  details	  of	  an	  event,	  more	  specific	  memories	  are	  
elicited	  thereby	  reducing	  recall	  bias	  and	  remembering	  error	  	  (Kahneman	  et	  al.,	  
2004).	  	  	  	  	  
Other	  methods	  designed	  to	  minimise	  recall	  bias	  include	  prospective	  experience	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sampling	  methods	  such	  as	  Ecological	  Momentary	  Assessment	  (EMA).	  	  EMA	  is	  a	  
repeated	  sampling	  method	  of	  data	  collection	  measuring	  participants’	  subjective	  
experience	  and	  behaviours	  in	  real	  time	  in	  ‘natural’	  environments	  	  (Moskowitz	  &	  
Young,	  2006).	  	  One	  strategy	  of	  EMA	  is	  event-­‐based	  monitoring,	  where	  assessments	  
are	  triggered	  by	  a	  predetermined	  event.	  	  Such	  reports,	  however,	  can	  be	  subject	  to	  
error	  due	  to	  poor	  compliance,	  or	  participants	  deviating	  from	  the	  research	  protocol	  
and	  assessment	  schedule	  	  (Shiffman,	  Stone,	  &	  Hufford,	  2008),	  and	  attrition	  rates	  for	  
prospective	  research	  are	  high.	  	  	  
The	  DRM	  and	  EMA	  have	  been	  compared	  in	  a	  study	  of	  fatigue	  and	  momentary	  
changes	  in	  mood	  over	  a	  fixed	  period,	  with	  no	  significant	  differences	  in	  the	  results	  
from	  each	  design.	  Although	  EMA	  may	  be	  superior	  in	  measuring	  momentary	  changes	  
over	  time,	  for	  a	  fixed	  study	  period	  DRM	  appears	  to	  be	  comparable	  in	  minimising	  bias	  
in	  retrospective	  report	  	  (Kim,	  Kikuchi,	  &	  Yamamoto,	  2013).	  
	  
Factors	  associated	  with	  adherence	  	  
There	  are	  significant	  consequences	  to	  not	  taking	  ART	  medication	  as	  prescribed.	  	  
However,	  insufficient	  adherence	  is	  problematic	  across	  a	  number	  of	  chronic	  illnesses	  
and	  across	  the	  lifespan,	  presenting	  a	  particular	  challenge	  during	  adolescence	  (Simoni	  
et	  al.,	  2007).	  	  There	  is	  a	  considerable	  interest	  amongst	  health	  services	  to	  investigate	  
adherence	  difficulties	  between	  individuals	  and	  barriers	  to	  optimal	  adherence	  have	  
been	  studied	  across	  conditions,	  in	  adults	  and	  teenagers.	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There	  are	  numerous	  ways	  to	  categorise	  types	  of	  adherence	  barriers.	  	  In	  a	  review	  
across	  asthma,	  cancer,	  depression,	  diabetes,	  epilepsy,	  HIV,	  hypertension,	  smoking	  
cessation	  and	  tuberculosis,	  the	  World	  Health	  Organisation	  describe	  five	  factors	  
important	  to	  treatment	  adherence:	  social	  and	  economic	  factors,	  health	  care	  team	  
and	  system	  related	  factors,	  condition	  related	  factors,	  therapy	  related	  factors	  and	  
patient	  related	  factors	  	  (WHO,	  2013).	  	  The	  following	  section	  presents	  selected	  
research	  into	  the	  correlates	  of	  ART	  adherence	  between	  individuals	  according	  to	  the	  
WHO	  categories	  of	  treatment-­‐related	  and	  patient-­‐related	  factors.	  	  A	  review	  of	  the	  
higher	  order	  factors	  of	  social,	  economic,	  health	  system	  and	  disease	  influence	  is	  
beyond	  the	  scope	  of	  this	  thesis.	  	  Treatment-­‐	  and	  patient-­‐related	  factors	  are	  selected	  
as	  most	  proximal	  determinants	  of	  adherence	  related	  to	  individuals.	  
Treatment-­‐related	  factors	  
Regimen	  
ART	  regimens	  carry	  a	  significantly	  greater	  burden	  than	  the	  treatment	  for	  many	  other	  
chronic	  medical	  conditions	  (Buchanan	  et	  al.,	  2012).	  	  A	  2000	  study	  reported	  that	  ART	  
regimens	  in	  adults	  consisted	  of	  an	  average	  of	  fourteen	  tablets	  daily	  (Murphy	  et	  al.,	  
2003).	  Pill	  burden	  has	  reduced	  in	  recent	  years	  with	  single-­‐dose	  preparations	  
becoming	  available	  in	  2006	  (Nachega	  et	  al.,	  2014).	  	  The	  latest	  World	  Health	  
Organisation	  guidelines	  advocate	  single-­‐dose	  regimens,	  while	  some	  drugs	  still	  
require	  up	  to	  five	  pills	  per	  dose	  to	  be	  taken	  (WHO,	  2010).	  	  A	  2012	  study	  in	  
adolescents	  cited	  a	  mean	  number	  of	  prescribed	  tablets	  at	  six	  and	  a	  half	  per	  day	  
(Chandwani	  et	  al.,	  2012).	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Increased	  treatment	  burden	  is	  likely	  to	  be	  associated	  with	  poorer	  adherence.	  	  In	  a	  
recent	  meta-­‐analysis	  of	  randomised	  control	  trials	  in	  adults,	  lower	  pill	  burden	  was	  
associated	  with	  increased	  ART	  adherence;	  a	  once-­‐daily	  regimen	  was	  related	  to	  
better	  adherence	  compared	  with	  twice-­‐daily	  regimens	  (Nachega	  et	  al.,	  2014).	  	  
Perceived	  difficulty	  of	  medication	  routine	  is	  associated	  with	  non-­‐adherence	  in	  adults	  
and	  adolescents	  (Williams	  et	  al.,	  2006),	  with	  both	  perinatally	  and	  behaviourally	  
acquired	  HIV	  	  (Chandwani	  et	  al.,	  2012).	  	  Complex	  regimens	  have	  been	  associated	  
with	  forgetting	  to	  take	  medication	  (an	  often-­‐cited	  barrier	  to	  adherence	  discussed	  
below)	  (Murphy	  et	  al.,	  2003).	  	  	  
Side	  effects	  
Unwanted	  adverse	  effects	  are	  a	  considerable	  barrier	  to	  adherence	  amongst	  the	  
PHIV+	  population	  (e.g.	  Macdonell,	  Naar-­‐King,	  Murphy,	  Parsons,	  &	  Huszti,	  2011).	  	  
These	  young	  people	  express	  difficulties	  in	  tolerating	  some	  ART	  medication,	  possibly	  
due	  to	  being	  on	  less	  palatable	  preparations	  as	  a	  result	  of	  drug	  resistance.	  	  However,	  
the	  distinction	  between	  exact	  drug	  regimens	  is	  seldom	  reported	  in	  the	  literature	  so	  
this	  suggestion	  is	  a	  tentative	  one.	  
Patient	  related	  factors	  
Caregiver/family	  factors	  
As	  adolescents	  strive	  for	  more	  autonomy	  and	  independence	  within	  their	  family,	  help	  
offered	  from	  relatives	  can	  be	  interpreted	  either	  as	  a	  stressor	  or	  support.	  	  Parents	  
and	  carers	  must	  balance	  the	  increased	  need	  for	  personal	  responsibility	  whilst	  not	  
over-­‐burdening	  a	  young	  person	  with	  obligations	  for	  which	  they	  are	  ill-­‐equipped,	  that	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is,	  being	  solely	  responsibly	  for	  their	  ART	  medication	  	  (Neinstein,	  2008).	  	  In	  a	  cross	  
sectional	  study	  of	  families	  including	  children	  (mean	  age	  7,	  range	  3-­‐13)	  and	  their	  
caregivers,	  responses	  were	  compared	  across	  those	  who	  reported	  missed	  doses	  
(nonadherent)	  or	  no	  missed	  doses	  (adherent)	  over	  the	  past	  month.	  	  Non-­‐adherence	  
was	  significantly	  associated	  with	  older	  child	  age,	  higher	  caregiver	  stress,	  worse	  
parent-­‐child	  communication,	  and	  poor	  caregiver	  quality	  of	  life.	  	  When	  age	  was	  
controlled	  for,	  worse	  parent-­‐child	  communication	  and	  higher	  caregiver	  stress	  were	  
strongly	  associated	  with	  non-­‐adherence	  (Mellins,	  Brackis-­‐Cott,	  Dolezal,	  &	  Abrams,	  
2004).	  	  This	  study	  was	  carried	  out	  in	  younger	  children,	  however	  did	  include	  some	  
teenagers.	  	  That	  family	  factors	  remained	  significant	  when	  controlling	  for	  age	  may	  
indicate	  continued	  influence	  on	  adherence	  as	  young	  people	  enter	  adolescence.	  	  	  	  	  
	  
Research	  indicates	  involvement	  of	  caregivers	  varies	  greatly	  during	  adolescence	  and	  
may	  be	  based	  on	  the	  age	  and	  health-­‐status	  of	  the	  adolescent	  patient	  	  (Denison	  et	  al.,	  
2015).	  	  The	  extent	  to	  which	  young	  people	  are	  able	  to	  take	  ownership	  of	  their	  
healthcare	  may	  not	  be	  solely	  related	  to	  their	  personal	  motivation,	  skills	  and	  abilities,	  
but	  may	  also	  be	  influenced	  by	  willingness	  of	  caregivers	  to	  allow	  the	  young	  people	  to	  
assume	  responsibility.	  	  Naar-­‐King	  and	  colleagues	  found	  a	  quarter	  of	  PHIV+	  young	  
people	  aged	  between	  eight	  and	  18	  reported	  being	  fully	  responsible	  for	  taking	  their	  
medication	  (2009).	  	  Degree	  of	  responsibility	  increased	  with	  age,	  but	  age	  was	  
unrelated	  to	  adherence;	  successful	  transition	  of	  responsibility	  was	  associated	  with	  
increased	  ART	  adherence.	  	  There	  is	  some	  indication	  in	  the	  literature	  that	  familial	  
support	  can	  be	  important	  in	  successfully	  transitioning	  from	  paediatric	  to	  adult	  health	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services	  in	  Australia	  	  (Newman,	  Persson,	  Miller,	  &	  Cama,	  2014),	  Zambia	  (Denison	  et	  
al,	  2015)	  and	  the	  UK	  	  (Foster	  et	  al.,	  2009).	  
Transitioning	  	  
Children	  who	  acquired	  HIV	  at	  birth	  have	  relied	  on	  adult	  caregivers	  to	  look	  after	  their	  
health	  for	  a	  significant	  period	  of	  their	  lives,	  unlike	  individuals	  infected	  in	  adulthood	  
who	  commence	  treatment	  for	  which	  they	  are	  solely	  responsible.	  	  PHIV+	  young	  
people	  must	  go	  through	  a	  period	  of	  transition	  as	  they	  begin	  to	  take	  increasing	  
ownership	  of	  their	  own	  healthcare	  (Buchanan	  et	  al.,	  2012;	  Koenig,	  Nesheim,	  &	  
Abramowitz,	  2011).	  	  	  
	  
In	  resource	  rich	  countries,	  children	  with	  PHIV+	  have	  experiences	  of	  paediatric	  
services,	  characterised	  by	  multi-­‐disciplinary,	  family-­‐centred	  working	  with	  access	  to	  
numerous	  support	  services.	  	  By	  contrast,	  adult	  clinics	  assume	  the	  individual’s	  
responsibility	  for	  their	  own	  care	  	  (Mofenson	  &	  Cotton,	  2013).	  	  In	  the	  UK,	  CHIVA	  
recommend	  transition	  services	  where	  local	  healthcare	  provision	  allow,	  whereby	  
adult	  and	  paediatric	  services	  offer	  co-­‐ordinated	  multidisciplinary	  clinics	  to	  ensure	  the	  
handover	  of	  care	  happens	  without	  young	  adult	  patients	  being	  lost	  to	  follow	  up	  	  
(Foster	  et	  al.,	  2009;	  CHIVA,	  2013).	  	  Weiner	  and	  colleagues	  conducted	  semi-­‐
structured	  interviews	  with	  59	  HIV+	  participants	  who	  were	  in	  the	  process	  of,	  or	  had	  
transitioned,	  from	  paediatric	  to	  adult	  care	  in	  the	  USA	  	  (Wiener,	  Kohrt,	  Battles,	  &	  Pao,	  
2011).	  	  Almost	  half	  reported	  difficulties	  with	  adherence	  during	  the	  changeover	  
period,	  which	  was	  evident	  in	  lower	  CD4+	  counts	  in	  those	  who	  had	  transitioned	  to	  
adult	  care	  on	  measures	  of	  pre-­‐	  and	  post-­‐transition	  (p=.08).	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Stigma	  &	  disclosure	  
Stigma	  and	  misconceptions	  about	  HIV	  are	  prevalent	  in	  much	  of	  society,	  causing	  HIV+	  
individuals	  to	  feel	  a	  need	  to	  conceal	  their	  diagnosis	  and	  maintain	  a	  level	  of	  secrecy	  	  
(Simoni	  et	  al.,	  2007).	  	  	  
	  
In	  a	  US	  focus	  group	  of	  25	  HIV+	  young	  people,	  half	  of	  the	  participants	  reported	  
deliberately	  missing	  a	  dose	  of	  ART	  due	  to	  fear	  of	  inadvertently	  disclosing	  their	  status	  
to	  a	  friend	  or	  family	  member	  	  (Rao,	  Kekwaletswe,	  Hosek,	  &	  Martinez…,	  2007).	  	  This	  
focus	  group	  contained	  only	  one	  PHIV+	  young	  person,	  but	  it	  is	  likely	  that	  the	  impact	  
of	  stigma	  may	  be	  just	  as	  great	  between	  PHIV+	  and	  BHIV+	  young	  people.	  	  In	  support	  
of	  this,	  Abramowitz	  and	  colleagues	  found	  BHIV+	  adolescents	  (age	  13-­‐21)	  had	  
disclosed	  their	  HIV	  status	  to	  significantly	  more	  friends	  or	  people	  outside	  the	  family	  
than	  their	  PHIV+	  peers	  (Abramowitz	  et	  al.,	  2009).	  
	  
Researchers	  in	  Uganda	  suggest	  HIV+	  children	  become	  aware	  of	  HIV-­‐related	  stigma	  
from	  a	  young	  age	  and	  respond	  to	  adult	  instructions	  to	  maintain	  secrecy	  	  (Kawuma,	  
Bernays,	  Siu,	  Rhodes,	  &	  Seeley,	  2014).	  	  In	  interviews	  with	  26	  older	  children	  (age	  11-­‐
13),	  these	  authors	  found,	  contrary	  to	  their	  hypothesis	  that	  forgetting	  would	  be	  a	  
main	  reason	  for	  non-­‐adherence,	  not	  wanting	  to	  be	  seen	  by	  others	  was	  key	  to	  not	  
taking	  their	  ART	  medication.	  	  	  
	  
These	  findings	  were	  replicated	  in	  an	  adolescent	  sample	  in	  Zambia.	  	  Interviews	  with	  
young	  people	  (age	  between	  15	  and	  18	  years)	  and	  their	  adult	  care-­‐givers	  in	  Zambia	  
elicited	  fear	  of	  stigma	  and	  disclosure	  as	  key	  reasons	  for	  not	  adhering	  to	  ART	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medication	  (Denison	  et	  al.,	  2015).	  	  Management	  of	  HIV	  was	  reported	  to	  be	  restricted	  
to	  the	  home	  environment	  and	  young	  people	  reported	  concerns	  regarding	  
anticipated	  stigma,	  or	  expectation	  of	  future	  discrimination	  (Earnshaw	  &	  Chaudoir,	  
2009)	  if	  they	  took	  medication	  outside	  of	  their	  home.	  	  Peer	  support	  groups	  with	  links	  
to	  their	  clinic	  were	  the	  only	  exception,	  where	  participants	  reported	  feeling	  
encouraged	  and	  accepted	  such	  that	  they	  were	  comfortable	  in	  taking	  their	  
medication	  in	  the	  group	  outside	  their	  home.	  	  	  
Neurocognitive	  factors	  
Deficits	  in	  neurocognitive	  development	  may	  equate	  to	  deficits	  in	  the	  general	  
cognitive	  processes	  involved	  in	  taking	  medication.	  	  Adherence	  to	  ART	  requires	  
personal	  organisation	  and	  adequate	  cognitive	  skill.	  	  Non-­‐adherence	  may	  be	  due	  to	  
poor	  abstract	  thinking	  ability,	  manifesting	  in	  poor	  planning	  and	  preparatory	  
techniques,	  or	  a	  poor	  perception	  of	  risk	  or	  future	  consequences	  	  (Malee	  et	  al.,	  2009).	  	  
Executive	  functions	  such	  as	  initiation,	  processing	  speed,	  voluntary	  inhibition,	  
flexibility	  of	  thinking	  and	  following	  rules	  can	  be	  impaired	  in	  PHIV+	  and	  therefore	  
impair	  an	  individual’s	  ability	  to	  adhere	  to	  a	  medical	  regimen	  (Laughton,	  Cornell,	  
Boivin,	  &	  Van	  Rie,	  2013).	  	  In	  a	  New	  Zealand	  cohort	  of	  typically	  developing	  
adolescents,	  performance	  on	  neuropsychological	  and	  executive	  function	  tests	  was	  
significant	  predictors	  of	  risk	  taking	  	  (Pharo,	  Sim,	  Graham,	  Gross,	  &	  Hayne,	  2011).	  	  
Non-­‐adherence	  has	  frequently	  been	  classified	  as	  a	  risk-­‐taking	  behaviour,	  therefore	  
there	  may	  be	  some	  influence	  of	  executive	  function	  impairment	  on	  ART	  adherence	  
(Laughton,	  Cornell,	  Boivin	  &	  Van	  Rie,	  2013)	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PHIV	  can	  affect	  frontal	  brain	  regions	  impacting	  on	  emotional	  and	  behavioural	  
regulation	  (Smith	  &	  Wilkins,	  2014),	  which	  may	  also	  account	  for	  comparatively	  more	  
psychiatric	  symptoms	  in	  the	  PHIV+	  population	  	  (Chernoff	  et	  al.,	  2009;	  Gadow	  et	  al.,	  
2010,	  2012).	  	  	  
Mental	  Health	  
PHIV+	  individuals	  are	  more	  likely	  to	  be	  diagnosed	  with	  mental	  health	  disorders,	  such	  
as	  depression,	  than	  their	  HIV-­‐	  peers	  	  (Mellins	  &	  Malee,	  2013).	  This	  can	  interfere	  with	  
ART	  adherence	  motivation	  and	  the	  ability	  to	  enact	  motivation.	  The	  psychosocial	  
correlates	  of	  increased	  mental	  health	  disorder	  are	  discussed	  above	  (in	  ‘Perinatally	  
Infected	  HIV+	  Adolescents	  and	  Young	  Adults’.	  
	  
In	  support	  of	  this	  relationship,	  in	  PHIV+	  women	  during	  pregnancy,	  a	  significant	  
difference	  in	  ART	  adherence	  and	  viral	  load	  at	  time	  of	  delivery	  has	  been	  found	  
between	  those	  with	  and	  without	  a	  history	  of	  depression	  	  (Sheth	  et	  al.,	  2015).	  	  	  
	  
The	  LEGACY	  (Longitudinal	  Epidemiologic	  Study	  to	  Gain	  Insight	  into	  HIV/AIDS	  in	  
Children	  and	  Youth)	  study	  in	  the	  USA	  is	  a	  prospective,	  multi-­‐site	  cohort	  study	  of	  HIV+	  
youth	  comprising	  197	  PHIV+	  young	  people	  age	  13	  and	  older.	  	  Over	  half	  the	  sample	  
had	  documented	  psychiatric	  diagnoses,	  current	  or	  historic,	  and	  72%	  had	  ART	  
adherence	  problems	  as	  documented	  in	  their	  medical	  notes.	  	  Psychiatric	  morbidity	  
was	  associated	  with	  risky	  behaviour	  (including	  treatment	  non-­‐adherence,	  substance	  
misuse	  and	  preadult	  sexual	  activity)	  in	  multivariate	  analysis	  	  	  (Kapetanovic	  et	  al.,	  
2011).	  	  However,	  other	  research	  between	  “good	  adherers”	  and	  “poor	  adherers”	  has	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suggested	  no	  differences	  in	  mental	  health	  disorders	  between	  groups	  	  (Rudy,	  
Murphy,	  Harris,	  Muenz,	  &	  Ellen,	  2010).	  	  	  
Self-­‐efficacy	  
Self-­‐efficacy	  in	  relation	  to	  medication,	  refers	  to	  one’s	  perceived	  abilities	  to	  be	  able	  to	  
adhere	  to	  a	  medication	  regimen	  as	  prescribed.	  	  It	  is	  consistently	  related	  to	  
adherence	  to	  treatment	  or	  therapy	  regimes	  in	  research	  with	  adults	  and	  adolescents	  
across	  conditions,	  including	  renal	  disease	  (Vasylyeva,	  Singh,	  Sheehan,	  
Chennasamudram,	  &	  Hernandez,	  2013)	  and	  diabetes	  (Griva,	  Myers,	  &	  Newman,	  
2000).	  	  
	  
In	  PHIV+,	  mean	  ratings	  on	  a	  scale	  of	  self-­‐efficacy	  were	  significantly	  higher	  in	  good	  
versus	  poor	  adherers	  in	  a	  large	  sample	  (n=368)	  of	  PHIV+	  youth	  (age	  12-­‐24)	  in	  USA	  	  
(Rudy	  et	  al.,	  2010).	  	  In	  a	  study	  of	  ninety-­‐two	  Thai	  PHIV+	  youth	  recruited	  from	  clinic	  
settings,	  higher	  ratings	  of	  self-­‐efficacy	  were	  associated	  with	  higher	  levels	  of	  ART	  
adherence,	  measured	  by	  self-­‐report	  over	  the	  past	  30	  days	  	  (Kang,	  Delzell,	  Chhabra,	  &	  
Oberdorfer,	  2014).	  	  This	  is	  in	  keeping	  with	  previous	  findings	  in	  adolescent	  
populations	  in	  the	  USA,	  where	  correlations	  were	  found	  between	  self-­‐efficacy	  and	  
adherence	  in	  a	  sample	  of	  both	  BHIV+	  and	  PHIV+	  aged	  between	  16-­‐24.	  	  When	  
controlling	  for	  psychological	  distress,	  self-­‐efficacy	  independently	  predicted	  
adherence	  in	  this	  group	  	  (Naar-­‐King	  et	  al.,	  2006).	  
	  
Self-­‐efficacy	  has	  frequently	  been	  measured	  in	  cross-­‐sectional	  studies	  in	  relation	  to	  
medication	  adherence.	  	  Momentary	  variation	  in	  self-­‐efficacy	  has	  also	  been	  studied	  in	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adolescents	  attempting	  to	  quit	  smoking	  (Van	  Zundert,	  Engels,	  &	  Kuntsche,	  2011).	  	  
Researchers	  found	  situational	  variation	  in	  young	  people’s	  confidence	  to	  enact	  
smoking	  cessation	  behaviours.	  	  Although	  self-­‐efficacy	  was	  measured	  with	  a	  single	  
question,	  this	  was	  repeatedly	  asked	  across	  a	  number	  of	  days.	  	  This	  approach	  might	  
suggest	  that	  daily,	  or	  episodic	  (relating	  to	  particular	  events),	  as	  well	  as	  global	  (over	  a	  
longer	  period	  of	  time)	  self-­‐efficacy	  could	  be	  influential	  in	  adherence	  behaviours.	  	  	  
	  
Only	  one	  study	  has	  explicitly	  investigated	  daily	  variation	  in	  medication-­‐related	  self-­‐
efficacy.	  	  In	  a	  study	  of	  adult	  beta	  Thalassaemia	  Major	  patients,	  the	  researchers	  found	  
significant	  differences	  in	  self-­‐efficacy	  within-­‐participants	  between	  an	  adherent	  
episode	  and	  a	  non-­‐adherent	  episode	  	  (Vosper,	  Evangeli,	  Porter,	  &	  Shah,	  2013).	  	  	  
Routine	  
The	  extent	  to	  which	  structure	  and	  routine	  are	  built	  into	  an	  individual’s	  lifestyle	  are	  
important	  factors	  in	  ART	  adherence.	  	  A	  young	  person	  being	  away	  from	  their	  home	  or	  
usual	  surroundings	  is	  a	  commonly	  cited	  barrier	  to	  adherence,	  as	  is	  difficulty	  in	  
scheduling	  doses	  so	  that	  they	  become	  incorporated	  into	  one’s	  usual	  routine	  
(Murphy	  et	  al.,	  2003;	  Rudy,	  Murphy,	  Harris,	  Muenz,	  &	  Ellen,	  2009;	  Buchanan	  et	  al.,	  
2012).	  
	  
A	  qualitative	  investigation	  of	  ART	  adherence	  in	  suboptimally	  adherent	  HIV+	  adults	  in	  
California,	  USA,	  investigated	  the	  level	  of	  structure	  of	  daily	  schedules	  and	  adherence	  	  
(Saberi,	  Comfort,	  &	  Johnson,	  2012).	  	  Participant	  interview	  data	  was	  grouped	  into:	  
‘not	  organised’,	  characterised	  by	  no	  recurring	  daily	  activity	  at	  all;	  ‘somewhat	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organised’,	  characterised	  by	  the	  recurrence	  of	  one	  or	  more	  regular	  activities;	  or	  
‘highly	  organised’,	  where	  medication	  was	  linked	  to	  a	  regular	  structured	  activity.	  	  
Participants	  in	  the	  ‘not	  organised’	  group	  were	  uniformly	  non-­‐adherent,	  at	  a	  rate	  of	  
0%	  as	  measured	  by	  self-­‐report	  over	  the	  previous	  30	  days.	  	  Participants	  in	  the	  
‘somewhat	  organised’	  or	  ‘highly	  organised’	  groups	  reported	  greater	  adherence	  of	  
>70%	  and	  93-­‐100%	  respectively,	  even	  if	  their	  living	  situation	  was	  unstable.	  	  That	  is,	  
the	  presence	  of	  at	  least	  one	  structured	  activity	  appeared	  to	  be	  associated	  with	  
increased	  ART	  adherence.	  	  However,	  the	  conclusions	  from	  this	  study	  are	  tentative	  
due	  to	  a	  small	  sample	  size	  (n=14)	  and	  a	  lack	  of	  inferential	  statistical	  analysis.	  	  	  
	  
A	  longitudinal	  study	  measuring	  types	  of	  barrier	  to	  ART	  adherence	  across	  four	  
separate	  clinic	  visits	  in	  HIV+	  adults	  revealed	  at	  least	  one	  problem	  with	  daily	  structure	  
or	  routine	  in	  66%	  of	  503	  appointments	  	  (Genberg,	  Lee,	  Rogers,	  &	  Wilson,	  2014).	  	  This	  
was	  the	  most	  frequently	  cited	  barrier	  to	  ART	  adherence	  and	  was	  associated	  with	  
reduced	  levels	  of	  adherence	  over	  time,	  as	  measured	  by	  an	  electronic	  monitoring	  
system.	  	  Genberg	  and	  colleagues	  report	  these	  results	  as	  supportive	  of	  similar	  
findings	  in	  other	  research	  in	  HIV+	  populations	  in	  developing	  and	  developed	  countries	  	  
(MacDonell	  et	  al.,	  2013;	  Mills	  et	  al.,	  2006;	  Murphy	  et	  al.,	  2003).	  	  
	  
Following	  structured	  interviews	  with	  BHIV+	  young	  people	  and	  medical	  record	  
review,	  Murphy	  and	  colleagues	  compiled	  a	  list	  of	  19	  potential	  barriers	  to	  adherence	  	  
(Murphy	  et	  al.,	  2003).	  A	  further	  114	  BHIV+	  adolescents	  (age	  12-­‐19)	  were	  asked	  to	  
rate,	  depending	  on	  how	  often	  they	  experienced	  each	  barrier;	  scores	  ranged	  from	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‘never’	  to	  ‘often’	  on	  a	  four-­‐point	  scale.	  	  Combining	  ‘sometimes’	  and	  ‘often’	  
responses,	  two	  of	  the	  three	  most	  endorsed	  reasons	  for	  non-­‐adherence	  in	  this	  group	  
were	  related	  to	  daily	  activity	  or	  routine:	  did	  not	  have	  medication	  with	  them	  (42%)	  
and	  change	  in	  daily	  routine	  (33%);	  the	  third	  reason	  was	  simply	  forgetting	  (46%).	  	  It	  is	  
possible	  that	  similar	  barriers	  may	  apply	  to	  PHIV+	  adolescents.	  	  In	  a	  survey	  of	  PHIV+	  
and	  BHIV+	  young	  people	  MacDonell	  and	  colleagues	  adapted	  the	  19	  potential	  barriers	  
from	  Murphy	  and	  colleagues’	  investigation,	  to	  investigate	  possible	  differences	  
between	  groups	  	  (MacDonell	  et	  al.,	  2013).	  	  Participants	  were	  required	  to	  respond	  
with	  ‘yes’	  or	  ‘no’	  depending	  on	  whether	  each	  factor	  had	  interfered	  with	  their	  
adherence	  over	  the	  past	  seven	  days.	  	  The	  authors	  found	  no	  significant	  difference	  
between	  groups’	  endorsement	  of	  “got	  in	  the	  way	  of	  my	  daily	  schedule”	  as	  a	  barrier	  
to	  adherence.	  	  Therefore,	  difficulties	  in	  daily	  routine	  may	  contribute	  to	  
nonadherence	  in	  PHIV+	  youth.	  	  	  
	  
These	  findings	  suggest	  routine	  is	  a	  key	  determinant	  of	  ART	  adherence.	  	  However,	  
routine	  may	  vary	  over	  time,	  which	  may	  differentially	  influence	  ART	  adherence	  in	  
particular	  contexts.	  	  Each	  of	  these	  investigations	  neglects	  potential	  contextual	  
influence,	  which	  could	  be	  measured	  in	  relation	  to	  ART	  adherence	  in	  PHIV+	  young	  
people.	  	  
Forgetting	  
Not	  all	  non-­‐adherence	  is	  intentional	  or	  conscious,	  rather	  forgetting	  is	  an	  often-­‐cited,	  
significant	  explanation	  for	  failing	  to	  take	  medication	  (e.g.	  Buchanan	  et	  al.,	  2012;	  
Macdonell,	  Naar-­‐King,	  Murphy,	  Parsons,	  &	  Huszti,	  2011;	  MacDonell	  et	  al.,	  2013).	  	  In	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a	  sample	  of	  PHIV+	  120	  children	  and	  young	  adults	  (age	  >8-­‐19)	  and	  their	  caregivers,	  
participants	  were	  supplied	  with	  possible	  reasons	  for	  missing	  ART	  doses	  and	  asked	  to	  
rate	  how	  often	  they/their	  child	  missed	  their	  medication	  due	  to	  each	  factor	  (on	  a	  
scale	  of	  never	  to	  always).	  	  Forgetting	  was	  the	  most	  common	  reported	  barrier	  
amongst	  both	  PHIV+	  youth	  and	  their	  caregivers	  	  (Buchanan	  et	  al.,	  2012).	  	  	  
Somatic	  symptoms	  
In	  a	  Nigerian	  study	  of	  children	  (age	  3	  to	  18),	  the	  most	  common	  reasons	  for	  non-­‐
adherence,	  as	  reported	  by	  caregivers	  and	  young	  patients,	  were	  due	  to	  being	  asleep	  
or	  because	  of	  vomiting.	  	  Although	  these	  children	  were	  of	  a	  young	  age,	  feeling	  
physically	  well	  or	  unwell	  has	  been	  linked	  with	  adherence	  in	  other	  chronic	  conditions	  
in	  adults,	  children	  and	  adolescents	  	  (Hanghøj	  &	  Boisen,	  2014).	  	  In	  HIV+	  participants	  
age	  16-­‐24,	  experiencing	  physical	  symptoms	  such	  as	  rash	  or	  headache,	  or	  feeling	  sick	  
or	  vomiting	  were	  rated	  as	  most	  likely	  to	  cause	  non-­‐adherence	  amongst	  those	  young	  
people	  who	  were	  prescribed	  ART	  	  (Macdonell	  et	  al.,	  2011).	  	  Between	  groups	  of	  
optimal	  and	  suboptimal	  adherers,	  the	  experience	  of	  adverse	  physical	  symptoms	  was	  
rated	  most	  highly	  as	  a	  barrier	  to	  adherence	  in	  adolescents	  with	  less	  than	  90%	  
adherence	  in	  the	  previous	  month.	  	  (This	  study	  is	  discussed	  further	  in	  regard	  to	  
substance	  use,	  below,	  and	  within-­‐participant	  differences	  in	  adherence,	  in	  a	  later	  
section	  (p	  43).)	  	  
Substance	  use	  
Alcohol	  and	  substance	  misuse	  is	  prevalent	  amongst	  teenagers	  and	  young	  adults.	  	  
Age	  at	  first	  use	  of	  marijuana	  was	  significantly	  predictive	  of	  self-­‐reported	  non-­‐
adherence	  in	  42	  adolescents	  age	  16-­‐25	  with	  HIV	  	  (Hosek,	  Harper,	  &	  Domanico,	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2005).	  	  It	  was	  not	  clear	  in	  this	  study	  by	  which	  route	  the	  participants	  were	  infected.	  	  	  
HIV+	  adolescents	  (n=186)	  were	  asked	  to	  predict	  possible	  factors	  that	  may	  tempt	  
them	  not	  to	  take	  ART.	  	  Being	  drunk	  or	  high	  was	  rated	  as	  the	  reason	  fourth	  most	  
likely	  to	  be	  a	  barrier	  to	  adherence	  (behind	  physical	  symptoms,	  vomiting	  and	  
forgetting)	  	  (Macdonell	  et	  al.,	  2011).	  	  In	  this	  sample,	  however,	  not	  all	  participants	  
were	  prescribed	  ART	  medications.	  	  Of	  those	  prescribed	  ART,	  there	  were	  no	  
differences	  on	  situational	  temptation	  not	  to	  adhere	  due	  to	  being	  under	  the	  influence	  
of	  alcohol	  or	  street	  drugs	  between	  optimal	  and	  suboptimal	  adherers.	  	  Furthermore,	  
the	  HIV+	  young	  people	  in	  this	  sample	  were	  both	  behaviourally-­‐	  and	  perinatally-­‐
infected.	  	  Therefore,	  it	  is	  unclear	  to	  what	  extent	  substance	  use	  may	  influence	  
adherence	  in	  an	  adolescent	  PHIV+	  sample.	  
Critique	  of	  existing	  literature	  
The	  factors	  presented	  here	  frequently	  occur	  in	  the	  literature	  as	  barriers	  associated	  
with	  adherence,	  but	  there	  are	  a	  number	  of	  methodological	  factors	  that	  prevent	  
conclusive	  inferences	  about	  determinants	  of	  ART	  adherence	  in	  young	  people	  with	  
PHIV+	  from	  being	  drawn.	  	  Firstly,	  the	  samples	  of	  young	  people	  are	  often	  not	  clearly	  
described	  in	  terms	  of	  route	  of	  transmission	  of	  the	  HIV	  infection.	  	  There	  are	  particular	  
characteristics	  of	  perinatal	  HIV	  infection	  that	  set	  it	  apart	  from	  other	  long-­‐term	  
diseases	  or	  behavioural	  HIV	  infection,	  such	  as	  a	  history	  of	  suboptimal	  or	  ineffective	  
ART	  regimen	  and	  more	  compromised	  health	  from	  greater	  exposure	  to	  HIV	  infection	  
prior	  to	  the	  introduction	  of	  ART.	  	  Although	  comparisons	  can	  be	  made	  with	  
adolescents	  growing	  up	  with	  other	  conditions,	  or	  with	  adults	  living	  with	  HIV,	  the	  
combination	  of	  being	  an	  adolescent	  growing	  up	  with	  HIV	  must	  be	  considered	  when	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studying	  adherence	  in	  this	  population.	  Secondly,	  some	  important	  constructs	  are	  not	  
measured	  in	  the	  majority	  of	  the	  studies	  described	  above,	  such	  as	  normative	  beliefs	  
about	  and	  attitudes	  towards	  ART,	  outcome	  expectancies,	  and	  affect.	  	  Thirdly,	  how	  
barriers	  to	  adherence	  were	  assessed	  or	  how	  adherence	  was	  measured	  is	  not	  always	  
stated;	  scales	  of	  established	  reliability	  or	  validity	  are	  rarely	  used	  in	  the	  above	  studies.	  
Furthermore,	  in	  all	  of	  the	  studies	  described	  thus	  far,	  adherence	  is	  assessed	  over	  a	  
period	  of	  time	  using	  averages	  and	  frequencies	  as	  a	  measure	  of	  global	  adherence,	  
rather	  than	  focusing	  on	  specific	  adherent	  or	  non-­‐adherent	  events	  as	  a	  measure	  of	  
episodic	  adherence.	  	  Assessing	  adherence	  over	  a	  time	  period	  may	  be	  less	  reliable	  
than	  asking	  participants	  about	  a	  specific	  episode.	  	  Much	  of	  the	  research	  into	  barriers	  
or	  facilitators	  of	  adherence	  reports	  on	  self-­‐reported	  reasons	  for	  generally	  adhering	  
or	  not	  adhering	  to	  their	  medication.	  	  Cited	  reasons	  may	  not	  be	  reliable	  due	  to	  a	  lack	  
of	  insight	  into	  what	  causes	  non-­‐adherence.	  	  	  In	  addition,	  the	  ways	  in	  which	  these	  
constructs	  are	  measured	  in	  relation	  to	  adherence	  or	  non-­‐adherence	  is	  mostly	  cross-­‐
sectional	  and	  assesses	  adherence	  differences	  between	  individuals.	  	  There	  is	  little	  
understanding	  of	  how	  factors	  relating	  to	  adherence	  may	  vary	  within	  an	  individual.	  	  
(The	  limited	  literature	  on	  within-­‐participants	  medication	  adherence	  is	  discussed	  in	  
the	  following	  section.)	  	  Finally,	  there	  is	  a	  paucity	  of	  adherence	  research	  informed	  by	  
health-­‐behaviour	  theory.	  	  This	  is	  discussed	  further	  in	  a	  later	  section	  of	  this	  chapter,	  
‘Health	  Behaviour	  Theory’.	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Within-­‐Participants	  Research	  
The	  majority	  of	  existing	  research	  in	  HIV	  focuses	  on	  between-­‐subjects	  correlates	  of	  
ART	  adherence	  whereby	  comparisons	  are	  made	  between	  generally	  ‘good	  adherers’	  
and	  ‘poor	  adherers’	  reporting	  their	  adherence	  over	  a	  period	  of	  time	  	  (Nichols	  et	  al.,	  
2012;	  Rudy	  et	  al.,	  2009).	  	  Much	  less	  attention	  has	  been	  paid	  to	  within-­‐participant	  
variation	  in	  adherence.	  	  Adherence	  is	  not	  a	  stable	  trait;	  research	  suggests	  40-­‐50%	  of	  
patients	  across	  conditions	  are	  ‘inconsistently	  adherent’,	  intentionally	  or	  
unintentionally	  skipping	  doses	  or	  taking	  breaks	  from	  medication	  for	  longer	  periods	  
(Bosworth	  et	  al.,	  2012).	  	  	  	  Therefore	  within-­‐participant	  designs	  allow	  one	  to	  
investigate	  the	  factors	  related	  to	  variability	  in	  adherence	  in	  different	  situations	  in	  
individuals.	  	  	  	  
	  
One	  qualitative	  study	  has	  described	  within-­‐participants	  differences	  in	  ART	  adherence	  
in	  HIV+	  adult	  drug	  users	  (Wagner	  &	  Ryan,	  2004).	  	  The	  authors	  found	  routine	  and	  
changes	  to	  daily	  activities	  were	  associated	  with	  taking	  medication.	  	  However,	  in	  this	  
research,	  psychological	  factors	  were	  not	  assessed.	  	  There	  may	  be	  particular	  
situational	  psychological	  factors	  that	  also	  influence	  adherence,	  perhaps	  as	  potential	  
mediators	  of	  the	  relationship	  between	  routine	  or	  changes	  to	  daily	  activity	  and	  
adherence.	  	  These	  findings	  were	  in	  a	  specific	  subpopulation	  of	  HIV+	  individuals:	  
there	  may	  be	  differences	  in	  within-­‐participants	  variation	  in	  routine	  or	  daily	  activities	  
in	  younger	  participants.	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Event-­‐level	  design	  
It	  is	  also	  possible	  that	  there	  is	  difference	  in	  factors	  related	  to	  adherence	  within	  the	  
individual	  according	  to	  specific	  contexts.	  	  Variation	  in	  actual	  or	  perceived	  barriers	  to	  
or	  facilitators	  of	  adherence	  could	  be	  measured	  episodically,	  or	  relating	  to	  particular	  
adherent	  or	  non-­‐adherent	  events.	  	  Such	  a	  design	  may	  help	  to	  describe	  differences	  in	  
situational	  ART	  adherence.	  
	  
Only	  one	  study	  in	  adolescents	  describes	  situational	  factors	  that	  may	  influence	  
adherence	  and	  non-­‐adherence	  within	  young	  participants.	  	  MacDonell	  and	  colleagues	  
recruited	  82	  suboptimally	  adherent	  (<90%	  in	  the	  past	  month,	  as	  measured	  by	  self-­‐
report)	  and	  23	  optimally	  adherent	  (>=90%	  in	  the	  past	  month)	  young	  people	  with	  
behaviourally-­‐	  and	  perinatally-­‐infected	  HIV	  	  (Macdonell,	  Naar-­‐King,	  Murphy,	  Parsons,	  
&	  Huszti,	  2011).	  	  They	  were	  asked	  to	  predict	  what	  might	  hypothetically	  tempt	  them	  
not	  to	  take	  their	  medication	  in	  a	  variety	  of	  circumstances	  using	  a	  14-­‐item	  scale	  
(α=0.93).	  	  Participants	  rated	  how	  tempted	  they	  might	  be	  to	  miss	  their	  ART	  on	  a	  scale	  
of	  1	  –	  not	  at	  all	  tempted	  –	  to	  5	  –	  extremely	  tempted.	  	  The	  authors	  present	  
descriptive	  statistics	  to	  demonstrate	  the	  degree	  of	  temptation	  per	  item	  within	  the	  
whole	  sample.	  	  Independent	  t-­‐tests	  were	  carried	  out	  between	  groups	  of	  optimal	  and	  
suboptimal	  adherers	  to	  determine	  whether	  the	  hypothetical	  factors	  were	  related	  to	  
non-­‐adherence,	  as	  measured	  by	  the	  degree	  of	  endorsement	  in	  the	  suboptimal	  
adherence	  sample.	  	  These	  results	  demonstrated	  disconnection	  between	  the	  
expectation	  of	  which	  factors	  might	  be	  tempting	  and	  which	  factors	  were	  actually	  
tempting.	  That	  is,	  young	  people	  endorsed	  different	  situations	  as	  most	  tempting	  not	  
to	  adhere	  to	  ART	  than	  those	  that	  were	  statistically	  different	  between	  optimally	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adherent	  and	  suboptimally	  adherent	  young	  people.	  	  This	  suggests	  a	  degree	  of	  
unreliability	  in	  self-­‐reporting	  related	  to	  hypothetical	  non-­‐adherence.	  	  Therefore,	  an	  
event-­‐level	  design,	  where	  participants	  are	  required	  to	  report	  on	  an	  actual	  episode	  of	  
adherence	  or	  non-­‐adherence,	  may	  be	  beneficial.	  	  	  
	  
An	  event-­‐level/episodic	  design	  enables	  investigation	  of	  factors	  that	  relate	  to	  a	  given	  
adherent	  or	  non-­‐adherent	  episode.	  	  This	  promotes	  validity	  of	  remembering	  due	  to	  
the	  structure	  and	  scaffolding	  of	  participant	  recall	  as	  related	  to	  a	  specific	  event.	  These	  
designs	  have	  not	  been	  used	  in	  ART	  research,	  but	  have	  been	  the	  focus	  of	  other	  
studies	  of	  health	  behaviour,	  including:	  alcohol	  and	  condom	  use	  in	  healthy	  adults	  	  
(Leigh,	  2002),	  substance	  misuse	  and	  sexual	  risk	  in	  men	  who	  have	  sex	  with	  men	  	  
(Colfax	  et	  al.,	  2004),	  and	  marijuana	  use	  and	  condom	  use	  in	  adolescent	  women	  	  
(Hensel,	  Stupiansky,	  Orr,	  &	  Fortenberry,	  2011).	  	  Two	  investigations	  in	  Thalassaemia	  
and	  smoking	  in	  relation	  to	  self-­‐efficacy	  using	  event-­‐level	  design	  have	  also	  been	  
described	  above	  	  (Vosper	  et	  al.,	  2013;	  Van	  Zundert	  et	  al.,	  2011).	  	  Although	  event-­‐
level	  designs	  remain	  observational	  studies,	  they	  enable	  more	  robust	  inferences	  to	  be	  
drawn	  about	  relationships	  between	  constructs	  and	  particular	  episodes.	  	  	  
Health	  Behaviour	  Theory	  
The	  majority	  of	  literature	  on	  medication	  adherence,	  particularly	  in	  paediatric	  
populations,	  is	  atheoretical	  	  (Simoni	  et	  al.,	  2007).	  	  A	  PubMed	  search	  of	  HIV	  
adherence	  literature	  based	  on	  theory	  (including:	  HIV	  +	  adherence	  +	  theory	  in	  the	  
title/abstract,	  carried	  out	  on	  18th	  February	  2015)	  yields	  only	  108	  results	  versus	  over	  
6000	  articles	  on	  HIV	  adherence	  without	  theoretical	  links.	  	  Even	  fewer	  studies	  are	  
	   46	  
published	  using	  theory	  to	  inform	  adherence	  research	  in	  children	  and	  young	  people	  
(3).	  	  Of	  these	  three	  publications,	  one	  theory	  (Bronfenbrenner’s	  Social	  Ecological	  
Model)	  (Bronfenbrenner,	  1977)	  was	  used	  to	  interpret	  qualitative	  interviews	  only	  	  
(Coetzee,	  Kagee,	  &	  Bland,	  2015).	  	  The	  remaining	  two	  studies	  were	  informed	  by	  the	  
Information-­‐Motivation-­‐Behavioural	  Skills	  Model	  	  (Fisher	  &	  Fisher,	  1992)	  and	  are	  
discussed	  in	  further	  detail	  below	  	  (Dima	  et	  al.,	  2013;	  Rongkavilit	  et	  al.,	  2010);	  both	  
were	  small,	  qualitative	  investigations.	  	  There	  are	  no	  studies	  to	  date	  that	  focus	  on	  
ART	  adherence	  in	  PHIV+	  young	  people	  that	  are	  informed	  by	  theory.	  	  
	  
In	  the	  adult	  literature,	  theoretical	  models	  that	  are	  applied	  most	  often	  to	  ART	  
adherence	  are	  those	  that	  incorporate	  multiple	  influences	  including	  self-­‐efficacy,	  
social	  support,	  problem	  solving	  and	  coping	  	  (Kaufman,	  Cornish,	  Zimmerman,	  &	  
Johnson,	  2014).	  Such	  models	  include:	  the	  Necessity	  Concern	  Framework	  (Horne,	  
2006),	  Social	  Cognitive	  Theory	  (Bandura,	  1986)	  and	  the	  Information-­‐Motivation-­‐
Behavioural	  Skills	  (IMB)	  model	  (Fisher	  &	  Fisher,	  1992).	  
Necessity	  Concerns	  Framework	  
The	  Necessity	  Concerns	  Framework	  (Horne,	  2006)	  identifies	  general	  attitudes	  
towards	  medication	  alongside	  specific	  beliefs	  about	  particular	  medicines.	  	  According	  
to	  this	  model,	  general	  beliefs	  are	  thought	  to	  impact	  on	  specific	  beliefs,	  which	  
subsequently	  impact	  on	  adherence	  behaviour.	  	  The	  specific	  beliefs	  are	  grouped	  into	  
beliefs	  about	  how	  necessary	  it	  is	  to	  take	  medication	  (necessity)	  and	  beliefs	  about	  
risks	  associated	  with	  taking	  or	  not	  taking	  the	  medication	  (concerns),	  relating	  to	  side	  
effects,	  for	  example.	  	  The	  Beliefs	  about	  Medicines	  Questionnaire	  	  (Horne,	  2006)	  was	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specifically	  developed	  to	  measure	  these	  constructs	  and	  has	  been	  used	  in	  a	  number	  
of	  populations	  across	  conditions,	  with	  a	  specific	  version	  related	  to	  ART	  	  (Horne	  et	  al.,	  
2007).	  	  In	  a	  randomised	  trial	  of	  ART,	  treatment	  adherence	  and	  beliefs	  about	  ART,	  low	  
adherence	  (as	  measured	  by	  <95%	  self-­‐reported	  adherence	  over	  48	  weeks	  or	  
discontinuing	  the	  study)	  was	  associated	  with	  significant	  doubts	  about	  the	  necessity	  
of	  ART	  and	  strong	  concerns	  about	  side	  effects.	  	  The	  concerns	  about	  side	  effects	  were	  
diminished	  when	  participants	  were	  switched	  to	  a	  once	  daily	  ART	  regimen	  with	  no	  
impact	  on	  viral	  load	  	  (Cooper	  et	  al.,	  2011).	  	  This	  may	  suggest	  that	  the	  concerns	  were	  
less	  important	  than	  the	  ART	  regimen	  itself	  as	  related	  to	  adherence.	  	  
	  
The	  Necessity	  Concern	  Framework	  primarily	  focuses	  on	  motivational	  constructs	  as	  
antecedents	  to	  health	  behaviour,	  not	  necessarily	  in	  keeping	  with	  some	  of	  the	  
empirical	  ART	  adherence	  literature	  which	  points	  to	  other	  determinants	  of	  adherence	  
or	  non-­‐adherence.	  	  The	  NCF	  may	  overlook	  the	  impact	  of	  personal	  adherence	  skills	  
and	  self-­‐efficacy,	  or	  the	  confidence	  to	  enact	  these	  skills.	  	  Post-­‐motivation	  processes	  
may	  also	  be	  important	  to	  enable	  motivation	  to	  be	  enacted	  in	  the	  form	  of	  adherence	  
behaviour.	  	  
	  
Social	  Cognitive	  Theory	  
Bandura’s	  Social	  Cognitive	  Theory	  (SCT)	  (1986)	  departs	  from	  a	  primarily	  motivational	  
model	  (such	  as	  the	  NCF)	  and	  proposes	  a	  reciprocal	  relationship	  between	  personal	  
factors	  (including	  cognitive,	  affective,	  and	  biological),	  environmental	  factors	  and	  
behaviour	  which	  interact	  to	  determine	  motivation	  and	  action.	  	  The	  model	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emphasises	  the	  important	  influence	  of	  the	  social	  world	  and	  external	  and	  internal	  
social	  reinforcement.	  	  It	  stresses	  observational	  learning,	  or	  witnessing	  and	  
reproducing	  others’	  behaviour,	  as	  key	  to	  an	  individual’s	  future	  actions.	  
	  
This	  theory	  evolved	  from	  Social	  Learning	  Theory	  to	  explain	  how	  humans	  acquire	  and	  
maintain	  behaviour	  within	  a	  social	  context.	  	  Self-­‐efficacy,	  or	  the	  confidence	  one	  has	  
to	  perform	  an	  action	  competently,	  is	  included	  in	  SCT.	  As	  such	  it	  was	  one	  of	  the	  first	  
theories	  to	  highlight	  this	  as	  an	  important	  construct.	  In	  this	  model,	  self-­‐efficacy	  is	  also	  
influenced	  by	  individual	  and	  environmental	  factors.	  	  SCT	  has	  been	  applied	  to	  a	  
number	  of	  health	  behaviours	  and	  interventions,	  including	  smoking	  cessation,	  weight	  
management	  and	  contraceptive	  use	  	  (Maibach	  &	  Murphy,	  1995;	  Strecher,	  DeVellis,	  
Becker	  &	  Rosenstock,	  1986).	  
	  
Using	  SCT,	  Brown	  and	  colleagues	  (2013),	  investigated	  barriers	  to	  adherence	  in	  116	  
HIV+	  adults	  in	  a	  mid-­‐sized	  city	  in	  northeastern	  USA.	  	  Self-­‐reported	  suboptimal	  (<95%)	  
ART	  adherence	  was	  associated	  with	  reduced	  ART	  adherence	  self-­‐efficacy;	  fewer	  
negative	  outcome	  expectancies	  for	  non-­‐adherence,	  reduced	  perceived	  risk	  of	  ART	  
non-­‐adherence	  and	  reduced	  perceived	  need	  for	  ART.	  	  A	  logistic	  regression	  model	  
controlling	  for	  age,	  gender,	  ethnicity,	  duration	  of	  ART	  and	  number	  of	  daily	  pills	  found	  
suboptimal	  adherence	  was	  associated	  with	  lower	  levels	  of	  adherence	  self-­‐efficacy,	  
lower	  subjective	  beliefs	  about	  the	  importance	  of	  ART	  and	  a	  greater	  number	  of	  
perceived	  acceptable	  missed	  doses,	  with	  a	  high	  goodness	  of	  fit	  (p<0.001).	  	  ART	  
outcome	  expectancies,	  attitudes	  towards	  ART	  and	  perceived	  necessity	  of	  ART	  were	  
	   49	  
not	  associated	  with	  suboptimal	  adherence	  	  (Brown,	  Littlewood,	  &	  Vanable,	  2013).	  	  
This	  study	  highlights	  the	  importance	  of	  self-­‐efficacy	  in	  ART	  adherence	  in	  adults,	  but	  
did	  not	  find	  expected	  significant	  associations	  with	  outcome	  expectancy.	  	  This	  may	  
suggest	  a	  strong	  influence	  of	  self-­‐efficacy	  and	  a	  more	  variable	  influence	  of	  outcome	  
expectancy	  that	  warrants	  further	  investigation.	  	  	  
	  
Although	  SCT	  addresses	  the	  need	  for	  objective	  and	  perceived	  skills,	  normative	  social	  
support	  and	  adequate	  information,	  it	  does	  not	  include	  normative	  beliefs	  or	  
knowledge	  about	  a	  medication	  regime,	  which	  may	  be	  important	  for	  adherence	  
behaviour.	  	  Furthermore,	  it	  has	  only	  rarely	  been	  used	  to	  investigate	  ART	  adherence	  
and	  was	  not	  specifically	  designed	  for	  use	  in	  HIV+	  populations.	  
The	  Information-­‐Motivation-­‐Behavioural	  Skills	  Model	  (IMB)	  (Fisher	  &	  Fisher,	  1992)	  
IMB	  is	  a	  multivariate	  model	  informed	  by	  the	  Theory	  of	  Reasoned	  Action	  and	  the	  
Theory	  of	  Planned	  Behaviour.	  	  This	  framework	  emerged	  directly	  from	  the	  HIV	  
prevention	  literature.	  	  It	  has	  been	  applied	  to	  HIV-­‐related	  risk	  behaviours,	  including	  
promotion	  of	  contraception	  amongst	  adolescents,	  and	  has	  been	  adapted	  to	  be	  
specific	  to	  ART	  adherence	  (Fisher,	  Fisher,	  Amico,	  &	  Harman,	  2006).	  	  The	  adapted	  
model	  draws	  on	  research	  at	  the	  individual	  level	  in	  an	  effort	  to	  improve	  
understanding	  of	  the	  complex	  relationships	  in	  prescribing	  and	  adhering	  to	  ART	  
medication	  regimens.	  	  It	  describes	  the	  relevant	  behavioural	  and	  psychological	  
constructs	  in	  maintaining	  sufficient	  ART	  adherence	  in	  individuals	  with	  HIV	  under	  the	  
categories	  of:	  information,	  or	  understanding	  of	  the	  regimen,	  side	  effects	  and	  
personal	  theories	  (including	  misinformation)	  about	  the	  medication;	  motivation,	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which	  encompasses	  both	  personal	  motivation,	  or	  outcome	  expectancies	  and	  their	  
perceived	  importance,	  and	  social	  motivation,	  or	  the	  perception	  and	  importance	  of	  
others’	  wishes	  in	  relation	  to	  ART	  adherence;	  and	  behavioural	  skill,	  incorporating	  
objective	  skills	  in	  being	  able	  to	  take	  medication	  as	  well	  as	  perceived	  self-­‐efficacy	  in	  
using	  those	  skills	  	  (Fisher	  et	  al.,	  2014).	  	  	  The	  model	  also	  includes	  moderating	  variables	  
including	  mental	  health	  issues,	  unstable	  living	  situation	  and	  current	  substance	  
misuse	  	  (Amico,	  Barta,	  Konkle-­‐Parker,	  &	  Fisher,	  2009).	  
	  
A	  diagrammatical	  representation	  of	  the	  IMB	  model	  can	  be	  found	  below	  (Figure	  1)	  	  
(Fisher,	  Amico,	  Fisher,	  &	  Harman,	  2008).	  	  Solid	  line	  arrows	  indicate	  directional	  
relationships	  between	  constructs.	  	  The	  main	  determinant	  of	  adherence	  is	  
behavioural	  skill,	  which	  has	  been	  found	  to	  be	  related	  to	  medication	  adherence	  in	  
multiple	  studies	  across	  cultures	  (Puerto	  Rico:	  Amico	  et	  al.,	  2005;	  Italy:	  Starace	  et	  al.,	  
2006),	  across	  HIV	  populations	  in	  and	  out	  of	  clinic	  settings	  (Horvath,	  Smolenski,	  &	  
Amico,	  2014)	  and	  in	  other	  chronic	  health	  conditions	  such	  as	  diabetes	  (Mayberry	  &	  
Osborn,	  2014).	  	  Links	  between	  motivation	  and	  adherence	  are	  hypothesised	  to	  be	  
mediated	  by	  behavioural	  skills.	  	  The	  information	  construct	  is	  not	  always	  found	  to	  be	  
significant	  in	  tests	  of	  the	  model	  (Horvath	  et	  al.,	  2014).	  
	  
Each	  of	  the	  IMB	  constructs	  might	  vary	  according	  to	  situation,	  making	  this	  model	  well	  
suited	  to	  research	  of	  differences	  within	  individuals	  across	  contexts.	  	  In	  a	  study	  of	  
condom	  use	  using	  the	  IMB	  model,	  changes	  in	  behavioural	  skill	  over	  time	  were	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related	  to	  changes	  in	  condom	  use	  (Walsh,	  Senn,	  Scott-­‐Sheldon,	  Vanable,	  &	  Carey,	  
2011).	  	  
	  
This	  model	  has	  been	  applied	  to	  developing	  a	  computerised	  clinical	  intervention	  
demonstrating	  significant	  improvements	  in	  ART	  medication	  adherence	  in	  a	  recent	  
randomized	  control	  trial	  in	  HIV+	  adults	  (Fisher	  et	  al.,	  2011)	  and	  to	  other	  
interventions	  (Konkle-­‐Parker,	  Amico,	  &	  McKinney,	  2014)	  to	  promote	  HIV-­‐prevention	  
and	  adherence	  behaviours	  in	  HIV	  a	  variety	  of	  other	  chronic	  conditions	  (Chang,	  Choi,	  
Kim,	  &	  Song,	  2014).	  
	  
Figure	  1.	  The	  Information-­‐Motivation-­‐Behavioural	  Skills	  Model	  of	  ART	  Adherence	  (from	  Fisher,	  et	  al,	  2006)	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In	  adherence	  research	  with	  HIV+	  adolescents,	  the	  IMB	  model	  has	  only	  been	  applied	  
in	  two	  qualitative	  studies:	  one	  investigation	  with	  BHIV+	  Thai	  youth	  	  (Rongkavilit	  et	  
al.,	  2010)	  and	  one	  with	  young	  Romanian	  individuals	  with	  long-­‐term	  HIV+	  status	  
(nosocomically	  infected,	  acquired	  through	  contaminated	  blood	  transfusion	  or	  non-­‐
sterile	  medical	  equipment,	  at	  an	  early	  age)	  	  (Dima,	  Schweitzer,	  &	  Amico…,	  2013)	  .	  	  
Dima	  and	  colleagues	  held	  small,	  semi-­‐structured	  focus-­‐group	  discussions	  to	  which	  
they	  invited	  small	  numbers	  of	  young	  patients	  (age	  13-­‐20)	  and	  healthcare	  
professionals.	  	  Their	  interview	  structure	  broadly	  grouped	  questions	  into	  information,	  
motivation,	  behavioural	  skills	  and	  general	  themes.	  	  They	  conducted	  thematic	  
analysis	  to	  assess	  the	  relevance	  of	  the	  IMB	  model’s	  concepts	  to	  their	  population	  and	  
concluded	  that	  it	  was	  a	  valid	  theoretical	  framework	  on	  which	  to	  investigate	  
facilitators	  of	  and	  barriers	  to	  medication	  adherence.	  	  The	  patient	  participants	  in	  this	  
study	  were	  nosocomially	  infected	  at	  an	  early	  age,	  so	  do	  not	  correspond	  exactly	  to	  
the	  PHIV+	  population	  under	  investigation	  in	  this	  study.	  	  However,	  they	  are	  likely	  to	  
share	  a	  number	  of	  characteristics	  due	  to	  the	  long	  duration	  of	  their	  infection.	  	  The	  
researchers	  in	  Thailand	  were	  interested	  in	  investigating	  whether	  the	  IMB	  model	  
would	  apply	  to	  youth	  living	  in	  a	  more	  collectivist	  culture	  (Rongkavilit,	  et	  al,	  2010).	  	  
They	  found	  support	  for	  all	  IMB	  constructs	  in	  their	  data.	  	  The	  motivation	  construct	  
was	  particularly	  endorsed	  through	  statements	  regarding:	  the	  social	  influence	  of	  
partners	  and	  other	  family	  members	  on	  adherence;	  a	  sense	  of	  responsibility	  to	  
others;	  and	  belief	  in	  the	  health	  benefits	  of	  ART.	  	  The	  authors	  emphasise	  social	  
motivation	  as	  key	  to	  adherence	  in	  their	  sample,	  however	  there	  appears	  to	  be	  a	  
conflating	  influence	  of	  practical	  social	  support	  in	  their	  conclusions.	  	  That	  is,	  within	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the	  IMB	  model,	  social	  motivation	  refers	  to	  the	  perception	  of	  having	  support	  to	  
adhere	  to	  ART	  from	  others,	  not	  the	  actual	  presence	  or	  absence	  of	  others.	  	  	  
	  
Research	  into	  individual	  differences,	  such	  as	  variation	  in	  adherence	  behaviour,	  must	  
remain	  grounded	  in	  theory	  (Johnston	  &	  Johnston,	  2013)	  .	  	  Furthermore,	  Fishbein	  
argues	  that	  the	  role	  of	  behavioural	  sciences	  in	  managing	  HIV	  is	  to	  develop	  theory-­‐
driven	  interventions	  to	  promote	  health	  affirming	  and	  reduce	  risky	  behaviours	  (2000).	  	  
There	  is	  a	  case	  for	  using	  the	  IMB	  model	  as	  a	  framework	  for	  the	  present	  study	  with	  a	  
UK-­‐based	  PHIV+	  adolescent	  population	  investigating	  within-­‐participant	  differences.	  	  	  
No	  quantitative	  investigation	  of	  ART	  adherence	  factors	  in	  adolescents	  has	  used	  the	  
IMB	  theory	  to	  inform	  the	  research.	  	  A	  quantitative	  approach	  allows	  one	  to	  look	  at	  
the	  magnitude	  of	  relationships	  and	  comparisons	  between	  variables.	  	  A	  within-­‐
participant,	  event	  level	  design	  enables	  the	  study	  of	  factors	  that	  are	  related	  to	  
specific	  episodes	  of	  individual	  variation	  in	  adherence	  behaviour.	  	  
	  
Interventions	  to	  Promote	  Adherence	  
The	  clinical	  utility	  of	  understanding	  adherence	  behaviour	  is	  to	  inform	  intervention	  to	  
improve	  and	  promote	  treatment	  adherence.	  	  A	  list	  of	  strategies	  that	  have	  been	  used	  
with	  PHIV+	  children	  and	  young	  people	  to	  promote	  ART	  adherence	  can	  be	  found	  in	  
the	  table	  below	  	  (Agwu	  &	  Fairlie,	  2013).	  	  Strategies	  are	  categorised	  into	  those	  that	  
address	  medication	  barriers,	  patient-­‐related	  factors	  and	  behavioural	  interventions.	  	  
Few	  intervention	  studies	  focus	  on	  PHIV+	  young	  people	  specifically.	  	  One	  recent	  trial	  
combined	  financial	  incentives	  with	  motivational	  interviewing	  for	  a	  small	  sample	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(n=11)	  of	  British	  PHIV+	  16-­‐25	  year	  olds	  with	  advanced	  disease	  (CD4	  <200	  cells/	  μl)	  
who	  had	  poor	  adherence	  and	  were	  transitioning	  from	  paediatric	  to	  adult	  services.	  	  
There	  were	  improvements	  on	  viral	  load	  and	  CD4	  count	  	  (Foster,	  McDonald,	  Frize,	  
Ayers,	  &	  Fidler,	  2014).	  	  This	  study	  was	  a	  small	  pilot	  with	  a	  subgroup	  of	  PHIV+	  young	  
people	  and	  it	  is	  not	  clear	  how	  successful	  this	  intervention	  would	  be	  in	  other	  
adolescents	  with	  more	  inconsistent	  adherence.	  	  A	  second	  pilot	  project	  with	  PHIV+	  
young	  people	  in	  the	  USA	  combined	  group	  and	  individual	  behavioural	  therapy	  with	  
the	  aim	  of	  improving	  HIV-­‐related	  knowledge,	  disease	  management	  skills	  and	  
reducing	  risky	  behaviours	  	  (Chandwani,	  Abramowitz,	  Koenig,	  Barnes,	  &	  D’Angelo,	  
2011).	  	  In	  their	  report,	  the	  authors	  describe	  only	  the	  acceptability	  of	  the	  intervention	  
to	  the	  young	  people	  by	  attendance	  rates:	  there	  is	  no	  measure	  of	  adherence	  
outcome.	  	  Other	  interventions	  have	  been	  tailored	  to	  particular	  HIV+	  subpopulations,	  
such	  as	  LGBT	  youth	  	  (Thurston	  et	  al.,	  2014).	  
	  
There	  is	  no	  ‘gold	  standard’	  intervention	  to	  address	  ART	  non-­‐adherence	  in	  
adolescents	  or	  adults	  	  (Agwu	  &	  Fairlie,	  2013),	  nor	  do	  published	  guidelines	  specify	  
exactly	  which	  strategies	  should	  be	  use	  to	  manage	  barriers	  to	  promote	  adherence	  
(BHIVA,	  2014).	  	  	  A	  number	  of	  systematic	  reviews	  have	  recently	  been	  published	  in	  
relation	  to	  adherence	  interventions	  in	  HIV+	  adults,	  children	  and	  adolescents	  	  
(Arrivillaga,	  Martucci,	  Hoyos,	  &	  Arango,	  2013;	  Bain-­‐Brickley,	  Butler,	  Kennedy,	  &	  
Rutherford,	  2011;	  Chaiyachati	  et	  al.,	  2014).	  	  Such	  interventions	  are	  often	  multi-­‐
faceted	  and	  combine	  two	  or	  more	  components.	  	  Most	  often,	  these	  approaches	  
include:	  education	  and/or	  general	  counselling,	  motivational	  interviewing,	  cognitive-­‐
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behavioural	  therapy,	  directly-­‐observed	  therapy,	  financial	  incentives	  and	  social	  
support,	  or	  treatment	  ‘buddies’	  	  (Chandwani	  et	  al.,	  2011;	  Cooperman	  &	  Arnsten,	  
2005;	  Lyon	  et	  al.,	  2003;	  Mbuagbaw,	  Ye,	  &	  Thabane,	  2012).	  	  However,	  many	  
adherence	  interventions	  have	  no	  observable	  or	  sustained	  effect	  on	  treatment	  
outcomes	  	  (Mathes,	  Pieper,	  Antoine,	  &	  Eikermann,	  2013).	  	  In	  a	  systematic	  review	  of	  
all	  published	  interventions	  for	  HIV+	  young	  people	  only,	  just	  four	  met	  criteria	  for	  
inclusion	  (randomised	  or	  non-­‐randomised	  controlled	  trials	  of	  interventions	  to	  
improve	  adherence	  to	  ART	  among	  children	  and	  adolescents	  (age	  ≤18	  years),	  with	  
ART	  adherence	  reported	  as	  an	  outcome).	  	  Of	  these	  four	  studies,	  no	  intervention	  
resulted	  in	  significant	  or	  sustained	  change	  in	  ART	  adherence	  	  (Bain-­‐Brickley	  et	  al.,	  
2011).	  	  Many	  other	  studies	  neglect	  to	  measure	  adherence	  as	  a	  specific	  outcome	  of	  
the	  intervention,	  or	  are	  observational	  in	  nature,	  and	  lack	  a	  control	  group.	  	  	  
	  
The	  process	  of	  adherence	  is	  idiosyncratic:	  facilitators	  of	  or	  barriers	  to	  adherence	  may	  
fluctuate;	  there	  may	  be	  a	  dynamic	  interaction	  between	  contextual	  and	  psychological	  
factors	  (Buchanan	  et	  al.,	  2012;	  Reisner	  et	  al.,	  2009).	  	  Therefore	  an	  episodic	  within-­‐
participants	  investigation	  of	  determinants	  of	  adherent	  and	  non-­‐adherent	  episodes	  is	  
indicated	  as	  complementary	  to	  the	  existing	  literature	  on	  factors	  associated	  with	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Table	  1:	  Strategies	  used	  to	  promote	  ART	  adherence	  in	  PHIV+	  youth	  (Agwu	  &	  Fairlie,	  2013)	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Introduction	  to	  the	  study	  
This	  study	  focuses	  on	  situational	  behavioural	  and	  theoretically	  driven	  psychological	  
factors	  and	  ART	  adherence	  in	  young	  people	  with	  PHIV+.	  	  This	  addresses	  the	  gap	  in	  
the	  adherence	  literature	  concerning	  within-­‐participant	  determinants	  of	  actual	  
adherent	  or	  non-­‐adherent	  events	  in	  this	  population.	  	  	  
	  
The	  aims	  are	  to	  quantitatively	  explore	  psychological	  situational	  factors	  and	  episodes	  
of	  adherence	  and	  non-­‐adherence	  to	  ART.	  	  An	  event-­‐level	  design	  is	  used	  to	  
investigate	  specific	  adherent	  and	  non-­‐adherent	  episodes.	  	  The	  study	  aims	  to	  
investigate	  whether	  the	  relationship	  between	  psychological	  situational	  variables	  and	  
adherence	  is	  consistent	  with	  the	  IMB	  model.	  	  Additional	  factors	  from	  previous	  




The	  main	  research	  questions	  for	  this	  study	  (consistent	  with	  the	  IMB	  model)	  are	  as	  
follows:	  
1) Are	  there	  differences	  in	  levels	  of	  HIV	  adherence	  information	  between	  an	  
episode	  of	  ART	  adherence	  and	  an	  episode	  of	  non-­‐adherence?	  
2) Are	  there	  differences	  in	  levels	  of	  HIV	  adherence	  motivation	  between	  an	  
episode	  of	  ART	  adherence	  and	  an	  episode	  of	  non-­‐adherence?	  
3) Are	  there	  differences	  in	  levels	  of	  HIV	  adherence	  behavioural	  skill(s)	  between	  
an	  episode	  of	  ART	  adherence	  and	  an	  episode	  of	  non-­‐adherence?	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4) Are	  there	  differences	  in	  situational	  emotional	  states	  between	  an	  episode	  of	  
ART	  adherence	  and	  an	  episode	  of	  non-­‐adherence?	  
5) Are	  there	  differences	  in	  situational	  street	  drug	  or	  alcohol	  use	  between	  an	  
episode	  of	  ART	  adherence	  and	  an	  episode	  of	  non-­‐adherence?	  
	  
In	  addition,	  secondary	  to	  the	  above:	  are	  there	  differences	  in	  behavioural	  situational	  
variables	  between	  an	  episode	  of	  adherence	  and	  an	  episode	  of	  non-­‐adherence?	  
Method	  
Event-­‐level	  design	  
An	  event-­‐level	  design	  was	  used.	  	  	  The	  approach	  required	  collection	  of	  quantitative	  
questionnaire	  data	  for	  the	  independent	  variables	  (described	  below)	  for	  separate	  
episodes	  of	  adherence	  and	  non-­‐adherence	  per	  participant.	  	  This	  within-­‐participant	  
design	  enabled	  static	  demographic	  variables	  (such	  as	  age,	  gender,	  ethnicity)	  to	  be	  
controlled	  for	  (as	  they	  did	  not	  vary	  within	  individual).	  
	  
The	  study	  had	  two	  components:	  a	  retrospective	  and	  a	  prospective	  component.	  
Identical	  questionnaires	  were	  administered	  retrospectively	  and	  prospectively	  (see	  
Appendix	  13).	  The	  prospective	  part	  of	  the	  study	  aimed	  to	  limit	  possible	  recall	  bias	  in	  
retrospective	  reporting.	  	  The	  questionnaire	  was	  constructed	  using	  elements	  of	  the	  
Day	  Reconstruction	  Method	  to	  reduce	  recall	  bias	  of	  the	  retrospective	  report	  	  
(Kahneman,	  Krueger,	  Schkade,	  Schwarz,	  &	  Stone,	  2004).	  	  Situational	  behavioural	  
variables	  were	  presented	  first,	  prior	  to	  any	  ratings	  of	  situational	  psychological	  states,	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to	  enhance	  the	  detail	  of	  the	  episodic	  memory.	  	  These	  included	  the	  particular	  day	  of	  
the	  adherent	  or	  non-­‐adherent	  event,	  where	  the	  participant	  was	  at	  the	  time	  and	  who	  
was	  with	  them	  at	  the	  time	  (discussed	  further	  below).	  	  These	  variables	  were	  under	  
investigation	  as	  possible	  predictors	  of	  adherence	  or	  non-­‐adherence,	  but	  served	  a	  
dual	  function	  in	  orienting	  participants	  to	  the	  specific	  contextual	  details	  of	  the	  
episode.	  
Within-­‐participant	  variables	  
The	  dependent	  variable	  for	  both	  retrospective	  and	  prospective	  components	  was	  
bivariate:	  adherent	  or	  non-­‐adherent	  episode.	  	  
	  	  
The	  main	  independent	  variables	  were	  chosen	  to	  be	  consistent	  with	  the	  IMB	  model	  	  
(Fisher	  &	  Fisher,	  1992):	  	  
• Information,	  or	  factors	  related	  to	  how	  knowledgeable	  young	  people	  felt	  
about	  their	  ART	  regimen	  	  (Fisher	  et	  al.,	  2006).	  	  For	  this	  study,	  the	  information	  
construct	  referred	  to	  the	  subjective	  level	  of	  knowledge	  young	  people	  
possessed	  at	  the	  time	  of	  the	  scheduled	  dose	  and	  how	  knowledgeable	  they	  
felt	  in	  taking	  their	  medication	  in	  the	  specific	  context	  at	  that	  time.	  Although	  
level	  of	  knowledge	  does	  not	  change	  according	  to	  situation,	  different	  
situations	  demand	  access	  to	  different	  aspects	  of	  information.	  	  For	  example,	  
having	  not	  eaten	  or	  having	  consumed	  alcohol	  at	  the	  time	  of	  a	  dose	  may	  
impact	  on	  the	  ways	  in	  which	  medication	  should	  be	  taken.	  	  Therefore,	  the	  
type	  of	  information	  or	  knowledge	  required	  in	  relation	  to	  ART	  adherence	  may	  
vary	  according	  to	  situation.	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• Motivation,	  relating	  to	  personal	  and/or	  social	  motivation	  for	  taking	  
medication	  at	  the	  time	  of	  the	  adherent/non-­‐adherent	  episode.	  	  Personal	  
motivation	  encompasses	  one’s	  own	  attitudes	  towards	  or	  beliefs	  about	  the	  
medicines	  and	  the	  outcomes	  of	  adhering	  or	  not	  adhering	  and	  the	  subjective	  
importance	  of	  these	  outcomes.	  	  Social	  motivation	  involves	  the	  appraisal	  of	  
others’	  beliefs	  about	  the	  individual	  taking	  medication	  as	  well	  as	  an	  evaluation	  
of	  the	  importance	  of	  the	  other	  to	  the	  individual	  (Amico,	  Barta,	  Konkle-­‐Parker,	  
&	  Fisher,	  2009).	  
	  
• Behavioural	  skills,	  or	  the	  degree	  to	  which	  participants	  felt	  confident	  in	  their	  
abilities	  to	  take	  their	  medication	  at	  the	  time	  of	  adherence	  or	  non-­‐adherence	  
as	  well	  as	  their	  actual	  level	  of	  skill	  in	  taking	  the	  medication.	  	  It	  was	  not	  
possible	  to	  measure	  objective	  behavioural	  skills	  through	  self-­‐report	  
questionnaire.	  	  Therefore,	  this	  variable	  was	  operationalized	  as	  perceived	  
behavioural	  skills	  only,	  which	  is	  consistent	  with	  the	  usual	  approach	  to	  IMB	  
investigations	  	  (e.g.	  Dima,	  Schweitzer,	  &	  Amico…,	  2013;	  Horvath,	  Smolenski,	  
&	  Amico,	  2014;	  Rongkavilit	  et	  al.,	  2010)	  
	  
• Positive	  and	  negative	  affect,	  or	  situational	  emotional	  states.	  	  A	  lack	  of	  
positive	  affect,	  or	  feelings	  of	  pleasurable	  engagement,	  enthusiasm	  and	  
activity,	  is	  associated	  with	  depression	  in	  the	  tripartite	  model	  in	  adults,	  
children	  and	  adolescents	  	  (Chorpita	  &	  Daleiden,	  2002;	  Clark	  &	  Watson,	  1991).	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Negative	  affect	  also	  relates	  to	  states	  of	  mood	  and	  describes	  emotionally	  
distressing	  states	  such	  as	  fear,	  sadness	  and	  guilt.	  	  Experience	  of	  negative	  
affect	  is	  a	  shared	  component	  of	  both	  anxiety	  and	  depression;	  low	  positive	  
affect	  is	  specific	  to	  depression.	  	  	  Depression	  and	  low	  mood	  have	  often	  been	  
found	  to	  be	  associated	  with	  poor	  adherence	  to	  treatment	  in	  HIV	  and	  other	  
chronic	  health	  conditions	  in	  adults	  and	  adolescents	  	  (Chandwani	  et	  al.,	  2012;	  
Sheth	  et	  al.,	  2015;	  Taddeo	  et	  al.,	  2008;	  Uthman	  et	  al.,	  2014;	  Vasylyeva	  et	  al.,	  
2013).	  	  Mental	  health	  is	  included	  as	  a	  moderator	  in	  the	  IMB	  model.	  
	  
• Street	  drug	  and	  alcohol	  use.	  Use	  of	  substances	  has	  been	  linked	  with	  
nonadherence	  in	  adults	  and	  teenagers	  with	  HIV	  (Dewing	  et	  al.,	  2015;	  Hosek,	  
Harper,	  &	  Domanico,	  2005).	  Substance	  use	  or	  addiction	  is	  included	  as	  a	  
moderator	  in	  the	  IMB	  model.	  	  	  
	  
Situational	  variables	  not	  included	  in	  the	  IMB	  model,	  that	  have	  been	  linked	  with	  
adherence	  in	  several	  between-­‐participants	  studies	  of	  adherence	  in	  PHIV+	  young	  
people	  	  (e.g.	  Chandwani	  et	  al.,	  2012;	  Kang,	  Delzell,	  Chhabra,	  &	  Oberdorfer,	  2014;	  
Mutwa	  et	  al.,	  2013)and	  HIV+	  adults	  (e.g.	  Wagner	  &	  Ryan,	  2004)	  were	  also	  
investigated.	  	  These	  included	  where,	  when,	  and	  with	  whom	  the	  individual	  was	  at	  the	  
time	  medication	  was	  due.	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The	  extents	  to	  which	  a	  non-­‐adherent	  dose	  was	  perceived	  to	  be	  due	  to	  forgetting	  and	  
whether	  the	  adherent	  dose	  was	  perceived	  to	  be	  the	  young	  person’s	  choice	  were	  also	  
measured.	  
Sample	  
Adolescents	  and	  Adults	  Living	  with	  Perinatal	  HIV	  (AALPHI)	  Study	  	  
The	  Adolescents	  and	  Adults	  Living	  with	  Perinatal	  HIV	  (AALPHI)	  project	  is	  a	  
prospective	  cohort	  study	  of	  young	  people	  living	  with	  or	  affected	  by	  perinatal	  HIV	  
carried	  out	  in	  collaboration	  with	  the	  Medical	  Research	  Council	  Clinical	  Trials	  Unit	  
(http://www.ctu.mrc.ac.uk/our_research/research_areas/hiv/studies/aalphi/).	  	  The	  
study	  has	  recruited	  two	  groups,	  one	  group	  of	  PHIV+	  young	  people	  who	  have	  been	  
followed	  up	  in	  the	  Collaborative	  HIV	  Paediatric	  Study	  (CHIPS)	  project	  through	  
childhood;	  the	  second	  (control)	  group	  are	  HIV	  negative	  young	  people	  who	  have	  a	  
parent,	  sibling	  or	  friend	  with	  HIV.	  	  	  
	  
The	  AALPHI	  project	  follows	  young	  people	  from	  the	  CHIPS	  cohort	  with	  the	  aim	  of	  
describing	  the	  transitional	  period	  from	  paediatric	  to	  adult	  care.	  	  Participants	  are	  
interviewed	  to	  investigate	  the	  impact	  of	  prolonged	  ART	  and	  growing	  up	  with	  HIV	  in	  
domains	  of	  physical	  health	  and	  development	  as	  well	  as	  neurocognitive	  function	  and	  
psychosocial	  issues.	  	  Follow	  up	  interviews	  take	  place	  yearly	  for	  a	  planned	  period	  of	  
five	  years.	  	  At	  the	  time	  of	  this	  project,	  AALPHI	  was	  in	  the	  second	  year	  of	  data	  
collection.	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AALPHI	  interviews	  are	  carried	  out	  by	  three	  research	  nurses	  with	  experience	  in	  
paediatric	  and/or	  HIV	  care	  under	  the	  supervision	  of	  the	  principal	  investigator,	  an	  
epidemiologist.	  	  The	  nurses	  supported	  the	  current	  project	  in	  approaching	  and	  
introducing	  the	  study	  to	  eligible	  young	  people	  at	  the	  recruitment	  sites	  at	  the	  same	  
time	  as	  organising	  the	  second-­‐year	  AALPHI	  follow	  up	  interviews.	  	  	  
AALPHI	  Participants	  
Young	  people	  were	  recruited	  to	  participate	  in	  the	  AALPHI	  study	  via	  20	  clinics	  and	  
voluntary	  organisations	  across	  the	  UK,	  of	  which	  seven	  were	  outside	  of	  London.	  	  
Inclusion	  criteria	  for	  PHIV+	  young	  people	  to	  the	  AALPHI	  study	  included:	  
1. History	  of	  paediatric	  care	  in	  the	  UK	  
2. Perinatally	  infected/acquired	  HIV	  	  
3. At	  least	  13	  years	  of	  age	  and	  not	  older	  than	  21	  years	  at	  the	  time	  of	  enrolment	  
to	  AALPHI	  
4. Living	  in	  the	  UK	  for	  greater	  than	  6	  months	  
5. Able	  to	  give	  informed	  consent	  or	  assent	  
6. Able	  to	  speak	  and	  understand	  English	  
7. Willing	  to	  be	  followed	  up	  annually	  for	  the	  duration	  of	  the	  study	  
Young	  people	  outside	  this	  age	  range	  or	  who	  acquired	  HIV	  behaviourally	  were	  
excluded	  from	  AALPHI.	  	  PHIV+	  young	  people	  who	  had	  been	  aware	  of	  their	  HIV	  status	  
for	  six	  months	  or	  less	  were	  also	  excluded.	  	  	  
	  
Seventy-­‐three	  percent	  of	  the	  total	  AALPHI	  sample	  were	  recruited	  from	  London	  sites.	  	  
The	  median	  age	  at	  time	  of	  enrolment	  to	  the	  study	  was	  16	  (IQR=15-­‐18)	  and	  41%	  of	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the	  sample	  are	  male.	  	  Participants	  of	  black	  ethnicity	  comprised	  86%	  of	  the	  sample.	  	  
Almost	  all	  young	  people	  in	  AALPHI	  are	  single	  (99.7%)	  and	  1%	  are	  parents.	  	  Of	  the	  
total	  sample,	  93%	  live	  with	  their	  parent	  or	  parents.	  	  The	  median	  age	  of	  paediatric	  
disclosure	  (when	  the	  young	  person	  was	  told	  their	  HIV	  status)	  in	  the	  total	  AALPHI	  
sample	  is	  12	  (IQR	  11-­‐13).	  	  Eighty-­‐eight	  percent	  of	  the	  total	  AALPHI	  sample	  were	  
currently	  taking	  ART,	  comprising	  259	  people.	  	  Of	  these	  259,	  32%	  missed	  two	  or	  more	  
days	  in	  a	  row	  in	  the	  month	  prior	  to	  the	  interview	  (n=83).	  	  	  
	  
Sample	  size	  calculation	  
The	  target	  sample	  size	  was	  estimated	  using	  the	  bivariate	  analyses	  to	  inform	  the	  a-­‐
priori	  power	  calculation.	  	  No	  comparable	  within-­‐participant	  studies	  have	  been	  
conducted	  for	  ART	  adherence;	  therefore	  two	  comparable	  studies	  using	  similar	  
methodology	  in	  different	  health	  behaviours	  were	  selected	  for	  calculating	  effect	  size.	  	  
Both	  studies	  measured	  episodic	  differences	  in	  self-­‐efficacy	  and	  outcome	  
expectancies	  in	  health	  behaviours.	  	  Self-­‐efficacy	  is	  equivalent	  to	  the	  behavioural	  
skills	  construct	  in	  the	  present	  study;	  outcome	  expectancies	  is	  similar	  to	  personal	  
motivation.	  	  
	  
The	  first	  study,	  an	  investigation	  of	  within-­‐participant	  differences	  in	  medication	  
adherence	  in	  Thalassaemia	  	  (Vosper,	  Evangeli,	  Porter,	  &	  Shah,	  2013),	  found	  an	  effect	  
size	  of	  d=0.41	  	  (Cohen,	  1992)	  for	  outcome	  expectancies	  and	  d=1.09	  for	  self-­‐efficacy.	  	  
The	  second	  study	  measured	  within-­‐participant	  variation	  in	  self-­‐efficacy	  and	  outcome	  
expectancies	  related	  to	  smoking	  behaviour	  between	  relapse	  and	  no	  relapse	  days	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(Gwaltney,	  Shiffman,	  Balabanis,	  &	  Paty,	  2005).	  	  The	  difference	  between	  self-­‐efficacy	  
between	  relapse	  and	  no	  relapse	  had	  an	  effect	  size	  of	  d=0.62	  	  (Cohen,	  1992).	  	  For	  
outcome	  expectancies,	  Cohen’s	  d	  was	  calculated	  as	  d=0.75.	  	  	  
	  
The	  mean	  effect	  sizes	  from	  these	  studies	  for	  each	  variable	  were	  calculated	  at	  0.58	  
for	  outcome	  expectancies	  and	  0.86	  for	  self-­‐efficacy.	  	  These	  figures	  were	  used	  in	  the	  
a-­‐priori	  power	  calculations.	  	  Using	  a	  paired	  two-­‐tailed	  t-­‐test	  for	  calculating	  the	  mean	  
scores	  on	  behavioural	  skills	  between	  adherent	  and	  non-­‐adherent	  episodes	  and	  
estimating	  the	  effect	  size	  of	  0.86,	  power	  statistic	  β=0.8	  and	  alpha	  level	  p=0.05,	  the	  
minimum	  number	  of	  participants	  required	  is	  n=20	  (as	  calculated	  in	  G*Power).	  	  For	  
personal	  motivation,	  using	  an	  effect	  size	  of	  0.58,	  power	  statistic	  β=0.8	  and	  alpha	  
level	  p=0.05,	  the	  minimum	  number	  of	  participants	  required	  is	  n=41.	  
Recruitment	  sites	  
It	  was	  not	  possible	  to	  recruit	  from	  all	  AALPHI	  sites	  for	  the	  present	  study.	  	  A	  sub-­‐
sample	  of	  participants	  were	  recruited	  from	  two	  London	  hospitals,	  one	  London	  
voluntary-­‐sector	  organisation	  and	  one	  clinic	  outside	  of	  London.	  	  Of	  the	  London	  sites,	  
one	  hospital	  held	  two	  clinics:	  one	  paediatric	  and	  one	  transitional	  clinic	  from	  which	  
participants	  were	  recruited.	  The	  second	  London	  hospital	  had	  a	  smaller	  number	  of	  
patients	  with	  a	  single	  transition	  clinic	  from	  which	  participants	  were	  recruited.	  
	  
The	  voluntary-­‐sector	  organisation	  was	  based	  in	  central	  London	  and	  provides	  a	  
supportive	  social	  space	  for	  young	  people	  age	  13+	  once	  a	  week.	  	  Young	  people	  
already	  recruited	  to	  AALPHI	  who	  attended	  this	  centre	  were	  approached	  to	  take	  part	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in	  this	  study	  in	  between	  the	  workshops	  and	  events	  at	  the	  centre,	  so	  as	  not	  to	  
interfere	  with	  their	  time.	  Young	  people	  recruited	  outside	  of	  London	  all	  attended	  a	  
regional	  hospital	  clinic	  supported	  by	  both	  adult	  and	  paediatric	  services.	  	  No	  young	  
people	  attended	  nor	  were	  recruited	  from	  adult-­‐only	  clinics.	  
Inclusion/Exclusion	  criteria	  
Inclusion	  criteria	  for	  the	  current	  study	  were	  based	  on	  those	  from	  the	  larger	  AALPHI:	  
participants	  must	  have	  been	  enrolled	  in	  AALPHI	  to	  be	  eligible	  for	  this	  project.	  	  
Additionally,	  participants	  were	  only	  recruited	  from	  the	  sites	  mentioned	  above.	  	  The	  
final	  inclusion	  criteria	  for	  this	  project	  were	  for	  the	  young	  people	  to	  have	  been	  
currently	  taking	  ART	  medication	  and	  the	  ability	  to	  recall	  one	  adherent	  and	  one	  non-­‐
adherent	  event	  in	  the	  preceding	  two	  months.	  	  	  
	  
A	  missed	  dose	  or	  non-­‐adherent	  event	  in	  the	  last	  two	  months	  was	  assessed	  by	  asking	  
participants	  if	  they	  could	  remember	  a	  particular	  episode	  where	  they	  did	  not	  take	  
their	  medication	  as	  prescribed,	  i.e.	  a	  dose	  was	  skipped	  altogether	  for	  that	  day	  or	  
there	  was	  a	  very	  significant	  delay	  from	  when	  they	  were	  supposed	  to	  take	  their	  
medication.	  	  The	  time	  frame	  of	  two	  months	  was	  decided	  upon	  to	  balance	  recall	  
issues	  with	  normalising	  adherence.	  	  This	  is	  the	  same	  period	  used	  successful	  in	  a	  
previous	  study	  using	  this	  methodology	  in	  adults	  with	  Thalassaemia	  	  (Vosper	  et	  al.,	  
2013).	  	  In	  this	  study,	  the	  mean	  number	  of	  days	  of	  the	  non-­‐adherent	  event	  prior	  to	  
measurement	  was	  10	  days;	  of	  the	  adherent	  event,	  the	  mean	  number	  of	  days	  was	  
1.3.	  	  This	  suggests	  that	  most	  people	  were	  reporting	  both	  episodes	  within	  the	  
previous	  two	  weeks.	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Participants	  without	  capacity	  to	  consent	  for	  themselves	  were	  excluded,	  as	  were	  
young	  people	  without	  a	  good	  understanding	  of	  written	  and	  spoken	  English	  (a	  good	  
understanding	  defined	  as:	  able	  to	  understand	  verbal	  instructions	  and	  capable	  of	  
reading	  the	  information	  sheet	  and	  questionnaire	  independently).	  	  Young	  people	  with	  
significant	  cognitive	  impairment	  were	  not	  eligible	  for	  the	  study.	  	  	  
Sampling	  procedure	  	  
A	  systematic	  sampling	  method	  was	  used	  to	  reduce	  bias	  in	  recruitment.	  	  During	  the	  
study	  period,	  clinic	  lists	  for	  each	  of	  the	  London	  hospital	  sites	  were	  obtained.	  	  AALPHI	  
research	  nurses	  identified	  AALPHI	  participants	  from	  each	  list.	  	  Those	  who	  were	  not	  
prescribed	  ART	  were	  removed	  from	  the	  list	  of	  whom	  to	  approach.	  	  All	  remaining	  
eligible	  patients	  were	  approached	  to	  invite	  them	  to	  take	  part	  in	  the	  study.	  	  At	  the	  
voluntary	  organisation,	  a	  list	  of	  young	  people	  who	  were	  expected	  to	  attend	  the	  
following	  evening	  session	  was	  sent	  to	  the	  AALPHI	  research	  nurse,	  who	  identified	  
AALPHI	  participants.	  	  These	  young	  people	  were	  then	  approached	  if	  they	  attended	  
and	  were	  not	  engaged	  in	  workshops	  that	  evening.	  	  The	  regional	  hospital	  (outside	  
London)	  was	  added	  to	  the	  list	  of	  recruitment	  sites	  towards	  the	  end	  of	  the	  
recruitment	  period.	  	  Therefore,	  all	  AALPHI	  participants	  between	  December	  2014	  and	  
April	  2015	  were	  approached	  to	  participate.	  	  A	  total	  of	  36	  young	  people	  were	  invited	  
to	  participate,	  of	  whom	  29	  completed	  the	  retrospective	  questionnaires	  for	  both	  
episodes.	  	  A	  total	  of	  six	  people	  completed	  at	  least	  one	  prospective	  questionnaire	  
(n=6	  for	  adherent	  episode;	  n=4	  for	  non-­‐adherent	  episode),	  of	  whom	  four	  completed	  
prospective	  questionnaires	  for	  both	  episodes.	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Characteristics	  of	  the	  sample	  
Participants’	  baseline	  data	  from	  enrolment	  into	  AALPHI	  were	  collated	  to	  characterise	  
the	  sample.	  	  Demographic	  information,	  including	  age,	  gender,	  country	  of	  birth	  and	  
ethnicity	  of	  the	  29	  recruited	  participants	  are	  presented	  in	  the	  table	  below.	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Table	  2:	  Demographic	  information	  
Variable	   	   	  
Age	   Mean	   17.3	  
	   Median	   17	  
	   SD	   1.99	  
	   Range	   14-­‐22	  
Gender	   Male	   12	  (41%)	  
	   Female	   17	  (59%)	  
Birthplace	   UK	   8	  




















Ethnicity	   Black	  African	   25	  (86%)	  
	   Black	  Caribbean	   1	  
	   Mixed:	  White	  &	  Black	  African	   2	  
	   Prefer	  not	  to	  say	   1	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The	  gender	  split	  in	  the	  current	  sample	  matches	  that	  of	  the	  wider	  AALPHI	  population	  
(41%	  male).	  	  The	  median	  age	  of	  participants	  matches	  the	  AALPHI	  population	  (median	  
age	  at	  enrolment	  16,	  second	  year	  of	  project	  =	  17).	  	  The	  percentage	  of	  participants	  of	  
Black	  African	  ethnicity	  exactly	  matches	  the	  AALPHI	  group.	  	  This	  suggests	  the	  
sampling	  strategy	  was	  successful	  in	  recruiting	  a	  demographically	  representative	  
group	  from	  AALPHI.	  
	  
Table	  3,	  below,	  presents	  descriptive	  characteristics	  of	  the	  sample	  at	  entry	  into	  
AALPHI,	  including	  their	  ART	  regimen	  frequency,	  a	  subjective	  rating	  of	  their	  overall	  
ART	  adherence,	  the	  number	  of	  people	  they	  had	  disclosed	  their	  HIV	  status	  to	  outside	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Table	  3:	  Descriptive	  information	  
Variable	   	   	   Frequencies	  
Medication	   ART	  once	  daily	   	   24	  
	   ART	  twice	  daily	   	   1	  
	   Missing	   	   4	  
Adherence	   Subjective	  rating	  of	  
overall	  adherence	  
Excellent	   12	  
	   Good	   11	  
	   Not	  so	  good	   2	  
	   	   Missing	   4	  
HIV	  Disclosure	   Number	  of	  people	  
disclosed	  to	  
10+	   3	  
	   5-­‐9	   1	  
	   3-­‐4	   1	  
	   1-­‐2	   10	  
	   0	   11	  
	   	   Missing	   3	  
Referred	  to	  
CAMHS?	  
Yes	   	   1	  
No	   	   24	  
Missing	   	   4	  
Alcohol	  use	   Never	   	   18	  
	   Monthly	  or	  less	   	   6	  
	   2-­‐4	  times/month	   	   2	  
	   4+	  times/week	   	   2	  
	   missing	   	   1	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Measures	  
Questionnaire	  Development	  
Adaptation	  of	  The	  LifeWindows	  Information	  Motivation	  Behavioural	  Skills	  ART	  
Adherence	  Questionnaire	  (LW-­‐IMB-­‐AAQ)	  (The	  LifeWindows	  Project	  Team,	  2006)	  
The	  LifeWindows	  Information	  Motivation	  Behavioural	  Skills	  ART	  Adherence	  
Questionnaire	  (LW-­‐IMB-­‐AAQ)	  (The	  LifeWindows	  Project	  Team,	  2006)	  is	  a	  33-­‐item	  
scale	  measuring	  IMB-­‐related	  adherence	  barriers	  (Appendix	  8).	  	  The	  questionnaire	  
was	  developed	  for	  computerised	  administration	  as	  part	  of	  a	  computerised	  
adherence	  intervention	  for	  adults	  living	  with	  HIV	  in	  clinical	  care	  settings	  in	  the	  USA	  
(Fisher,	  et	  al,	  2011).	  	  The	  measure	  was	  designed	  with	  two	  primary	  functions:	  to	  
quantify	  strengths	  and	  needs	  in	  ART	  related	  information,	  motivation	  and	  behavioural	  
skills;	  and	  to	  identify	  potential	  specific	  deficits	  in	  one	  or	  more	  of	  these	  areas	  for	  
targeted	  and	  effective	  intervention.	  	  	  
	  
The	  LW-­‐IMB-­‐AAQ	  comprises	  three	  subscales	  to	  measure	  each	  of	  the	  IMB	  constructs.	  	  
A	  nine-­‐item	  subscale	  measures	  information	  with	  internal	  consistency	  of	  α=0.59	  
(LifeWindows	  Project	  Team,	  2006).	  	  The	  authors	  explain	  the	  low	  reliability	  due	  to	  the	  
variety	  of	  information	  about	  diverse	  aspects	  of	  ART	  regimen;	  higher	  levels	  of	  internal	  
consistency	  would	  not	  be	  expected.	  	  Ten	  items,	  seven	  of	  which	  measure	  personal	  
motivation	  and	  three	  measure	  social	  motivation,	  measure	  the	  overall	  motivation	  
construct	  (α=0.70).	  The	  remaining	  14	  items	  form	  the	  behavioural	  skills-­‐subscale	  with	  
excellent	  internal	  consistency	  α=0.90.	  	  The	  questionnaire	  has	  been	  adopted	  for	  use	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in	  out-­‐of-­‐clinic	  settings	  in	  the	  US	  	  (Horvath	  et	  al.,	  2014)	  and	  cross-­‐culturally	  in	  
Argentina	  (Torija,	  Vázquez,	  Montijo,	  &	  Romo,	  2015)	  and	  South	  Africa	  (Dewing	  et	  al.,	  
2015).	  
	  
The	  LW-­‐IMB-­‐AAQ	  appears	  not	  to	  have	  been	  used	  in	  research	  with	  adolescents,	  
although	  the	  authors	  suggest	  that	  the	  questions	  are	  likely	  generalizable	  to	  other	  
HIV+	  populations	  (Fisher,	  et	  al,	  2006).	  	  	  
	  
Process	  of	  Adaptation	  
The	  LW-­‐IMBQ-­‐AAQ	  required	  adaptation	  because	  the	  wording	  was	  unsuitable	  for	  
referring	  to	  specific	  episodes	  of	  adherence	  or	  nonadherence;	  no	  other	  measures	  
were	  available.	  	  When	  adapting	  the	  measure	  for	  use	  in	  the	  present	  study,	  it	  was	  
important	  to	  consider	  the	  original	  context	  of	  its	  development.	  	  The	  LW-­‐IMB-­‐AAQ	  was	  
developed	  for	  adults,	  in	  clinical	  care	  setting	  and	  as	  a	  measure	  of	  global	  adherence.	  	  
Therefore,	  it	  was	  necessary	  to	  consider	  what	  amendments	  were	  necessary	  to	  make	  
the	  tool	  applicable	  to	  young	  people	  and	  relevant	  to	  particular	  episodes	  of	  adherence	  
and	  non-­‐adherence.	  	  	  
	  
Advice	  was	  sought	  from	  the	  one	  of	  the	  original	  authors	  of	  the	  LW-­‐IMB-­‐AAQ	  prior	  to	  
and	  throughout	  the	  adaptation	  process	  (Amico,	  personal	  communication).	  	  The	  first	  
step	  taken	  was	  to	  remove	  items	  that	  would	  not	  be	  relevant	  situationally	  or	  apply	  to	  
the	  target	  group.	  	  This	  was	  done	  prior	  to	  piloting	  by	  the	  author	  and	  supervisors.	  The	  
proposed	  omitted	  items	  were	  later	  presented	  to	  a	  focus	  group	  made	  up	  of	  the	  target	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population	  (discussed	  below)	  who	  corroborated	  that	  these	  items	  had	  not	  been	  
erroneously	  excluded.	  
	  
The	  second	  step	  was	  to	  remove	  items	  that	  did	  not	  make	  conceptual	  sense	  
situationally.	  	  Some	  items	  measured	  static	  constructs	  or	  attitudes,	  such	  as	  “As	  long	  
as	  I’m	  feeling	  healthy,	  skipping	  my	  HIV	  medications	  from	  time	  to	  time	  was	  OK”.	  	  
Three	  information	  items,	  seven	  motivation	  items	  and	  ten	  behavioural	  skills	  items	  
remained	  after	  this	  process.	  
	  
Additional	  items	  were	  added	  to	  the	  subscales	  based	  on	  factors	  found	  to	  be	  
significant	  in	  between-­‐participant	  ART	  adherence	  studies	  in	  PHIV+	  	  (Agwu	  &	  Fairlie,	  
2013;	  Macdonell,	  Naar-­‐King,	  Murphy,	  Parsons,	  &	  Huszti,	  2011;	  Rudy,	  Murphy,	  Harris,	  
Muenz,	  &	  Ellen,	  2010),	  such	  as	  perception	  of	  effectiveness	  of	  ART,	  or	  outcome	  
expectancies,	  (e.g.	  “I	  thought	  my	  medication	  was	  helping”).	  	  	  
	  
Questions	  relating	  to	  complexity	  and	  burden	  of	  regimen	  did	  not	  appear	  in	  the	  LW-­‐
IMB-­‐AAQ,	  but	  has	  been	  suggested	  as	  an	  important	  determinant	  of	  adherence	  	  
(Nachega	  et	  al.,	  2014).	  	  Therefore,	  an	  additional	  item	  was	  added	  to	  the	  Information	  
subscale,	  in	  terms	  of	  participants’	  understanding	  of	  their	  specific	  regimen	  (“I	  
understood	  what	  medication	  to	  take”).	  	  An	  extra	  item	  was	  added	  to	  the	  personal	  
motivation	  subscale	  relating	  to	  perceptions	  of	  the	  size,	  taste	  or	  amount	  of	  
medication.	  	  One	  item	  was	  added	  to	  the	  behavioural	  skills	  subscale	  to	  measure	  
confidence	  in	  adhering	  to	  the	  regimen	  correctly.	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A	  component	  of	  outcome	  expectancy,	  perceived	  effectiveness	  of	  medication,	  was	  
neglected	  in	  the	  LW-­‐IMB-­‐AAQ.	  	  Therefore,	  two	  items	  measuring	  this	  were	  added	  to	  
the	  personal	  motivation	  subscale.	  
	  
	  A	  link	  between	  ease	  of	  access	  to	  medications	  and	  situational	  adherence	  has	  been	  
found	  in	  adults	  with	  HIV	  (Wagner	  &	  Ryan,	  2004)	  and	  Thalassaemia	  	  (Vosper,	  
Evangeli,	  Porter,	  &	  Shah,	  2013).	  	  The	  LW-­‐IMB-­‐AAQ	  asks	  only	  about	  prescription	  refills	  
rather	  than	  situational	  access	  to	  medication,	  therefore	  this	  item	  was	  amended.	  
	  
A	  question	  about	  confidence	  to	  remember	  ART	  was	  included	  from	  the	  LW-­‐IMB-­‐AAQ,	  
but	  there	  was	  no	  question	  about	  degree	  of	  forgetting	  or	  volitional	  adherence	  (or	  
choosing	  to	  take	  medication).	  	  Extra	  items	  were	  added	  to	  the	  non-­‐adherent	  episode	  
questionnaire	  and	  adherent	  questionnaire,	  respectively:	  “I	  completely	  forgot”	  was	  
rated	  in	  relation	  to	  non-­‐adherence;	  “Taking	  the	  medication	  was	  my	  choice”	  was	  
rated	  in	  relation	  to	  adherence.	  	  The	  final	  questionnaire	  can	  be	  found	  in	  Appendix	  13.	  
Wording	  
In	  the	  design	  of	  a	  questionnaire,	  it	  is	  necessary	  to	  strike	  a	  balance	  between	  being	  
comprehensive	  and	  not	  too	  onerous	  to	  complete,	  therefore	  careful	  attention	  must	  
be	  paid	  to	  the	  wording.	  	  Wording	  and	  phrasing	  changes	  were	  made	  subsequent	  to	  
focus	  group	  consultation.	  	  However,	  a	  consistent	  wording	  format	  was	  mostly	  
followed.	  For	  Information,	  questions	  began	  with	  “I	  knew…”	  or	  “I	  understood…”;	  for	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Personal	  motivation,	  questions	  mostly	  began	  with	  “I	  thought…”;	  for	  Behavioural	  
Skills,	  questions	  mostly	  began	  with	  “I	  felt/was	  confident…”	  
Focus	  Group	  Piloting	  
A	  group	  of	  12	  young	  people	  from	  the	  Children’s	  HIV	  Association	  (CHIVA)	  were	  
approached	  to	  pilot	  the	  adapted	  questionnaire;	  all	  were	  PHIV+	  and	  were	  prescribed	  
ART.	  	  	  Each	  young	  person	  was	  given	  a	  copy	  of	  the	  draft	  questionnaire	  to	  look	  at	  and	  
asked	  to	  feedback	  in	  terms	  of	  clarity	  and	  understanding	  of	  each	  item,	  relevance,	  
comprehensiveness	  and	  feasibility	  of	  the	  questionnaire.	  	  The	  pilot	  group	  were	  also	  
asked	  about	  their	  views	  on	  the	  layout	  and	  style	  of	  response	  options.	  	  A	  “think	  aloud”	  
technique	  was	  used,	  whereby	  participants	  were	  asked	  to	  verbalise	  their	  thoughts	  
around	  how	  they	  would	  answer	  the	  question	  and	  their	  thoughts	  about	  how	  relevant	  
the	  question	  was	  to	  their	  own	  medication	  adherence	  	  (Ericsson	  &	  Fox,	  2011).	  	  
Administration	  Format	  
The	  questionnaire	  was	  available	  in	  both	  paper	  and	  pencil	  and	  online	  format.	  	  The	  
original	  questionnaire	  was	  administered	  in	  a	  computerised	  format;	  therefore	  this	  is	  
in	  keeping	  with	  the	  original	  mode	  of	  administration.	  	  	  
	  
The	  standard	  software	  of	  the	  Royal	  Holloway	  University	  of	  London	  Psychology	  
department	  was	  used	  for	  the	  online	  version	  of	  the	  questionnaire	  (SelectSurveyASP	  
Advanced	  [version	  8.6.4]).	  	  The	  URL	  hyperlinks	  to	  the	  questionnaire	  were	  
exceptionally	  long,	  therefore	  would	  have	  been	  prone	  to	  error	  when	  typing	  or	  
copying	  into	  an	  internet	  browser.	  	  Therefore	  the	  links	  to	  the	  questionnaire	  were	  
	   77	  
routed	  through	  tinyurl.com	  to	  simplify	  the	  online	  procedure.	  	  	  This	  is	  an	  online	  tool	  
for	  condensing	  long	  URL	  links	  into	  a	  more	  useable	  format.	  
Length	  &	  Order	  of	  Questions	  
The	  relationship	  between	  response	  rate	  and	  length	  of	  questionnaire	  was	  a	  concern	  
for	  this	  study.	  	  Participant	  boredom	  and	  fatigue	  induced	  by	  overly	  lengthy	  
questionnaires	  may	  impact	  on	  the	  validity	  of	  responses.	  	  Participants	  may	  employ	  
particular	  response	  strategies,	  be	  subject	  to	  learning	  effects,	  or	  be	  careless	  in	  
questionnaire	  completion	  	  (Warnecke	  et	  al.,	  1997).	  	  Learning	  effects	  would	  reduce	  
variance	  of	  responses	  and	  response	  strategy	  would	  increase	  variance	  of	  responses.	  	  
These	  would	  cause	  difficulties	  with	  statistical	  analysis	  due	  to	  non-­‐random	  patterns	  of	  
variance.	  	  	  
	  
In	  the	  current	  study,	  consideration	  was	  given	  to	  the	  number	  of	  questions	  and	  how	  
lengthy	  the	  questionnaire	  would	  appear	  in	  each	  format.	  	  The	  paper	  version	  was	  kept	  
to	  four	  sides	  of	  paper	  per	  episode	  and	  the	  online	  version	  was	  limited	  to	  a	  total	  10	  
screens	  to	  avoid	  over-­‐burdening	  participants.	  	  	  
Single	  Question	  Survey	  Response	  &	  Scales	  
To	  measure	  a	  psychological	  construct	  most	  reliably,	  it	  is	  recommended	  that	  a	  
number	  of	  items	  representing	  this	  construct	  are	  included	  in	  the	  questionnaire	  and	  
the	  responses	  rated	  on	  a	  summative	  scale	  (Oppenheim,	  1992).	  	  Therefore,	  
psychological	  variables	  including	  the	  IMB	  constructs,	  positive	  and	  negative	  affect	  
(described	  below),	  feeling	  ill,	  forgetting	  and	  choice	  were	  rated	  on	  a	  five-­‐point	  Likert	  
scale,	  where	  responses	  indicated	  to	  what	  extent	  participants	  agreed	  or	  disagreed	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with	  the	  statement.	  Behavioural	  situational	  variables	  (described	  below)	  were	  
measured	  with	  single	  item	  survey	  responses.	  
	  
Final	  Questionnaire	  Items	  
The	  introduction	  to	  the	  questionnaire	  asked	  participants	  to	  think	  about	  the	  time	  
when	  they	  did	  or	  did	  not	  (depending	  on	  episode)	  take	  their	  medication,	  and	  answer	  
the	  questions	  based	  on	  how	  they	  felt	  and	  what	  they	  thought	  at	  that	  time.	  
Situational	  Context	  
Situational	  non-­‐adherence	  in	  adult	  patients	  who	  are	  prescribed	  ART	  has	  been	  found	  
to	  be	  related	  to	  daily	  activities	  	  (Wagner	  &	  Ryan,	  2004),	  as	  discussed	  in	  the	  
Introduction.	  	  A	  number	  of	  questions	  with	  categorical	  responses	  were	  asked	  in	  
relation	  to	  each	  episode,	  which	  covered:	  
• Day	  of	  the	  week	  
• Whether	  another	  person	  was	  there	  to	  remind	  about	  the	  medication	  (yes	  or	  
no)	  
• Routine	  (if	  usual	  day	  or	  routine	  different	  to	  normal	  due	  to	  planned	  or	  
unplanned	  activity)	  
• Location	  (if	  at	  home;	  a	  friend’s	  house;	  partner’s	  house;	  a	  public	  place	  such	  as	  
work,	  school	  or	  college;	  a	  family	  member’s	  house)	  
• Whether	  other	  people	  were	  present	  and,	  if	  so,	  who	  (alone;	  with	  friend;	  with	  
partner;	  with	  family;	  with	  acquaintance;	  with	  work	  colleague)	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• Whether	  street	  drugs	  or	  alcohol	  were	  used	  around	  the	  time	  of	  medication	  
(yes	  or	  no).	  
IMB	  Constructs	  
The	  IMB	  constructs	  were	  measured	  by	  scale	  questions	  and	  rated	  on	  a	  five	  point	  
Likert	  scale,	  in	  keeping	  with	  the	  LW-­‐IMB-­‐AAQ.	  	  Each	  item	  was	  introduced	  with	  “At	  
the	  time:	  (please	  tick	  one)”	  and	  presented	  as	  a	  statement,	  such	  as	  “I	  knew	  the	  
correct	  way	  to	  take	  my	  medicines”.	  Responses	  ranged	  from	  ‘Strongly	  Disagree’	  to	  
‘Strongly	  Agree’.	  	  
	  
Four	  items	  measuring	  situational	  Information	  were	  included	  in	  the	  final	  
questionnaire.	  	  Ten	  items,	  relating	  to	  personal	  and	  social	  motivation,	  comprised	  the	  
motivation	  scale.	  	  Subjective	  behavioural	  skill	  was	  measured	  by	  eight	  items.	  	  	  
Mood	  
Adapted	  Positive	  and	  Negative	  Affect	  Schedule	  (PANAS)	  –	  10	  item	  Children’s	  Version	  
	  	  
The	  original	  Positive	  and	  Negative	  Affect	  Schedule	  (PANAS)	  	  (Watson,	  Clark,	  &	  
Tellegen,	  1988)	  was	  developed	  as	  a	  tool	  to	  discriminate	  between	  symptoms	  of	  
anxiety	  and	  depression	  in	  adults.	  	  It	  was	  subsequently	  adapted	  for	  use	  in	  children	  
and	  adolescents	  (Laurent	  et	  al.,	  1999)	  resulting	  in	  a	  27	  item	  self-­‐report	  measure	  
comprising	  two	  subscales	  of	  positive	  and	  negative	  affect.	  	  
	  
Given	  the	  importance	  of	  minimising	  participant	  burden	  in	  the	  current	  questionnaire,	  
a	  concise	  measure	  of	  positive	  and	  negative	  affect	  was	  required.	  	  The	  PANAS-­‐Child	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version	  has	  recently	  been	  adapted	  to	  a	  10	  item	  scale	  (Ebesutani,	  Regan,	  Smith,	  &	  
Reise,	  2012)	  using	  Item	  Response	  Theory	  (IRT)	  	  (Thomas,	  2011).	  	  IRT	  is	  a	  
psychometric	  approach	  that	  focuses	  on	  individual	  items	  to	  estimate	  a	  value	  of	  a	  
construct,	  rather	  than	  an	  observed	  total	  as	  an	  estimate	  of	  a	  true	  test	  score	  (as	  would	  
be	  the	  case	  in	  Classical	  Test	  Theory).	  	  This	  approach	  enables	  scales	  to	  be	  shortened	  
without	  compromising	  accuracy.	  	  In	  a	  study	  of	  IRT	  applied	  to	  the	  PANAS-­‐C,	  
questionnaire	  items	  were	  reduced	  to	  5	  per	  scale	  without	  compromising	  the	  
psychometric	  value	  of	  the	  tool.	  	  There	  were	  higher	  inter-­‐item	  correlations	  in	  the	  
shortened	  version,	  indicating	  a	  slightly	  less	  broad	  measure	  of	  both	  positive	  and	  
negative	  affect,	  relative	  to	  the	  original	  measure.	  	  However,	  good	  internal	  consistency	  
remained	  for	  both	  positive	  affect	  (0.85)	  and	  negative	  affect	  (0.82),	  divergent	  validity	  
was	  not	  significantly	  different	  from	  the	  original	  scales	  and	  discriminant	  validity	  for	  
specific	  mood	  disorders	  was	  good	  (as	  tested	  on	  a	  mental	  health	  clinic-­‐based	  sample)	  	  
(Ebesutani	  et	  al.,	  2012).	  	  Therefore,	  the	  shortened	  scale	  was	  chosen	  over	  other	  
available	  measures	  due	  to	  its	  brevity	  and	  adaptability	  to	  an	  event-­‐level	  design.	  	  In	  
the	  current	  study,	  the	  internal	  reliability	  for	  both	  positive	  and	  negative	  scales	  
between	  episode	  can	  be	  found	  in	  the	  table	  below.	  
	  
Table	  4:	  Cronbach's	  alpha	  reliability	  by	  subscale	  (standard	  5	  item)	  
Episode	   Positive	  Affect	   Negative	  Affect	  	  
Non-­‐adherent	   .94	   .93	  
Adherent	   .91	   .86	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An	  additional	  four	  negative	  affect	  items	  were	  suggested	  in	  the	  piloting	  stage	  by	  the	  
focus	  group.	  	  Although	  the	  PANAS-­‐C	  short	  form	  is	  a	  standardised	  measure,	  it	  has	  not	  
been	  validated	  in	  the	  PHIV+	  population.	  	  Therefore,	  it	  may	  be	  that	  the	  constructs	  
vary	  between	  populations.	  As	  such,	  focus	  group	  participants	  were	  asked	  whether	  
there	  were	  other	  mood	  states	  that	  were	  present	  at	  the	  time	  of	  scheduled	  
medication	  times	  (not	  covered	  in	  the	  PANAS-­‐C).	  The	  following	  mood	  states	  were	  
elicited:	  blamed,	  helpless,	  out	  of	  control	  and	  weak.	  To	  avoid	  bias	  towards	  negative	  
affect	  items	  (with	  9	  negative	  items	  and	  5	  positive	  affect	  items),	  an	  additional	  four	  
positive	  affect	  items	  were	  included	  to	  the	  questionnaire,	  derived	  from	  a	  critique	  of	  
the	  PANAS	  (Peterson	  et	  al.,	  2013).	  	  These	  items	  were:	  calm,	  content,	  at	  ease	  and	  
satisfied	  and	  measured	  the	  non-­‐activated	  component	  of	  positive	  affect.	  
	  
Participants	  were	  asked	  to	  rate	  the	  degree	  to	  which	  they	  felt	  each	  emotion	  at	  the	  
time	  of	  their	  adherent	  or	  non-­‐adherent	  event.	  	  The	  items	  were	  introduced	  with:	  How	  
did	  you	  feel	  when	  it	  was	  time	  to	  take	  your	  medication?	  	  	  
Intention	  and	  volition	  
One	  item	  measured	  forgetting	  for	  the	  non-­‐adherent	  episode.	  One	  item	  measured	  
degree	  of	  personal	  choice	  in	  taking	  medication	  for	  the	  adherent	  episode.	  	  These	  
were	  rated	  on	  the	  same	  five-­‐point	  Likert	  scale,	  presented	  with	  the	  IMB	  items.	  
Somatic	  symptoms	  
Feeling	  ill	  at	  the	  time	  when	  the	  ART	  dose	  was	  due	  was	  also	  measured	  on	  the	  five-­‐
point	  Likert	  scale	  with	  the	  IMB	  items.	  	  This	  was	  included	  for	  both	  episodes.	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Study	  Procedure	  
A	  diagram	  of	  the	  study	  procedure	  can	  be	  found	  below.	  	  	  
	  
Participants	  enrolled	  in	  AALPHI	  were	  identified	  from	  clinic	  lists.	  	  All	  those	  who	  
attended	  the	  clinic	  were	  approached	  either	  by	  a	  member	  of	  their	  clinical	  team	  or	  an	  
AALPHI	  research	  nurse	  to	  inform	  them	  of	  the	  study.	  	  Interested	  and	  eligible	  young	  
people	  were	  given	  paper	  information	  sheets	  by	  either	  the	  AALPHI	  research	  nurse	  or	  
the	  author.	  	  Occasional	  non-­‐adherence	  was	  normalised	  (“We	  know	  that	  sometimes	  it	  
might	  be	  easier	  or	  more	  difficult	  to	  take	  medication	  and	  it	  is	  not	  uncommon	  for	  
young	  people	  to	  occasionally	  miss	  a	  dose”),	  and	  participants	  were	  made	  aware	  that	  
the	  information	  or	  their	  choice	  to	  participate	  or	  not	  would	  not	  be	  fed	  back	  to	  their	  
clinical	  team.	  	  	  
The	  same	  procedure	  was	  followed	  for	  the	  non-­‐clinic	  voluntary	  sector	  site:	  AALPHI	  
participants	  were	  identified	  from	  a	  list	  of	  who	  was	  due	  to	  attend	  that	  evening.	  	  
Those	  young	  people	  who	  were	  available	  for	  some	  part	  of	  the	  evening	  were	  
approached	  by	  a	  volunteer	  or	  research	  nurse	  to	  introduce	  the	  study;	  young	  people	  
who	  were	  engaged	  in	  other	  activities	  were	  not	  approached.	  	  	  
	  
Young	  people	  who	  wished	  to	  participate	  were	  consented	  by	  the	  author	  or	  research	  
nurse	  and	  given	  the	  option	  to	  consent	  and	  complete	  their	  questionnaire	  on	  paper	  or	  
online.	  	  Online	  consenting	  was	  carried	  out	  in	  accordance	  with	  the	  BPS	  guidelines	  for	  
internet	  mediated	  research	  (British	  Psychological	  Society,	  2013).	  	  Participants	  were	  
allocated	  a	  unique	  study	  number	  linked	  to	  their	  date	  of	  birth	  to	  maintain	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confidentiality	  and	  anonymity	  of	  responses.	  	  The	  research	  nurses	  kept	  a	  record	  of	  
which	  AALPHI	  participants	  had	  completed	  this	  study	  on	  the	  main	  AALPHI	  database.	  	  
Fifteen	  participants	  completed	  a	  pen	  &	  paper	  version	  of	  the	  questionnaire,	  with	  the	  
remainder	  online.	  	  Paper	  questionnaires	  were	  scanned	  and	  saved	  to	  an	  encrypted	  
USB	  storage	  device.	  	  Online	  data	  was	  downloaded	  from	  the	  survey	  software	  and	  
stored	  on	  the	  same	  encrypted	  USB	  device.	  	  The	  order	  of	  questionnaires	  was	  counter-­‐
balanced	  to	  control	  for	  order	  effects	  and	  14	  participants	  completed	  the	  adherent	  
episode	  first.	  	  Participants	  were	  given	  a	  £10	  voucher	  for	  taking	  part.	  
Prospective	  questionnaires	  
Following	  the	  completion	  of	  the	  retrospective	  questionnaire,	  participants	  were	  given	  
the	  choice	  to	  enrol	  in	  the	  second	  half	  of	  the	  study:	  to	  receive	  SMS	  messages	  every	  
three	  days	  to	  remind	  them	  to	  complete	  the	  questionnaire	  again,	  once	  after	  a	  non-­‐
adherent	  event	  and	  once	  after	  an	  adherent	  event.	  	  Participants	  had	  been	  informed	  
of	  the	  two-­‐part	  nature	  of	  the	  study	  during	  the	  consenting	  process,	  but	  were	  
reminded	  of	  the	  second	  part	  and	  given	  the	  choice	  to	  opt	  out.	  	  Twenty-­‐two	  
participants	  chose	  to	  participate	  in	  this	  part	  of	  the	  study	  and	  were	  given	  a	  link	  to	  the	  
online	  questionnaire	  with	  their	  unique	  study	  number	  to	  login	  to	  the	  survey.	  	  
Participants	  were	  made	  aware	  that	  they	  could	  opt-­‐out	  of	  the	  messaging	  at	  any	  time	  
and	  were	  instructed	  on	  how	  to	  do	  so.	  	  	  
SMS	  reminders	  
SMS	  messages	  were	  sent	  via	  RedOxygen,	  a	  web-­‐based	  service,	  which	  allowed	  
scheduled	  reminders	  to	  be	  sent	  (RedOxygen	  Pty.	  Ltd.,	  Brisbane,	  Queensland,	  
Australia).	  	  This	  service	  has	  been	  used	  in	  other	  prospective	  research	  of	  health	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behaviours	  (e.g.	  Berkman,	  Dickenson,	  Falk,	  &	  Lieberman,	  2011).	  	  The	  URL	  links	  to	  
each	  questionnaire	  (separate	  for	  each	  episode	  to	  avoid	  confusion)	  were	  sent	  via	  
SMS.	  	  In	  keeping	  with	  the	  terms	  of	  use,	  whom	  the	  message	  was	  from	  (RHUL	  
Research	  Project)	  and	  how	  to	  opt	  out	  of	  messages	  (Reply:	  “Stop”	  to	  opt	  out)	  was	  
included	  in	  the	  SMS.	  	  Three	  people	  opted	  out	  of	  messaging,	  evidence	  by	  “failure	  to	  
send”	  reports	  from	  the	  software.	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Figure	  2:	  Study	  Procedure	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Ethics	  and	  Ethical	  Issues	  
This	  study	  was	  granted	  NHS	  approval	  by	  Berkshire	  B	  Ethics	  Committee.	  	  The	  study	  
also	  received	  ethical	  approval	  from	  Royal	  Holloway	  University	  of	  London	  Psychology	  
Departmental	  Ethics	  Committee	  (for	  approval	  letters,	  see	  Appendix	  1-­‐4).	  	  An	  
amendment	  was	  submitted	  to	  adjust	  the	  upper	  age	  limit	  from	  21	  to	  22,	  accounting	  
for	  the	  age	  at	  which	  young	  people	  were	  initially	  enrolled	  in	  AALPHI,	  and	  to	  add	  the	  
regional	  out	  of	  London	  hospital.	  
	  
Research	  and	  Development	  approval	  was	  obtained	  for	  each	  NHS	  hospital	  site.	  
Analysis	  
Analysis	  was	  carried	  out	  in	  SPSS	  Statistics,	  version	  21	  (IBM	  Corp,	  2012).	  	  Additional	  
investigation	  of	  multivariate	  analysis	  assumptions	  took	  place	  in	  STATA	  IC	  version	  11	  
(StataCorp,	  2009).	  
Bivariate	  
Planned	  bivariate	  comparisons	  were	  conducted	  between	  responses	  for	  adherent	  and	  
non-­‐adherent	  episodes.	  	  Variables	  that	  met	  assumptions	  for	  parametric	  statistics	  
were	  analysed	  using	  paired-­‐samples	  t-­‐tests.	  	  	  
Categorical	  variables	  between	  episodes	  were	  compared	  using	  McNemar’s	  chi	  square	  
tests.	  
Multivariate	  
Conditional	  logistic	  regression	  was	  used	  to	  explore	  associations	  between	  more	  than	  
one	  independent	  variables	  and	  the	  dependent	  variable	  (adherent/non-­‐adherent	  
	   87	  
episode).	  	  This	  was	  carried	  out	  as	  Cox	  regression	  in	  SPSS,	  due	  to	  a	  lack	  of	  conditional	  
logistic	  regression	  function	  in	  this	  software.	  	  This	  model	  was	  selected	  because	  the	  
dependent	  variable	  was	  binary	  (adherent	  versus	  non	  adherent	  event).	  	  It	  would	  have	  
been	  inappropriate	  to	  use	  binary	  logistic	  regression	  because	  the	  observations	  were	  
not	  independent.	  	  For	  case-­‐control	  studies,	  or	  related	  observations,	  conditional	  
logistic	  regression	  is	  the	  most	  appropriate	  multivariate	  model	  (Field,	  2014).	  	  
	  
Significance	  (as	  measured	  by	  a	  p-­‐value	  >0.05)	  on	  the	  bivariate	  analysis	  and	  relevance	  
to	  the	  IMB	  model	  were	  used	  to	  select	  the	  variables	  for	  inclusion	  in	  the	  regression	  
model.	  	  The	  number	  of	  variables	  in	  the	  model	  was	  restricted	  due	  to	  power	  
considerations.	  	  The	  model	  could	  support	  just	  two	  predictors	  because	  29	  participants	  
were	  recruited	  (following	  the	  guidance	  of	  10	  cases	  per	  predictor	  (Tabachnik	  &	  Fidel,	  
2006).	  
Missing	  data	  
Missing	  data	  was	  omitted,	  not	  replaced	  with	  mean	  values.	  	  For	  the	  inferential	  
analysis,	  missing	  observations	  were	  omitted	  on	  a	  pairwise	  basis.	  	  	  
Results	  
Retrospective	  Data	  
Twenty-­‐nine	  participants	  completed	  the	  measures	  for	  both	  adherent	  and	  non-­‐
adherent	  episodes.	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Categorical	  Variables:	  Data	  screening,	  Exploration	  and	  Grouping	  
Table	  5,	  below,	  presents	  the	  frequencies	  of	  responses	  for	  non-­‐adherent	  and	  
adherent	  episode	  for	  the	  categorical	  variables.	  	  Due	  to	  small	  cell	  sizes	  for	  some	  
categories,	  the	  following	  variables	  were	  grouped	  into	  dichotomous	  categories:	  with	  
whom	  the	  adherent	  or	  non-­‐adherent	  episode	  occurred	  (alone	  or	  with	  someone	  
else),	  daily	  routine	  (the	  same	  as	  or	  different	  to	  normal),	  location	  at	  the	  time	  (at	  
home	  or	  elsewhere)	  and	  day	  of	  the	  week	  for	  each	  episode	  (Monday	  to	  Thursday	  and	  
Friday	  to	  Sunday).	  	  Additional	  categorical	  variables	  included	  in	  Table	  5,	  below,	  are:	  
whether	  there	  was	  a	  person	  to	  remind	  about	  the	  medication	  and	  whether	  there	  was	  
substance	  use	  at	  the	  time	  of	  the	  episode.	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Table	  5:	  Categorical	  variables	  between	  adherent	  and	  non-­‐adherent	  episodes	  






29	   	   	   	   	  
Weekday	  	   Monday	   4	   Mon-­‐Thurs	  
11	  
8	   Mon-­‐Thurs	  
22	  	   Tuesday	   1	   8	  
	   Wednesday	   5	   2	  
	   Thursday	   1	   4	  
	   Friday	   5	   Fri-­‐Sun	  	  
16	  
2	   Fri-­‐Sun	  	  
5	  	   Saturday	   9	   2	  
	   Sunday	   2	   	   1	   	  
Missing	   2	   	   2	   	  
Routine	  	   Normal	   12	   Same	  
12	  
24	   Same	  	  
24	  
	   Unexpected	   8	   Different	  	  
15	  
2	   Different	  	  
4	  	   Planned	   7	   2	  
	   Missing	   2	   	   1	   	  
Location	  	   At	  home	   15	   At	  home	  	  
15	  
25	   At	  home	  	  
25	  
	   Friend’s	  
home	  
8	   Not	  at	  home	  
14	  
0	   Not	  at	  home	  
3	  
	   Public	  place	   4	   2	  
	   Family	  home	   2	   1	  
	   Missing	   0	   	   1	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Alone	   8	   Alone	  
	  8	  
12	   Alone	  	  
12	  
Friend	   10	   Not	  alone	  21	   0	   Not	  alone	  16	  
Partner	   2	   0	  
Family	   9	   16	  




Yes	   11	   	   9	   	  
No	   18	   19	  
Missing	   0	   1	  
Substance	  
use	  
Yes	   4	   	   2	   	  
No	   25	   26	  
Missing	   0	   1	  
	  
Reliability	  of	  the	  IMB	  subscales	  
The	  reliability	  of	  the	  IMB	  subscales	  in	  the	  measure	  was	  particularly	  important	  in	  this	  
study,	  as	  the	  items	  were	  adapted	  from	  an	  existing	  measure.	  Internal	  consistency	  
(measured	  by	  Cronbach’s	  alpha)	  was	  calculated	  for	  each	  subscale	  in	  the	  IMB	  model	  
for	  each	  of	  the	  episodes.	  	  The	  non-­‐adherent	  information	  subscale	  alpha	  was	  0.98	  
and	  0.71	  for	  the	  adherent	  episode.	  	  The	  motivation	  subscale	  alpha	  was	  0.79	  for	  the	  
non-­‐adherent	  episode	  and	  0.76	  for	  the	  adherent	  episode.	  	  For	  the	  non-­‐adherent	  
episode,	  behavioural	  skills	  alpha	  was	  0.88	  and	  for	  the	  adherent	  episode	  alpha	  was	  
0.83.	  	  Each	  of	  these	  statistics	  indicates	  acceptable	  reliability	  (Field,	  2014).	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Reliability	  analysis	  in	  SPSS	  calculates	  the	  correlation	  of	  each	  individual	  scale	  item	  to	  
the	  total	  scale	  and	  the	  Cronbach’s	  alpha	  if	  any	  one	  item	  is	  removed.	  This	  analysis	  
was	  conducted	  to	  assess	  whether	  the	  adapted	  subscales	  could	  be	  refined	  to	  improve	  
their	  psychometric	  properties.	  	  For	  the	  motivation	  subscale,	  the	  Cronbach’s	  alpha	  
improved	  from	  0.79	  to	  0.85	  for	  the	  non-­‐adherent	  episode	  and	  0.76	  to	  0.87	  for	  the	  
adherent	  episode	  if	  items	  8	  and	  14	  were	  dropped.	  	  The	  item-­‐total	  correlations	  for	  
these	  items	  were	  low.	  	  On	  further	  investigation,	  the	  two	  items	  differed	  from	  the	  
remaining	  items	  in	  the	  subscale.	  	  Item	  8	  (“People	  around	  me	  that	  I	  care	  about	  were	  
supportive	  about	  my	  medication”)	  was	  the	  only	  social	  motivation	  item,	  whereas	  the	  
other	  items	  related	  to	  personal	  motivation.	  	  The	  IMB	  model	  separates	  out	  these	  two	  
components	  of	  motivation;	  therefore	  it	  was	  decided	  to	  investigate	  this	  social	  
motivation	  item	  separately.	  	  Item	  14	  (“I	  was	  bothered	  by	  the	  size,	  taste	  or	  amount	  of	  
medication”)	  was	  a	  personal	  motivation	  item	  that	  was	  added	  from	  the	  service	  user	  
consultation.	  	  Given	  its	  poor	  correlation	  to	  the	  subscale	  total,	  the	  increase	  in	  the	  
Cronbach’s	  alpha	  when	  the	  item	  was	  deleted	  and	  the	  fact	  it	  was	  not	  in	  the	  original	  
measure,	  the	  item	  was	  dropped	  from	  the	  analysis	  entirely.	  	  An	  eight-­‐item	  Personal	  
Motivation	  scale	  was	  used	  for	  analysis	  (α=0.85,	  non-­‐adherent	  episode;	  α=0.87,	  
adherent	  episode).	  	  The	  remaining	  items	  on	  each	  of	  the	  subscales	  were	  highly	  
correlated	  (>0.5)	  to	  the	  respective	  totals	  for	  behavioural	  skills	  and	  information.	  	  
There	  were	  no	  items	  that	  would	  have	  improved	  the	  reliability	  by	  being	  dropped	  on	  
these	  subscales.	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Continuous	  variables:	  Data	  screening	  and	  descriptive	  statistics	  
The	  distributions	  of	  the	  continuous	  variables	  were	  tested	  for	  skew	  and	  kurtosis	  to	  
determine	  whether	  normality	  could	  be	  assumed	  and	  if	  the	  data	  could	  be	  analysed	  
with	  parametric	  statistics.	  	  In	  paired	  t-­‐test	  analysis	  (which	  was	  planned),	  it	  is	  the	  
distribution	  of	  the	  difference	  between	  matched	  scores	  that	  must	  satisfy	  the	  
normality	  assumption,	  rather	  than	  the	  distribution	  of	  the	  individual	  variable	  scores	  
(Field,	  2014;	  Field,	  personal	  communication).	  	  Data	  for	  both	  non-­‐adherent	  and	  
adherent	  episodes	  were	  investigated	  as	  well	  as	  the	  differences	  between	  matched	  
variables	  are	  presented	  in	  Table	  6,	  below.	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Episode	   Median	  
(IQR)	  
Mean	   SD	  
Information	  	  
(4-­‐20)	  
Non-­‐adherent	   20	  
(17-­‐20)	  
18.04	   3.64	  
Adherent	   20	  
(18-­‐20)	  
19.04	   1.64	  
Difference	   	   -­‐.96	   4.40	  
Personal	  Motivation	  
(8-­‐40)	  
Non-­‐adherent	   21	  
(12-­‐28)	  
21.14	   8.59	  
Adherent	   22	  
(16-­‐27)	  
21.54	   8.06	  
Difference	   	   -­‐.33	   5.99	  
Social	  Motivation	  	  
(1-­‐5)	  
	  
Non-­‐adherent	   3	  
(1-­‐3)	  
2.52	   1.33	  
Adherent	   1.5	  
(1-­‐3)	  
2	   1.28	  
Difference	   	   -­‐.54	   1.48	  
Behavioural	  Skills	  	  
(10-­‐50)	  
Non-­‐adherent	   29.5	  	  
(23-­‐37)	  
29.75	   9.52	  
Adherent	   39.5	  	  
(32-­‐42)	  
37.92	   7.29	  
Difference	   	   -­‐7.92	   8.16	  
	  
With	  the	  exception	  of	  Information,	  all	  variables	  were	  normally	  distributed	  as	  
determined	  by	  skew	  and	  kurtosis	  z	  scores	  <3.29	  (Field,	  2014).	  	  The	  Information	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variable	  was	  negatively	  skewed,	  therefore	  this	  variable	  was	  transformed.	  	  Reverse-­‐
Log	  transformation	  successfully	  achieved	  a	  normal	  distribution	  (skew:	  z=-­‐1.46,	  
kurtosis:	  z=1.31).	  	  Following	  this	  transformation,	  there	  were	  no	  univariate	  outliers.	  	  
The	  additional	  items	  measuring	  positive	  and	  negative	  affect	  (4	  positive,	  4	  negative)	  
were	  investigated	  separately	  to	  the	  standard	  10	  PANAS-­‐C	  items.	  	  Descriptive	  
statistics	  for	  the	  affective	  variables	  and	  the	  somatic	  item	  (“I	  felt	  ill”)	  between	  
episodes	  are	  presented	  below.	  	  None	  of	  these	  variables	  violated	  the	  assumption	  of	  
normality,	  except	  for	  ‘helpless’,	  which	  was	  log-­‐transformed	  from	  a	  positive	  skew	  to	  a	  
normal	  distribution.	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Episode	   Mean	  	  
(SD)	  
Range	   Mean	  
Difference	  
(SD)	  
PANAS-­‐C	  5	  item	  
Positive	  Affect	  
(5-­‐25)	  
Non-­‐adherent	   8.55	  	  
(4.55)	  
5-­‐21	   3.33	  	  
(5.72)	  
Adherent	   12.15	  	  
(6.02)	  
5-­‐25	  
PANAS-­‐C	  5	  item	  
Negative	  Affect	  
(5-­‐25)	  
Non-­‐adherent	   11.34	  	  
(5.97)	  
5-­‐25	   2.00	  
(5.67)	  





“I	  felt	  ill”	  
(1-­‐5)	  
Non-­‐adherent	   2.52	  
(1.37)	  
1-­‐5	   0.08	  
(0.00)	  
Adherent	   2.54	  
(1.38)	  
1-­‐5	  
Blamed	   Non-­‐adherent	   2.17	  	  
(1.39)	  
1-­‐5	   0.85	  
(1.41)	  
(1-­‐5)	   Adherent	   1.41	  	  
(0.80)	  
1-­‐3	  
Weak	   Non-­‐adherent	   2.10	  	  
(1.21)	  
1-­‐5	   0.15	  
(0.91)	  
(1-­‐5)	   Adherent	   2.00	  	  
(1.44)	  
1-­‐5	  
Helpless	   Non-­‐adherent	   2.17	  	   1-­‐5	   0.35	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(1.47)	   (1.06)	  
(1-­‐5)	   Adherent	   1.77	  	  
(1.07)	  
1-­‐4	  
Out	  of	  control	  
(1-­‐5)	  
Non-­‐adherent	   2.21	  	  
(1.40)	  
1-­‐5	   0.33	  
(1.04)	  





Non-­‐adherent	   2.34	  	  
(1.32)	  
1-­‐5	   0.89	  
(1.76)	  





Non-­‐adherent	   2.28	  	  
(1.31)	  
1-­‐5	   0.70	  
(1.54)	  





Non-­‐adherent	   2.14	  	  
(1.19)	  
1-­‐5	   0.63	  
(1.42)	  





Non-­‐adherent	   2.17	  
(1.34)	  
1-­‐5	   0.74	  
(1.60)	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Two	  items	  relating	  to	  non-­‐intentional	  and	  volitional	  adherence	  were	  included	  for	  the	  
separate	  adherent	  and	  non-­‐adherent	  episodes,	  rated	  on	  the	  same	  five-­‐point	  Likert	  
scale	  from	  1	  –	  Strongly	  Disagree	  to	  5	  –	  Strongly	  Agree.	  	  Reponses	  on	  these	  variables	  
were	  normally	  distributed	  as	  determined	  by	  skew	  and	  kurtosis	  z	  scores	  <3.29	  (Field,	  
2014).	  	  	  	  The	  median	  rating	  of	  “I	  forgot”	  for	  the	  non-­‐adherent	  episode	  was	  4	  
(IQR=2.25-­‐5).	  	  The	  median	  rating	  of	  choice	  for	  the	  adherent	  episode	  was	  5	  (IQR	  3.75-­‐
5).	  
Exploratory	  bivariate	  analysis	  
Paired	  samples	  bivariate	  analysis	  of	  the	  potential	  differences	  between	  adherent	  and	  
non-­‐adherent	  episodes	  was	  carried	  out	  for	  the	  variables	  relating	  to	  the	  secondary	  
research	  questions.	  	  Potential	  differences	  on	  behavioural	  situational	  variables	  and	  
somatic	  symptoms	  (measured	  by	  “I	  felt	  ill”)	  between	  adherent	  and	  non-­‐adherent	  
episodes	  were	  tested.	  	  
Paired	  t-­‐tests	  were	  used	  for	  the	  continuous	  variables	  and	  McNemar’s	  Chi-­‐Square	  
analyses	  (using	  Fisher’s	  exact	  estimates	  for	  expected	  frequencies	  less	  than	  5)	  for	  the	  
categorical	  variables.	  	  McNemar’s	  tests	  for	  the	  difference	  between	  divergent	  pairs	  
(Altman,	  1991).	  	  The	  McNemar’s	  statistic	  and	  Cramer’s	  phi	  (as	  a	  measure	  of	  effect	  
size)	  were	  calculated	  manually	  using	  the	  following	  formulae	  (Nandy,	  2012):	  
χ2	  =	   !!! !!!! 	  
ϕ	  =	  √ !!!(!!!)	  
Cramer’s	  phi	  values	  for	  2x2	  contingency	  tables	  (as	  below)	  indicate	  effect	  sizes	  as	  
follows:	  .10	  –	  small;	  .30	  –	  medium;	  .50	  –	  large	  (Cohen,	  1992).	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Bonferroni	  corrections	  were	  not	  used	  to	  protect	  against	  type	  II	  errors,	  given	  the	  
small	  sample	  size.	  	  Therefore,	  an	  alpha	  level	  of	  0.05	  (two-­‐tailed)	  was	  used	  
throughout.	  
Relationships	  between	  behavioural	  situational	  factors	  and	  adherence	  	  
Substance	  use	  difference	  between	  adherent	  and	  non-­‐adherent	  episodes	  were	  not	  
analysed	  due	  to	  the	  very	  small	  cell	  frequencies	  (Field,	  2014).	  	  
“Was	  there	  someone	  to	  remind	  you?”	  
As	  shown	  in	  Table	  8,	  one	  person	  reported	  having	  someone	  to	  remind	  them	  to	  take	  
their	  medication	  at	  the	  time	  of	  adherent	  episode	  and	  not	  at	  the	  time	  of	  non-­‐
adherent	  episode,	  three	  people	  reported	  there	  was	  someone	  around	  to	  remind	  
them	  at	  the	  time	  of	  the	  non-­‐adherent	  episode	  but	  not	  at	  the	  time	  of	  the	  adherent	  
episode.	  	  There	  was	  no	  significant	  difference	  between	  these	  divergent	  pair	  of	  
findings	  (χ2	  =1,	  p=0.625,	  ϕ=0.189).	  






No	  one	  to	  
remind	  you	  
Someone	  to	  
remind	  you	   Total	  
No	  one	  to	  
remind	  you	   16	   1	   17	  
Someone	  to	  
remind	  you	   3	   8	   11	  
Total	   19	   9	   28	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“Who	  were	  you	  with?”	  
As	  shown	  in	  Table	  9,	  three	  people	  reported	  being	  with	  someone	  else	  at	  the	  time	  of	  
the	  adherent	  episode	  and	  alone	  at	  the	  time	  of	  non-­‐adherent	  episode;	  seven	  people	  
reported	  the	  opposite	  pattern	  of	  being	  alone	  at	  the	  time	  of	  adherent	  episode	  and	  
with	  someone	  at	  the	  time	  of	  non-­‐adherence.	  	  The	  difference	  between	  these	  was	  not	  
significant,	  representing	  a	  small	  to	  medium	  effect	  size	  (χ2=1.6,	  p=0.344,	  ϕ	  =	  0.239).	  	  	  





	   Alone	   With	  someone	   Total	  
Alone	   5	   3	   8	  
With	  someone	   7	   13	   20	  
Total	   12	   16	   28	  
	  
“What	  day	  was	  it?”	  
As	  shown	  in	  Table	  10,	  eleven	  people	  reported	  their	  adherent	  episode	  occurring	  
between	  Monday	  to	  Thursday	  and	  their	  non-­‐adherent	  event	  occurring	  between	  
Friday	  and	  Sunday.	  	  No	  participant	  reported	  the	  opposite	  pattern	  of	  the	  non-­‐
adherent	  event	  occurring	  Monday	  to	  Thursday	  and	  the	  adherent	  episode	  on	  Friday	  
to	  Sunday.	  	  The	  difference	  in	  this	  pattern	  was	  significant	  with	  a	  large	  effect	  size,	  
demonstrating	  participants	  were	  more	  likely	  to	  adhere	  Monday	  to	  Thursday	  and	  not	  
Friday	  to	  Sunday,	  compared	  to	  the	  reverse	  pattern	  (χ2=11,	  p=.001;	  ϕ=0.650)	  	  
	  
	  
	   100	  
Table	  10:	  Contingency	  table	  for	  "What	  day	  was	  it?"	  




	   Mon-­‐Thur	   Fri-­‐Sun	   	  	  	  	  	  	  	  	  	  Total	  
Mon-­‐Thur	   10	   0	   10	  
Fri-­‐Sun	   11	   5	   16	  
Total	   21	   5	   26	  
	  
“Where	  were	  you?”	  
As	  shown	  in	  Table	  11,	  McNemar’s	  test	  also	  demonstrated	  a	  difference	  in	  being	  at	  
home	  or	  elsewhere	  between	  episodes.	  	  Adherent	  episode	  at	  home	  and	  non-­‐
adherent	  episode	  elsewhere	  was	  more	  common	  than	  non-­‐adherent	  episodes	  
occurring	  at	  home	  and	  adherent	  episodes	  happening	  elsewhere	  (χ2=9.308	  p=.003,	  
ϕ=0.577).	  	  
Table	  11:	  Contingency	  table	  for	  "Where	  were	  you?"	  




	   Home	   Elsewhere	   	  	  	  	  	  	  	  	  	  Total	  
Home	   13	   1	   14	  
Elsewhere	   12	   2	   14	  
Total	   25	   3	   28	  
	  
Daily	  routine	  
As	  shown	  in	  Table	  12,	  there	  was	  also	  a	  significant	  difference	  in	  daily	  routine	  between	  
episodes.	  	  Participants	  were	  more	  likely	  to	  be	  non-­‐adherent	  on	  a	  day	  when	  the	  
routine	  was	  different	  to	  normal	  and	  adherent	  when	  their	  routine	  was	  the	  same	  as	  
normal	  compared	  to	  the	  reverse	  pattern	  (χ2=9,	  p=.004,	  ϕ=0.588).	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from	  normal	   	  	  	  	  	  	  	  	  	  Total	  
Same	  as	  normal	   9	   2	   11	  
Different	  from	  
normal	   14	   1	   15	  
Total	   23	   3	   26	  
	  
	  “I	  felt	  ill”	  
Bivariate	  comparisons	  between	  episode	  on	  the	  measures	  of	  somatic	  experience	  
were	  carried	  out	  using	  paired	  t-­‐tests.	  	  Cohen’s	  d	  was	  calculated	  as	  a	  measure	  of	  
effect	  size	  using	  an	  online	  effect	  size	  calculator	  
(www.psychometrica.de/effect_size.html#dep)	  based	  on	  the	  formulae	  in	  Borenstein	  
(p.	  228,	  2009).	  	  Conventions	  for	  Cohen’s	  d	  are	  as	  follows:	  .20	  –	  small	  effect;	  .50	  –	  
medium	  effect;	  .80	  –	  large	  effect)	  (Cohen,	  1992)	  
	  
There	  was	  no	  significant	  difference	  in	  reports	  of	  “I	  felt	  ill”	  between	  episodes	  
(t(23)=0.31,	  p=0.756,	  d=0.06).	  
Forgetting	  
It	  was	  not	  a	  key	  aim	  of	  this	  study	  to	  make	  any	  between-­‐participants	  comparisons.	  	  
However,	  given	  the	  variation	  in	  responses	  to	  “I	  completely	  forgot”	  on	  non-­‐adherent	  
episodes,	  it	  was	  of	  interest	  to	  explore	  potential	  differences	  on	  the	  primary	  variables	  
	   102	  
between	  those	  participants	  who	  endorsed	  forgetting	  as	  related	  to	  their	  non-­‐
adherence	  and	  those	  who	  did	  not.	  	  The	  sample	  was	  split	  between	  participants	  who	  
strongly	  agreed	  or	  agreed	  with	  this	  statement	  and	  those	  who	  did	  not	  (n1=12,	  
n2=15).	  	  This	  was	  a	  basic	  categorisation	  of	  those	  who	  may	  have	  indicated	  their	  non-­‐
adherence	  was	  unintentional	  and	  those	  where	  non-­‐adherence	  may	  have	  been	  
intentional	  to	  some	  degree.	  	  This	  exploratory	  analysis	  revealed	  no	  significant	  
differences	  on	  the	  IMB	  or	  affective	  variables	  on	  non-­‐adherent	  episodes	  between	  
groups	  on	  two-­‐tailed	  independent	  t-­‐tests.	  
	  
Theory-­‐driven	  Bivariate	  Analysis	  
To	  investigate	  the	  main	  research	  questions,	  bivariate	  analysis	  consisting	  of	  paired	  t-­‐
test	  comparisons	  on	  subscale	  scores	  of	  information,	  motivation	  and	  behavioural	  
skills	  between	  episodes	  was	  carried	  out.	  	  Differences	  between	  positive	  and	  negative	  
affect	  scores	  were	  also	  tested.	  	  	  
	  
It	  was	  not	  possible	  to	  analyse	  the	  substance	  use	  data	  due	  to	  very	  small	  cell	  
frequencies	  for	  this	  variable;	  that	  is	  the	  majority	  of	  the	  sample	  reported	  no	  
substance	  use,	  therefore	  there	  was	  insufficient	  variance	  to	  test.	  	  	  
Information	  
Analysis	  of	  the	  information	  subscale	  was	  carried	  out	  using	  both	  the	  transformed	  
variable	  and	  a	  bootstrapped	  paired	  t-­‐test	  on	  the	  original	  variable.	  	  There	  were	  no	  
significant	  differences	  between	  adherent	  and	  non-­‐adherent	  episode	  on	  the	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information	  subscale	  (transformed	  variable	  (t(25)=.684,	  p=0.50,	  d=0.2)	  and	  
bootstrapped	  paired	  t-­‐test	  (t=-­‐1.113,	  p=.276,	  d=0.055)).	  
Personal	  Motivation	  
There	  were	  no	  significant	  differences	  on	  scores	  of	  personal	  motivation	  between	  
adherent	  or	  non-­‐adherent	  episodes	  (t(26)=.286,	  p=0.78,	  d=0.041).	  
Social	  Motivation	  
One	  item	  pertaining	  to	  social	  norms	  was	  analysed	  separately	  to	  the	  preceding	  
personal	  motivation	  items.	  	  There	  was	  a	  trend	  towards	  higher	  perceived	  social	  
support	  for	  taking	  medication	  at	  the	  time	  of	  adherent	  episode	  compared	  to	  non-­‐
adherent	  episode,	  although	  this	  was	  not	  significant	  (t(27)=1.918,	  p=0.066;	  d=.377).	  
The	  effect	  size	  statistic	  indicates	  a	  small	  to	  medium	  effect	  size	  in	  standard	  
convention	  (Cohen,	  1992).	  
Behavioural	  Skills	  
The	  difference	  in	  behavioural	  skills	  between	  episodes	  was	  highly	  significant,	  with	  
participants	  rating	  their	  abilities	  in	  taking	  medication	  much	  lower	  in	  the	  non-­‐
adherent	  episode	  compared	  to	  the	  adherent	  episode	  (t(25)=-­‐4.949,	  p<0.001;	  
d=0.913).	  	  The	  effect	  size	  for	  this	  analysis	  was	  found	  to	  exceed	  Cohen’s	  (1992)	  
convention	  for	  a	  large	  effect	  (d=.80)	  
Affect	  
There	  was	  a	  significant	  difference	  in	  positive	  affect	  (as	  measured	  by	  the	  PANAS-­‐C	  5	  
item	  positive	  affect	  scale)	  between	  episodes:	  young	  people	  rated	  their	  positive	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emotions	  more	  highly	  at	  the	  time	  of	  taking	  their	  medication	  than	  when	  they	  missed	  
their	  medication	  (t(26)=-­‐3.029,	  p=0.005	  d=0.614).	  
	  
The	  difference	  in	  negative	  affect	  between	  adherent	  and	  non-­‐adherent	  episode	  was	  
not	  significant,	  with	  a	  small-­‐medium	  effect	  size	  (t(25)=1.798,	  p=0.084	  d=0.363).	  
	  
There	  were	  some	  significant	  differences	  between	  additional	  individual	  affect	  items	  
suggested	  by	  the	  focus	  group	  and	  critique	  of	  PANAS	  (Peterson	  et	  al.,	  2013).	  	  Of	  the	  
additional	  negative	  affect	  items,	  feeling	  weak	  (t(26)=0.848,	  p=0.404,	  d=0.118),	  out	  of	  
control	  (t(26)=1.669,	  p=0.107,	  d=0.291)	  and	  helpless	  (t=1.671,	  p=0.130,	  d=0.266)	  
were	  not	  rated	  differently	  across	  adherent	  and	  non-­‐adherent	  episode	  in	  the	  present	  
study.	  	  However,	  ratings	  of	  feeling	  blamed	  (t(26)=3.148,	  p=0.004	  d=0.727)	  were	  
significantly	  higher	  at	  the	  time	  of	  the	  	  non-­‐adherent	  episode	  than	  the	  adherent	  
episode	  and	  show	  a	  medium	  to	  large	  effect.	  	  All	  of	  the	  additional	  positive	  affect	  
items:	  feeling	  calm	  (t(26)=-­‐2.622,	  p=0.014	  d=0.632);	  at	  ease	  (t(26)=-­‐2.267,	  p=0.032	  
d=0.491);	  content	  (t(26)=-­‐2.307,	  p=0.029	  d=0.475);	  and	  satisfied	  (t(26)=-­‐2.394,	  
p=0.024	  d=0.510)	  were	  rated	  significantly	  higher	  when	  participants	  reported	  
adhering	  to	  their	  medication	  compared	  to	  missing	  their	  dose.	  
Associations	  between	  IMB	  variables	  
The	  relationships	  between	  the	  IMB	  primary	  independent	  variables	  were	  analysed	  
using	  Pearson’s	  correlation	  to	  investigate	  whether	  relationships	  between	  the	  
constructs	  were	  consistent	  with	  predictions	  from	  the	  IMB	  model.	  	  The	  correlation	  
coefficients	  per	  episode	  are	  presented	  in	  the	  two	  tables	  below.	  	  Bootstrapped	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correlations	  were	  used	  when	  the	  relationships	  investigated	  included	  the	  non-­‐
normally	  distributed	  non-­‐adherent	  episode	  Information	  variable	  (Field,	  2014).	  	  	  
	  
Table	  13:	  Pearson's	  correlations	  (r)	  between	  IMB	  variables	  for	  adherent	  episode	  





































*statistically	  significant	  p<.05	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Table	  14:	  Pearson's	  correlations	  (r)	  between	  IMB	  variables	  for	  non-­‐adherent	  episode	  





































*statistically	  significant	  p<.05	  
	  
There	  was	  a	  significant	  association	  between	  personal	  motivation	  and	  behavioural	  
skills,	  which	  was	  consistent	  across	  both	  episodes	  (adherent	  episode	  r=-­‐.537,	  p=.006;	  
non-­‐adherent	  episode	  r=-­‐.486,	  p=.010).	  
	  
Theory-­‐Driven	  Exploratory	  Multivariate	  Analysis	  
To	  explore	  the	  relationship	  between	  the	  IMB	  variables	  and	  adherence	  beyond	  the	  
bivariate	  associations,	  multivariate	  analysis	  was	  conducted.	  	  The	  effect	  size	  of	  the	  
relationship	  between	  behavioural	  skills	  and	  adherence	  was	  very	  large.	  	  Multivariate	  
analysis	  would	  enable	  investigation	  of	  the	  combined	  and	  independent	  contribution	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of	  behavioural	  skills	  and	  the	  other	  significant	  predictors	  (positive	  affect,	  routine,	  day	  
and	  location)	  of	  non-­‐adherent	  episodes.	  	  
	  
The	  outcome	  variable	  was	  dichotomous	  (adherent	  or	  non-­‐adherent	  episode),	  
therefore	  a	  logistic	  regression	  model	  was	  used.	  	  Conditional	  logistic	  regression	  is	  the	  
appropriate	  model	  for	  repeated	  measures	  or	  matched-­‐pairs	  data,	  as	  in	  this	  case,	  to	  
avoid	  violating	  the	  assumption	  of	  independence	  in	  logistic	  regression	  (Tabachnik	  &	  
Fidel,	  2006).	  
	  
Logistic	  regression	  models	  are	  based	  on	  binomial	  distributions	  where	  the	  
independent	  variables	  predict	  the	  log	  odds	  of	  binary	  group	  membership	  (the	  
adherent	  or	  non-­‐adherent	  event)	  rather	  than	  the	  proportion	  of	  variance	  in	  the	  
dependent	  variable.	  	  Conditional	  logistic	  regression	  is	  a	  fixed	  effects	  model,	  with	  
matched	  data	  points	  from	  the	  same	  participant,	  compared	  to	  the	  random	  effects	  
model	  in	  standard	  logistic	  regression.	  	  This	  minimises	  the	  degrees	  of	  freedom	  and	  
maximises	  the	  statistical	  power	  of	  the	  model	  (Chatterjee	  &	  Hadi,	  2006).	  However,	  
one	  should	  adopt	  a	  cautious	  approach	  to	  conditional	  logistic	  regression	  in	  small	  
samples	  and	  be	  aware	  of	  possible	  violations	  to	  its	  assumptions	  (Greenland,	  
Schwartzbaum,	  &	  Finkle,	  2000).	  Influential	  and	  outlier	  variables,	  as	  well	  as	  
multicollinearity,	  were	  tested	  as	  the	  assumptions	  of	  conditional	  logistic	  regression.	  	  	  
Multicollinearity	  
Multicollinearity	  refers	  to	  the	  degree	  to	  which	  two	  or	  more	  independent	  variables	  
are	  related	  in	  a	  linear	  way,	  or	  could	  be	  predicted	  from	  one	  another	  with	  significant	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accuracy.	  	  Severe	  multicollinearity	  causes	  invalid	  results	  about	  individual	  predictors	  
in	  a	  regression	  model,	  without	  necessarily	  impacting	  on	  the	  model	  as	  a	  whole	  
(Chatterjee	  &	  Hadi,	  2006).	  	  To	  test	  the	  multicollinearity	  between	  predictor	  variables,	  
the	  variation	  inflation	  factor	  (VIF)	  and	  tolerance	  should	  be	  calculated.	  	  The	  extent	  to	  
which	  the	  regression	  model	  can	  withstand	  multicollinearity	  is	  measured	  by	  
tolerance;	  a	  value	  close	  to	  0	  indicates	  a	  problem.	  	  The	  VIF	  indicates	  how	  much	  the	  
multicollinearity	  is	  inflating	  the	  estimates	  of	  standard	  error;	  a	  value	  greater	  than	  5	  
indicates	  the	  independent	  variables	  are	  very	  closely	  related	  (O’brien,	  2007).	  If	  no	  
relationship	  exists	  between	  any	  of	  the	  predictor	  variables,	  the	  VIF	  and	  tolerance	  will	  
equal	  1	  (Chatterjee	  &	  Hadi,	  2006).	  	  	  
	  
Outliers	  and	  influential	  observations	  are	  quantified	  using	  leverage	  metrics	  (Field,	  
2014).	  	  In	  regression	  models,	  an	  observation	  with	  a	  large	  difference	  between	  the	  
predicted	  and	  observed	  value	  (which	  can	  be	  measured	  by	  statistics	  such	  as	  Pearson’s	  
standard	  residual)	  is	  defined	  as	  an	  outlier.	  	  Such	  variables	  may	  indicate	  a	  data	  error	  
or	  reflect	  an	  unusual	  case	  and	  may	  have	  undue	  influence	  on	  the	  analysis.	  	  The	  
leverage	  value	  (such	  as	  DfBeta)	  measures	  how	  far	  the	  observation	  deviates	  from	  the	  
mean	  (Field,	  2014).	  	  A	  critical	  value	  greater	  than	  3	  for	  Pearson’s	  standard	  residual	  
and	  greater	  than	  1	  for	  DfBeta	  indicate	  problematic	  observations	  (Chatterjee	  &	  Hadi,	  
2006).	  
	  
Given	  the	  small	  sample	  size,	  it	  was	  likely	  that	  individual	  cases	  could	  have	  a	  large	  
influence	  on	  the	  regression	  models.	  	  ‘Overfitting’	  occurs	  when	  the	  number	  of	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parameters	  is	  too	  great	  relative	  to	  the	  number	  of	  observations,	  therefore	  was	  also	  a	  
particular	  issue	  with	  the	  current	  sample	  (Babyak,	  2009).	  	  A	  danger	  with	  overfitting	  is	  
for	  the	  model	  to	  be	  explaining	  random	  error,	  rather	  than	  the	  data	  itself,	  due	  to	  too	  
few	  observations.	  	  Conditional	  logistic	  regression	  can	  exhibit	  considerable	  bias	  in	  the	  
absence	  of	  a	  large	  sample	  when	  there	  are	  too	  many	  covariates	  for	  the	  data	  to	  
support	  (Greenland,	  Schwartzbaum,	  &	  Finkle,	  2000).	  	  Furthermore,	  with	  categorical	  
data	  there	  is	  a	  risk	  of	  large	  standard	  error	  caused	  by	  small	  cell	  sizes.	  
	  
Field	  (2014)	  advises	  at	  least	  ten	  observations	  per	  independent	  variable	  for	  logistic	  
regression	  analysis.	  	  Because	  of	  the	  small	  sample	  size	  and	  dangers	  of	  overfitting	  
(Babyak,	  2009;	  Greenland,	  Schwartzbaum,	  &	  Finkle,	  2000),	  it	  was	  necessary	  to	  
restrict	  the	  multivariate	  analysis	  to	  two	  predictor	  variables	  (and	  these	  models	  should	  
still	  be	  interpreted	  with	  caution).	  	  	  
	  
Because	  non-­‐significant	  results	  had	  been	  obtained	  for	  information	  and	  motivation	  in	  
the	  bivariate	  analysis,	  behavioural	  skill	  was	  selected	  as	  the	  main	  theoretical	  variable	  
of	  interest	  in	  the	  regression	  modelling.	  	  	  
	  
Multivariate	  analysis	  was	  conducted	  to	  explore	  the	  key	  relationship	  between	  
behavioural	  skills	  and	  adherence.	  The	  IMB	  model	  predicts	  that	  mental	  health	  
moderates	  the	  central	  IMB	  variables	  (information,	  motivation	  and	  behavioural	  skills).	  
As	  there	  was	  a	  bivariate	  relationship	  between	  positive	  affect	  (conceptually	  related	  to	  
mental	  health)	  and	  adherence,	  positive	  affect	  was	  added	  to	  behavioural	  skills	  as	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independent	  variables	  in	  a	  conditional	  logistic	  regression	  model.	  .	  	  The	  positive	  affect	  
5-­‐item	  scale	  was	  included	  and	  not	  the	  individual	  additional	  items	  suggested	  by	  
Peterson	  and	  colleagues	  (2013)	  to	  reduce	  the	  chance	  of	  type	  II	  error	  by	  using	  a	  scale	  
with	  greater	  variance	  and	  reliability.	  	  	  	  
	  
Correlations	  between	  behavioural	  skills	  and	  positive	  affect	  were	  investigated	  as	  an	  
initial	  test	  for	  potential	  mulitcollinearity	  problems.	  	  To	  be	  problematic	  in	  conditional	  
logistic	  regression,	  correlation	  coefficients	  would	  need	  to	  be	  greater	  than	  0.70	  
(Chatterjee	  &	  Hadi,	  2006).	  	  For	  non-­‐adherent	  episode	  behavioural	  skills	  and	  positive	  
affect	  were	  significantly	  correlated	  (r=.502,	  p=.011).	  	  There	  was	  no	  correlation	  
between	  behavioural	  skills	  and	  positive	  affect	  for	  adherent	  episode	  (r=.070,	  p=.734).	  	  
These	  statistics	  suggested	  there	  may	  not	  be	  a	  multicollinearity	  issue	  with	  these	  
variables.	  
	  
Conditional	  logistic	  regression	  was	  run	  as	  Cox	  regression	  in	  SPSS	  as	  there	  is	  no	  
available	  option	  to	  run	  conditional	  logistic	  regression	  in	  this	  software.	  	  Cox	  and	  
conditional	  logistic	  regression	  (CLR)	  are	  algebraically	  equivalent	  (Greenland,	  
Schwartzbaum,	  &	  Finkle,	  2000).	  
CLR	  model	  including	  behavioural	  skills	  and	  positive	  affect	  
The	  CLR	  assumptions	  were	  tested	  for	  this	  model	  (Table	  15):	  VIF	  and	  tolerance	  values	  
were	  both	  close	  to	  1;	  Pearson’s	  standard	  residuals	  demonstrated	  no	  values	  higher	  
than	  3;	  DfBeta	  measure	  of	  leverage	  were	  not	  above	  1,	  therefore	  no	  assumptions	  
were	  violated.	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Table	  15:	  CLR	  Model	  with	  Behavioural	  Skills	  and	  Positive	  Affect	  
	  
B	   Std.	  Err.	  
	  
	  
Sig.	   Exp(B)	  




Skills	   -­‐.434	   .236	  
	  
.066	   .648	   .408	   1.029	  
Positive	  
affect	   -­‐.181	   .122	  
	  
.138	   .834	   .657	   1.060	  
	  
An	  overall	  model	  including	  both	  behavioural	  skills	  and	  positive	  affect	  was	  
significantly	  predictive	  of	  adherent	  episode	  (χ2(2)=14.634,	  p=0.001).	  	  After	  
controlling	  for	  shared	  variance	  between	  behavioural	  skills	  and	  positive	  affect,	  there	  
were	  non-­‐significant	  associations	  with	  non-­‐adherent	  episode	  for	  each	  predictor	  
(behavioural	  skills	  AOR=0.65,	  95%CI	  0.41-­‐1.03,	  p=0.066;	  positive	  affect	  AOR=0.83,	  
95%CI	  0.66-­‐1.06,	  p=0.138).	  	  
	  
As	  part	  of	  the	  exploratory	  multivariate	  analysis,	  behavioural	  skill	  was	  tested	  with	  
other	  significant	  bivariate	  predictors	  of	  episode,	  even	  though	  the	  latter	  were	  not	  
included	  in	  the	  IMB	  model.	  	  The	  results	  of	  these	  CLR	  models	  are	  below.	  
Behavioural	  skills	  and	  routine	  
A	  model	  including	  behavioural	  skills	  and	  routine	  significantly	  predicted	  episode	  
outcome	  (χ2(2)=14.271,	  p=0.001).	  	  However,	  the	  bivariate	  effects	  of	  both	  these	  
variables	  were	  eliminated	  when	  controlling	  for	  shared	  variance	  (routine	  AOR=0.14,	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95%CI	  0.01-­‐2.70,	  p=0.195)	  although	  there	  is	  a	  weak	  association	  with	  non-­‐adherence	  
for	  behavioural	  skills	  (AOR=0.64,	  95%CI	  0.39-­‐1.06).	  	  	  
	  
Table	  16:	  CLR	  Model:	  Behavioural	  Skills	  and	  Routine	  
	  
B	   Std.	  Err.	  
	  
	  
Sig.	   Exp(B)	  




Skills	   -­‐.446	   .255	  
	  
.080	   .640	   .388	   1.055	  
Routine	   -­‐1.942	   1.499	  
	  
.195	   .143	   .008	   2.704	  
	  
The	  large	  confidence	  intervals	  for	  routine	  indicate	  a	  problem	  with	  this	  model.	  	  Upon	  
investigating	  the	  CLR	  assumptions,	  although	  multicollinearity	  and	  outliers	  were	  
within	  acceptable	  limits,	  one	  DfBeta	  value	  was	  problematic.	  	  From	  inspection	  of	  the	  
data,	  one	  person	  was	  both	  adherent	  and	  non-­‐adherent	  when	  their	  normal	  routine	  
was	  not	  followed	  and	  this	  pattern	  appears	  to	  have	  significantly	  influenced	  the	  
model.	  	  This	  may	  be	  expected	  in	  CLR	  models	  with	  small	  sample	  sizes,	  as	  mentioned	  
above.	  	  In	  this	  model,	  two	  of	  the	  four	  cells	  have	  cell	  frequencies	  less	  than	  5,	  which	  is	  
highly	  problematic	  for	  this	  statistical	  test	  (as	  mentioned	  earlier	  in	  this	  chapter)	  
(Greenland,	  2000).	  Therefore,	  this	  model	  should	  be	  interpreted	  with	  caution.	  
Behavioural	  skills	  and	  day	  
It	  was	  not	  possible	  to	  fit	  a	  CLR	  model	  with	  behavioural	  skills	  and	  day,	  evidenced	  by	  
very	  large	  standard	  errors.	  	  Investigation	  of	  DFBeta	  diagnostics	  and	  Pearsons’	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standard	  residuals	  demonstrated	  there	  both	  were	  outliers	  (on	  three	  cases)	  and	  
influential	  cases	  (on	  three	  cases)	  within	  the	  dataset.	  	  In	  addition,	  one	  of	  the	  cells	  (for	  
non-­‐adherent	  episode	  on	  weekday	  and	  adherent	  episode	  on	  weekend)	  contained	  0	  
responses.	  	  All	  of	  these	  factors	  prevented	  the	  interpretation	  of	  a	  regression	  model	  
with	  behavioural	  skills	  and	  these	  two	  variables.	  	  	  
Behavioural	  skills	  and	  location	  
It	  was	  not	  possible	  to	  fit	  a	  CLR	  model	  with	  behavioural	  skills	  and	  location,	  evidenced	  
by	  very	  large	  standard	  errors.	  	  The	  diagnostics	  were	  not	  interpretable	  due	  to	  
exceptionally	  large	  variation	  in	  the	  values.	  	  It	  is	  likely	  this	  is	  due	  to	  the	  small	  sample	  
size	  limiting	  the	  cell	  frequencies	  for	  the	  location	  variable.	  	  	  
Prospective	  data	  
Six	  people	  completed	  at	  least	  one	  prospective	  questionnaire.	  	  Frequencies	  of	  
categorical	  data	  are	  not	  reported	  here	  due	  to	  the	  small	  numbers.	  	  Descriptive	  data	  of	  
the	  IMB,	  affective	  and	  somatic	  variables	  are	  presented	  in	  Table	  17	  below.	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Table	  17:	  Descriptive	  statistics	  for	  prospective	  data	  
Variable	  	  
(minimum	  –	  maximum	  
score)	  




	   Mean	  (SD)	   Mean	  (SD)	  
Information	  
(4-­‐20)	  
19	  (1.54)	   19	  (1.55)	  	  
Personal	  Motivation	  
(8-­‐40)	  
17.5	  (4.04)	   20.17	  (7.83)	  
Social	  Motivation	  
(1-­‐5)	  
3.75	  (1.89)	   4.33	  (0.82)	  
Behavioural	  Skills	  
(8-­‐40)	  
37.25	  (11.59)	   36.17	  (9.70)	  
Positive	  affect	  PANAS-­‐C	  5	  
item	  
(5-­‐25)	  
6.00	  (2.00)	   13.83	  (4.67)	  
Negative	  affect	  PANAS-­‐C	  5	  
item	  
(5-­‐25)	  
8.75	  (3.30)	   7.67	  (2.66)	  
I	  felt	  ill	  
(1-­‐5)	  
3.75	  (1.89)	   4.00	  (1.55)	  
Choice	  
(1-­‐5)	  
	   2.33	  (1.21)	  
Forgot	  
(1-­‐5)	  
1.25	  (0.50)	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Unfortunately,	  the	  sample	  size	  was	  too	  small	  to	  carry	  out	  any	  inferential	  statistics	  on	  
this	  data.	  
Summary	  of	  Findings	  
In	  summary,	  bivariate	  analyses	  of	  differences	  within	  individuals	  between	  adherent	  
and	  non-­‐adherent	  episodes	  demonstrated	  the	  central	  IMB	  construct	  of	  behavioural	  
skills,	  as	  well	  as	  positive	  affect,	  were	  significantly	  higher	  at	  the	  time	  of	  adherent	  
compared	  to	  non-­‐adherent	  events.	  	  The	  following	  individual	  affect	  items	  were	  
significantly	  higher	  at	  the	  time	  of	  the	  adherent	  episode	  than	  the	  non-­‐adherent	  
episode:	  calm,	  at	  ease,	  content,	  satisfied.	  	  Ratings	  of	  blamed	  were	  significantly	  lower	  
at	  the	  time	  of	  the	  adherent	  event.	  	  The	  situational	  behavioural	  variables	  that	  
differed	  between	  episodes	  were:	  day	  of	  the	  week	  (week	  day	  or	  weekend),	  being	  
home	  or	  elsewhere	  and	  daily	  routine	  being	  the	  same	  as	  normal	  or	  different	  to	  
normal.	  	  Non-­‐adherent	  episodes	  were	  more	  likely	  at	  the	  weekend,	  outside	  of	  the	  
home	  and	  when	  routine	  was	  different	  to	  usual.	  	  There	  were	  no	  statistically	  
significant	  differences	  between	  adherent	  and	  non-­‐adherent	  episodes	  on	  negative	  
affect	  or	  social	  motivation,	  although	  both	  of	  these	  comparisons	  demonstrated	  small-­‐
medium	  effect	  sizes.	  
	  
Multivariate	  analyses	  (conditional	  logistic	  regression)	  demonstrated	  that	  behavioural	  
skills	  and	  positive	  affect	  together	  significantly	  predicted	  non-­‐adherent	  episodes.	  	  
There	  were	  statistically	  non-­‐significant	  effects	  of	  each	  predictor	  when	  controlling	  for	  
the	  other,	  although	  the	  adjusted	  odds	  ratio	  for	  behavioural	  skills	  probably	  
represents	  a	  small	  to	  medium	  effect	  that	  did	  not	  reach	  significance	  due	  to	  low	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power.	  	  Conclusions	  could	  not	  be	  drawn	  from	  the	  conditional	  logistic	  regression	  
models	  including	  behavioural	  skills	  and	  routine,	  day	  or	  location	  due	  to	  the	  small	  
sample	  size	  leading	  to	  violations	  of	  the	  CLR	  assumptions	  or	  creating	  problems	  in	  
interpreting	  the	  CLR	  models.	  	  	  
Discussion	  
The	  aim	  of	  this	  research	  was	  to	  investigate	  situational	  psychological	  and	  behavioural	  
correlates	  of	  episodic	  medication	  adherence	  amongst	  young	  people	  with	  PHIV+.	  	  The	  
IMB	  model	  informed	  the	  main	  psychological	  constructs	  under	  investigation,	  which	  
included	  adherence-­‐related	  behavioural	  skills,	  personal	  and	  social	  motivation,	  
information,	  and	  mood,	  as	  measured	  by	  positive	  and	  negative	  affect.	  	  	  
Overview	  of	  study	  findings	  
Behavioural	  skills	  
A	  person’s	  objective	  and	  perceived	  abilities	  to	  adhere	  to	  their	  medications	  are	  
referred	  to	  as	  behavioural	  skills	  in	  the	  IMB	  model.	  	  This	  includes	  having	  both	  
confidence	  and	  skill	  to	  self-­‐cue	  and	  self-­‐administer	  ART,	  incorporate	  these	  into	  the	  
daily	  routine,	  manage	  possible	  unwanted	  effects	  and	  reinforce	  oneself	  to	  continue	  
to	  adhere	  over	  time	  (Fisher,	  Fisher,	  &	  Shuper,	  2014).	  The	  significant	  effect	  of	  
behavioural	  skills	  on	  adherence	  was	  particularly	  strong	  in	  the	  present	  study,	  
exceeding	  Cohen's	  (1992)	  convention	  for	  a	  large	  effect.	  	  This	  is	  in	  keeping	  with	  the	  
theoretical	  model,	  which	  positions	  behavioural	  skills	  as	  the	  central	  construct	  and	  
most	  proximal	  to	  adherence	  behaviour.	  That	  is,	  an	  individual’s	  adherence-­‐related	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information	  and	  motivation	  are	  limited	  by	  their	  ability	  to	  enact	  adherence-­‐related	  
behavioural	  skills	  (Fisher	  et	  al.,	  2008).	  	  	  
	  
Behavioural	  skill	  was	  predictive	  of	  non-­‐adherence	  when	  combined	  with	  situational	  
positive	  affect	  in	  a	  multivariate	  model.	  	  In	  controlling	  for	  shared	  variance	  with	  
positive	  affect,	  the	  effect	  of	  behavioural	  skills	  was	  no	  longer	  statistically	  significant	  
(p=.066).	  	  However,	  it	  is	  likely	  this	  finding	  was	  due	  to	  a	  lack	  of	  adequate	  power	  to	  
support	  the	  multivariate	  analysis;	  the	  adjusted	  odds	  ratio	  indicates	  a	  small	  sized	  
effect.	  	  With	  a	  larger	  sample,	  therefore,	  it	  may	  have	  reached	  statistical	  significance	  
(discussed	  further	  in	  ‘Limitations’	  section,	  below).	  	  This	  may	  suggest	  that	  perceived	  
confidence	  in	  one’s	  abilities	  to	  adhere	  could	  be	  an	  important	  determinant	  of	  non-­‐
adherence	  regardless	  of	  situational	  levels	  of	  positive	  feelings.	  	  Therefore,	  although	  
this	  finding	  was	  not	  significant	  with	  the	  current	  sample,	  the	  potential	  clinical	  
implications	  of	  this	  are	  tentatively	  discussed	  in	  a	  later	  section	  of	  this	  chapter.	  	  	  
	  
In	  the	  present	  study,	  the	  behavioural	  skills	  subscale	  targeted	  the	  young	  person’s	  
perception	  of	  their	  adherence-­‐related	  skills.	  	  This	  perceived	  abilities	  component	  has	  
also	  been	  labelled	  ‘self-­‐efficacy’	  in	  the	  adherence	  literature.	  	  Bandura’s	  theory	  of	  
self-­‐efficacy	  asserts	  that	  possession	  of	  knowledge	  or	  skills	  is	  insufficient	  to	  impact	  on	  
behaviour,	  and	  that	  confidence	  in	  one’s	  abilities	  is	  a	  crucial	  determinant	  of	  action	  
(Bandura,	  1986;	  Brown,	  Littlewood,	  &	  Vanable,	  2013).	  	  Self-­‐efficacy	  is	  not	  a	  stable	  
trait	  (Strecher,	  et	  al,	  1986).	  	  The	  level	  of	  confidence	  in	  the	  capacity	  to	  enact	  a	  
behaviour	  is	  likely	  to	  vary	  over	  time	  and	  across	  situations,	  impacting	  on	  one’s	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performance	  of	  the	  behaviour.	  	  Self-­‐efficacy	  has	  been	  studied	  extensively	  across	  a	  
variety	  of	  health	  behaviours	  in	  adults	  and	  adolescents,	  including	  smoking	  behaviours	  
(Gwaltney,	  Shiffman,	  Balabanis,	  &	  Paty,	  2005;	  Van	  Zundert,	  Engels,	  &	  Kuntsche,	  
2011),	  consumption	  of	  dietary	  fat	  and	  sugar	  (McClain,	  Chappuis,	  Nguyen-­‐Rodriguez,	  
Yaroch,	  &	  Spruijt-­‐Metz,	  2009;	  Pawlak	  &	  Colby,	  2009)	  and	  condom	  use	  (Chirinda	  &	  
Peltzer,	  2014;	  Walsh	  et	  al.,	  2011)	  and	  demonstrated	  to	  vary	  according	  to	  situation.	  	  	  
	  
Self-­‐efficacy	  has	  also	  consistently	  been	  associated	  with	  adherence	  between	  
individuals	  in	  a	  variety	  of	  populations	  and	  health	  conditions	  (e.g.	  Bucks	  et	  al.,	  2009;	  
Griva,	  Myers,	  &	  Newman,	  2000).	  	  Relationships	  between	  higher	  levels	  of	  self-­‐efficacy	  
and	  higher	  ART	  adherence	  have	  been	  demonstrated	  between-­‐participants	  in	  the	  
PHIV+	  population	  in	  Thailand	  (Kang,	  Delzell,	  Chhabra,	  &	  Oberdorfer,	  2014)	  and	  the	  
USA	  (Rudy,	  Murphy,	  Harris,	  Muenz,	  &	  Ellen,	  2010).	  	  The	  findings	  of	  the	  current	  study	  
support	  the	  theoretical	  understanding	  of	  self-­‐efficacy	  as	  a	  dynamic	  construct	  that	  
changes	  situationally.	  	  Causality	  cannot	  be	  inferred	  from	  the	  current	  study,	  that	  is	  
low	  levels	  of	  behavioural	  skills	  cannot	  be	  said	  to	  cause	  non-­‐adherence	  to	  ART,	  
because	  the	  design	  of	  this	  study	  was	  not	  experimental.	  	  However,	  there	  appears	  to	  
be	  a	  clear	  variation	  in	  self-­‐efficacy	  within	  individuals,	  which	  seems	  to	  be	  related	  to	  
inconsistent	  ART	  adherence.	  
	  
There	  are	  a	  number	  of	  possible	  theoretical	  explanations	  for	  the	  variation	  in	  self-­‐
efficacy	  observed	  between	  adherent	  and	  non-­‐adherent	  episodes.	  	  Bandura	  
suggested	  that	  higher	  confidence	  is	  followed	  by	  greater	  effort	  and	  persistence	  in	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solving	  a	  problem,	  even	  when	  faced	  with	  a	  challenge	  (Bandura,	  1986).	  	  There	  may	  
have	  been	  different	  challenges	  faced	  by	  the	  young	  participants	  between	  adherent	  
and	  non-­‐adherent	  episodes	  in	  the	  present	  study,	  which	  subsequently	  may	  have	  
impacted	  on	  the	  degree	  of	  effort	  and	  confidence	  in	  adhering	  to	  ART.	  
	  
Other	  possible	  explanations	  for	  the	  differences	  in	  behavioural	  skills	  between	  episode	  
could	  be	  methodological.	  Despite	  using	  a	  new	  and	  unvalidated	  scale,	  the	  reliability	  
was	  very	  good	  across	  the	  behavioural	  skills	  subscales.	  	  Measurement	  error	  would	  
reduce	  the	  size	  of	  effect	  found,	  yet	  the	  results	  indicate	  a	  large	  effect	  of	  behavioural	  
skills	  on	  adherence.	  	  Finally,	  expected	  correlations	  with	  motivation	  were	  found	  
(discussed	  under	  ‘Personal	  Motivation’	  below).	  
	  
It	  is	  possible	  that	  there	  was	  recall	  bias	  in	  the	  participants’	  responses,	  leading	  to	  
significant	  differences	  between	  episodes.	  	  However,	  there	  were	  no	  differences	  in	  the	  
motivation	  or	  information	  scales	  between	  episodes,	  therefore	  it	  is	  unlikely:	  recall	  
bias	  would	  be	  more	  likely	  to	  have	  consistently	  affected	  the	  findings	  across	  all	  
subscales,	  which	  was	  not	  the	  case.	  	  
	  
The	  difference	  in	  behavioural	  skills	  between	  episode	  could	  also	  be	  due	  to	  post-­‐hoc	  
rationalising	  on	  the	  part	  of	  the	  participants.	  	  A	  young	  person	  may	  have	  decided	  they	  
must	  not	  have	  felt	  confident	  at	  the	  time	  of	  non-­‐adherence	  by	  virtue	  of	  having	  not	  
taken	  their	  medication	  at	  that	  same	  time.	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Social	  motivation	  	  
There	  were	  no	  statistically	  significant	  differences	  found	  between	  episodes	  on	  social	  
motivation.	  	  However,	  there	  was	  a	  small-­‐medium	  sized	  effect	  towards	  higher	  
perceived	  social	  pressure	  at	  the	  time	  of	  adherent	  episodes	  than	  non-­‐adherent	  
episodes.	  	  This	  trend	  may	  have	  reached	  statistical	  significance	  with	  a	  greater	  number	  
of	  participants	  and	  it	  is	  possible	  that	  these	  findings	  were	  subject	  to	  a	  type	  II	  error.	  	  
The	  social	  motivation	  subscale	  could	  be	  expanded	  to	  include	  more	  items,	  to	  enable	  
this	  construct	  to	  be	  measured	  in	  a	  more	  robust	  way.	  	  	  This	  construct	  was	  measured	  
with	  a	  single	  item,	  taken	  from	  the	  LifeWindows	  IMB	  Adherence	  Questionnaire,	  from	  
which	  limited	  conclusions	  can	  be	  drawn	  (The	  LifeWindows	  Project	  Team,	  2006).	  	  
However,	  this	  was	  the	  primary	  social	  motivation	  from	  the	  LW-­‐IMB-­‐AAQ;	  two	  
additional	  social	  motivation	  items	  referred	  to	  the	  perception	  of	  support	  from	  clinic	  
staff.	  	  This	  was	  unlikely	  to	  vary	  my	  situation,	  thus	  was	  excluded	  from	  the	  scale	  in	  this	  
stud.	  	  By	  increasing	  the	  number	  of	  scale	  items,	  the	  subscale	  reliability	  might	  
increase.	  	  	  	  	  
	  
Kalichman,	  and	  colleagues,	  criticise	  the	  IMB	  model	  because	  of	  the	  inconsistent	  
association	  between	  motivation	  and	  adherence	  behaviour	  (Kalichman,	  Picciano,	  &	  
Roffman,	  2008).	  	  Construct	  validity	  may	  be	  problematic	  in	  some	  measurements	  of	  
social	  motivation;	  objective	  social	  support	  and	  perception	  of	  social	  support	  (one	  
aspect	  of	  social	  motivation)	  may	  be	  conflated	  (e.g.	  Rongkavilit,	  et	  al,	  2010).	  	  In	  the	  
current	  study,	  the	  single	  social	  motivation	  item	  asked	  participants	  to	  what	  extent	  
they	  thought	  important	  people	  were	  supportive	  of	  their	  ART	  regimen.	  This	  item	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seems	  to	  clearly	  ask	  about	  perception,	  not	  about	  the	  presence	  or	  absence	  of	  social	  
support.	  	  	  
Personal	  motivation	  	  
There	  were	  no	  significant	  differences	  between	  adherent	  and	  non-­‐adherent	  episodes	  
on	  the	  personal	  motivation	  subscale.	  	  It	  is	  unlikely	  the	  current	  findings	  were	  due	  to	  
measurement	  error	  or	  sample	  size	  due	  to	  the	  very	  small	  size	  of	  effect.	  	  There	  were,	  
however,	  significant	  relationships	  between	  personal	  motivation	  and	  behavioural	  
skills	  on	  both	  adherent	  and	  non-­‐adherent	  episodes.	  	  This	  relationship	  is	  in	  keeping	  
with	  the	  IMB	  model:	  the	  main	  effect	  of	  motivation	  on	  adherence	  is	  mediated	  
through	  behavioural	  skills,	  although	  it	  was	  not	  possible	  to	  test	  a	  mediating	  
relationship	  due	  to	  the	  lack	  of	  power	  for	  multivariate	  analysis.	  	  
	  
It	  is	  possible	  that	  some	  aspects	  of	  adherence	  motivation	  do	  change	  over	  time	  or	  
according	  to	  situation,	  but	  in	  the	  aspects	  measured	  in	  the	  present	  study	  were	  stable.	  	  
The	  relationship	  between	  personal	  motivation	  (or	  outcome	  expectancies	  –	  one	  of	  its	  
components)	  and	  adherence	  is	  inconsistent	  in	  the	  literature	  and	  does	  not	  always	  
differentiate	  good	  adherers	  from	  bad	  adherers	  in	  between-­‐participant	  studies	  	  
(Brown	  et	  al.,	  2013).	  	  In	  the	  current	  study,	  personal	  motivation	  to	  adhere	  does	  not	  
appear	  to	  differentiate	  adherence	  within	  individuals.	  	  This	  is	  consistent	  with	  the	  
findings	  of	  an	  investigation	  in	  adults	  with	  Thalassaemia	  that	  used	  a	  similar	  
methodology	  to	  the	  present	  study	  (Vosper,	  Evangeli,	  Porter,	  &	  Shah,	  2013).	  	  
Although	  there	  were	  significant	  effects	  of	  self-­‐efficacy	  and	  outcome	  expectancy	  in	  a	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multivariate	  model,	  there	  was	  no	  independent	  effect	  of	  outcome	  expectancy	  on	  
episodic	  adherence.	  	  	  
	  
The	  IMB	  model	  also	  suggests	  some	  influence	  of	  personal	  motivation	  (albeit	  to	  a	  
lesser	  degree)	  on	  adherence	  behaviour	  itself,	  which	  was	  not	  found	  in	  the	  present	  
study.	  	  There	  may	  be	  alternative	  theoretical	  explanations	  for	  this,	  drawing	  on	  
principles	  from	  other	  health-­‐behaviour	  theory.	  	  A	  critique	  of	  continuum	  models,	  such	  
as	  IMB,	  is	  the	  absence	  of	  “post-­‐intention”	  explanations	  (Sheeran,	  Webb,	  &	  
Gollwitzer,	  2005).	  	  That	  is,	  once	  motivation	  is	  established,	  there	  is	  little	  account	  of	  
how	  these	  are	  actually	  translated	  into	  behaviour:	  there	  may	  be	  further	  barriers	  to	  
adhere	  despite	  good	  motivation	  to	  do	  so	  and	  high	  confidence	  in	  one’s	  abilities	  to	  do	  
so.	  	  One	  theory,	  the	  Health	  Action	  Process	  Approach	  (HAPA)	  (Schwarzer,	  1992;	  
Schwarzer	  &	  Luszczynska,	  2008),	  describes	  postintentional	  volitional	  processes	  that	  
enable	  an	  intended	  behaviour	  to	  be	  enacted,	  such	  as	  action	  planning	  and	  
implementation	  intentions	  (discussed	  further	  below,	  in	  relation	  to	  ‘forgetting’)	  
(Brandstätter,	  Lengfelder,	  &	  Gollwitzer,	  2001;	  Sheeran	  et	  al.,	  2005).	  	  In	  the	  present	  
research,	  in	  relation	  to	  the	  lack	  of	  significant	  difference	  in	  personal	  motivation	  
between	  adherent	  and	  non-­‐adherent	  episode,	  there	  may	  have	  been	  a	  difference	  in	  
post-­‐motivational	  processes	  that	  would	  account	  for	  the	  difference	  in	  adherence	  
behaviour.	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Information	  	  
There	  were	  no	  significant	  differences	  within-­‐participants	  on	  the	  measure	  of	  
information.	  	  Scores	  on	  this	  scale	  were	  very	  high	  for	  all	  participants	  on	  both	  
episodes,	  therefore	  it	  is	  possible	  the	  lack	  of	  difference	  is	  due	  to	  a	  ceiling	  effect.	  	  It	  is	  
also	  possible	  that	  information	  remains	  static	  and	  does	  not	  vary	  by	  situation	  despite	  
attempts	  by	  the	  author	  to	  phrase	  the	  questionnaire	  items	  situationally.	  	  	  
	  
In	  the	  IMB	  model,	  information	  (about	  regimen,	  the	  importance	  of	  high	  levels	  of	  
adherence,	  potential	  drug	  interactions	  and	  possible	  side	  effects)	  is	  described	  as	  an	  
essential	  prerequisite	  for	  adequate	  adherence	  	  (Fisher	  et	  al.,	  2014).	  	  The	  influence	  of	  
information	  is	  mostly	  mediated	  through	  behavioural	  skills	  except	  for	  simple	  and	  
automated	  behaviours,	  which	  might	  be	  driven	  directly	  by	  information	  	  (Fisher	  et	  al.,	  
2008).	  	  However,	  given	  ART	  adherence	  is	  neither	  simple	  nor	  automated	  due	  to	  the	  
complexity	  of	  most	  regimens,	  it	  may	  not	  be	  the	  case	  that	  information	  has	  a	  direct,	  
influence	  on	  adherence.	  	  Previous	  studies	  using	  the	  IMB	  model	  have	  found	  a	  lack	  of	  
direct	  relationship	  between	  information	  and	  ART	  adherence	  (Starace,	  Massa,	  Amico	  
&	  Fisher,	  2006;	  Horvath,	  et	  al,	  2014).	  	  In	  previous	  studies	  with	  HIV+	  adolescents,	  
ART-­‐related	  knowledge	  has	  seldom	  been	  found	  to	  be	  a	  barrier	  to	  actual	  adherence	  
behaviour.	  	  In	  Murphy	  and	  colleagues’	  (2003)	  study	  of	  the	  association	  between	  non-­‐
adherence	  and	  possible	  predictors,	  less	  than	  6%	  of	  114	  young	  people	  endorsed	  an	  
information-­‐related	  item	  (“confused	  about	  what	  to	  take”)	  as	  a	  reason	  for	  not	  taking	  
ART.	  	  Self-­‐assessed	  HIV	  knowledge	  was	  not	  related	  to	  adherence	  in	  a	  study	  of	  HIV+	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adults	  in	  the	  USA	  	  (Nelsen	  et	  al.,	  2013).	  	  It	  may	  be	  that	  ART-­‐related	  information	  and	  
knowledge	  is	  necessary	  but	  not	  sufficient	  for	  adherence	  to	  occur.	  
	  
The	  information	  subscale	  had	  high	  internal	  consistency,	  contrary	  to	  the	  LifeWindows	  
validation	  study.	  	  In	  the	  original	  measure,	  there	  were	  nine	  information	  subscale	  
items	  with	  low	  internal	  consistency,	  explained	  by	  the	  diverse	  aspects	  of	  an	  ART	  
regimen	  of	  which	  one	  would	  need	  knowledge,	  therefore	  items	  were	  not	  expected	  to	  
inter-­‐relate	  (The	  LifeWindows	  Project	  Team,	  2006).	  	  Less	  variation	  may	  have	  
occurred	  in	  this	  study,	  where	  all	  items	  were	  related	  to	  a	  very	  specific	  knowledge	  
base,	  relating	  to	  those	  aspects	  of	  the	  information	  construct	  that	  could	  plausibly	  
change	  according	  situation.	  	  
	  
Affect	  
Within-­‐participant	  differences	  in	  negative	  emotions	  were	  not	  significantly	  associated	  
with	  adherent	  or	  non-­‐adherent	  episodes	  as	  measured	  on	  the	  standard	  five-­‐item	  
PANAS-­‐C	  scale,	  although,	  there	  was	  a	  small-­‐medium	  sized	  effect	  towards	  greater	  
reported	  negative	  affect	  at	  times	  of	  non-­‐adherence.	  Previous	  studies	  have	  found	  
variable	  relationships	  between	  negative	  affect	  and	  adherence	  behaviour	  (Gonzalez	  
et	  al.,	  2007).	  	  In	  the	  current	  study,	  however,	  there	  may	  have	  been	  insufficient	  power	  
to	  support	  the	  analysis	  of	  the	  negative	  affect	  scale	  and	  additional	  items,	  the	  size	  of	  
effect	  indicates	  a	  larger	  sample	  may	  have	  yielded	  significant	  results.	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The	  additional	  negative	  affect	  items	  suggested	  by	  the	  pilot	  group	  were	  generally	  
non-­‐significant	  between	  episodes.	  	  However,	  feeling	  blamed	  was	  significantly	  higher	  
at	  the	  time	  of	  a	  non-­‐adherent	  event	  with	  a	  medium-­‐large	  effect.	  	  This	  could	  have	  
been	  due	  to	  the	  non-­‐adherent	  event	  itself,	  rather	  than	  a	  causal	  influence	  of	  feeling	  
‘blamed’	  on	  the	  non-­‐adherent	  event.	  	  That	  is,	  young	  people	  may	  have	  felt	  blamed	  
because	  they	  did	  not	  take	  their	  ART,	  rather	  than	  not	  taking	  their	  ART	  because	  they	  
felt	  blamed.	  	  This	  association	  could	  be	  explored	  further	  using	  Ecological	  Momentary	  
Assessment	  methods	  	  (Shiffman,	  Stone,	  &	  Hufford,	  2008),	  which	  would	  enable	  closer	  
study	  of	  the	  temporal	  associations	  between	  the	  feeling	  and	  the	  non-­‐adherent	  event.	  	  
Such	  methods	  have	  been	  employed	  to	  investigate	  momentary	  changes	  in	  affect	  
related	  to	  stages	  of	  smoking	  cessation	  in	  adolescents	  	  (Hoeppner,	  Kahler,	  &	  
Gwaltney,	  2014).	  	  By	  recording	  scale	  ratings	  of	  young	  participants’	  affect	  at	  fixed	  
time	  intervals,	  the	  authors	  were	  able	  to	  conclude	  that	  there	  were	  momentary	  
changes	  in	  affect	  related	  to	  momentary	  self	  efficacy	  immediately	  before	  and	  after	  a	  
quit	  attempt.	  	  A	  similar	  technique	  would	  enable	  fluctuations	  in	  ‘blamed’	  feelings	  (or	  
other	  feelings)	  to	  be	  measured	  and	  analysed	  according	  to	  the	  proximity	  to	  the	  non-­‐
adherent	  episode.	  
	  
Situational	  pleasant	  emotions	  were	  associated	  with	  episodic	  medication	  adherence,	  
with	  higher	  ratings	  of	  positive	  affect	  on	  the	  standardised	  five-­‐item	  scale	  at	  the	  time	  
of	  an	  adherent	  episode	  compared	  to	  a	  non-­‐adherent	  episode.	  	  As	  well	  as	  this,	  all	  
additional	  positive	  affect	  items	  (added	  to	  measure	  non-­‐activated	  positive	  affect)	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were	  significantly	  higher	  during	  ART	  adherent	  episodes	  than	  non-­‐adherent	  episodes.	  
This	  highlights	  the	  utility	  of	  scale	  measurement	  for	  psychological	  states.	  
	  
An	  alternative	  approach	  to	  measurement	  of	  affect	  would	  be	  to	  draw	  on	  the	  
circumplex	  model	  of	  core	  affect	  	  (Yik,	  Russell,	  &	  Steiger,	  2011).	  	  In	  this	  framework,	  
affect	  is	  divided	  according	  to	  dimensions	  of	  valence	  and	  activation,	  resulting	  in	  four	  
quadrants	  of	  emotion:	  pleasant/activated,	  unpleasant/activated,	  pleasant/non-­‐
activated,	  unpleasant/non-­‐activated.	  	  In	  the	  current	  study,	  it	  appears	  that	  both	  
activated	  and	  non-­‐activated	  positive	  affect	  varies	  according	  to	  adherent	  or	  non-­‐
adherent	  episode.	  	  However,	  there	  is	  no	  comparable	  measure	  of	  negative	  affect.	  	  
Future	  research	  could	  investigate	  differences	  in	  situational	  affect	  along	  these	  four	  
dimensions.	  
	  
This	  finding	  correlates	  with	  the	  wider	  ART	  adherence	  literature	  implicating	  mental	  
health	  difficulties	  as	  a	  barrier	  to	  adherence	  (Kapetanovic	  et	  al.,	  2011;	  Mellins	  &	  
Malee,	  2013).	  	  Previous	  research	  investigating	  mental	  health	  has	  tended	  to	  focus	  on	  
diagnosis	  as	  an	  index	  of	  psychopathology.	  	  The	  presence	  or	  absence	  of	  a	  current	  or	  
historic	  psychiatric	  diagnosis	  may	  be	  inadequate	  in	  measuring	  symptoms	  of	  
psychological	  distress.	  	  The	  absence	  of	  a	  diagnostic	  label	  does	  not	  necessarily	  equate	  
to	  an	  absence	  of	  psychological	  distress.	  	  Alternatively,	  a	  diagnosis	  may	  suggest	  that	  a	  
person	  has	  received	  psychological	  support	  or	  treatment,	  which	  might	  reduce	  the	  
impact	  of	  mental	  health	  symptoms	  on	  adherence.	  	  Further,	  in	  assigning	  people	  to	  
groups	  of	  diagnoses	  or	  presence	  or	  absence	  of	  mental	  disorder,	  there	  is	  loss	  of	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variability	  in	  the	  data	  collected.	  	  That	  is,	  the	  extent	  to	  which	  individuals	  experience	  
particular	  symptoms	  or	  psychological	  states	  is	  not	  recorded	  in	  as	  comprehensive	  a	  
way	  that	  would	  be	  more	  possible	  with	  scale	  measurement.	  	  Therefore,	  particularly	  in	  
event-­‐level	  designs,	  it	  may	  be	  appropriate	  to	  use	  scales	  to	  measure	  affective	  states	  
(as	  in	  the	  current	  study).	  
Forgetting	  
Young	  people	  were	  not	  asked	  about	  intentional	  non-­‐adherence.	  	  However,	  more	  
than	  a	  third	  of	  the	  sample	  in	  the	  present	  study	  did	  not	  agree	  that	  their	  non-­‐adherent	  
event	  was	  due	  to	  forgetting.	  This	  is	  an	  often-­‐cited	  explanation	  for	  failing	  to	  take	  
medication	  in	  the	  between-­‐subjects	  adherence	  literature	  with	  this	  population	  	  
(MacDonell,	  Naar-­‐King,	  Huszti,	  &	  Belzer,	  2013).	  	  It	  may	  be	  reasonable	  to	  cautiously	  
assume	  an	  element	  of	  intentional	  non-­‐adherence	  with	  this	  subset	  of	  participants.	  
Participants	  may	  have	  deliberately	  chosen	  not	  to	  take	  their	  medication	  for	  particular	  
reasons	  in	  a	  particular	  situation.	  	  The	  significant	  episodic	  variables	  in	  this	  study	  may	  
have	  differential	  relationships	  depending	  on	  whether	  the	  non-­‐adherence	  was	  
intentional	  or	  unintentional.	  	  In	  comparisons	  between	  the	  subset	  of	  participants	  who	  
agreed	  with	  forgetting	  as	  a	  reason	  for	  non-­‐adherence	  and	  those	  who	  did	  not	  agree,	  
there	  were	  no	  significant	  differences	  on	  any	  of	  the	  primary	  variables	  (IMB	  or	  affect).	  	  
However,	  due	  to	  the	  small	  number	  of	  participants	  in	  each	  group,	  there	  is	  an	  
increased	  risk	  of	  Type	  II	  error.	  	  The	  study	  was	  not	  powered	  for	  any	  between-­‐groups	  
comparisons,	  which	  require	  larger	  samples,	  therefore	  these	  analyses	  may	  have	  
lacked	  sufficient	  power	  to	  detect	  significant	  effects.	  	  Further,	  the	  way	  in	  which	  
participants	  were	  grouped	  may	  not	  have	  been	  valid.	  	  Participants	  who	  ‘strongly	  
	   128	  
disagreed’	  and	  ‘neither	  agreed	  or	  disagreed’	  with	  forgetting	  as	  a	  barrier	  to	  their	  non-­‐
adherent	  episode	  may	  not	  have	  been	  a	  homogenous	  group.	  	  In	  further	  studies	  with	  
larger	  samples,	  analysis	  of	  variance	  tests	  would	  allow	  for	  investigation	  of	  potential	  
differences	  between	  participants	  depending	  on	  to	  what	  extent	  they	  endorsed	  
forgetting	  as	  an	  explanation	  (without	  having	  to	  condense	  participant	  responses	  into	  
groups,	  thereby	  reducing	  the	  statistical	  power).	  	  A	  larger	  dataset	  would	  have	  
enabled	  further	  investigation	  of	  whether	  the	  relationships	  between	  other	  variables	  
of	  interest	  might	  be	  different	  according	  to	  intention	  to	  adhere	  or	  not.	  
	  
Forgetting	  may	  be	  a	  particularly	  pertinent	  factor,	  given	  what	  is	  known	  about	  
potential	  cognitive	  difficulties	  experienced	  by	  PHIV+	  young	  people	  	  (Puthanakit	  et	  al.,	  
2010).	  	  Deficits	  in	  working	  memory	  may	  help	  to	  explain	  episodic	  non-­‐adherence.	  	  
Particularly	  in	  the	  case	  of	  changes	  to	  usual	  routine	  and	  location,	  an	  absence	  of	  
relied-­‐upon	  structural	  cues	  would	  necessitate	  a	  greater	  reliance	  on	  working	  memory,	  
which	  may	  be	  impaired	  to	  some	  degree	  in	  the	  PHIV+	  population,	  as	  discussed	  in	  the	  
introduction	  	  (Laughton,	  Cornell,	  &	  Boivin,	  2013;	  Smith	  &	  Wilkins,	  2014).	  	  There	  was	  
no	  measure	  of	  cognitive	  function	  or	  working	  memory	  ability	  in	  the	  current	  study.	  	  In	  
future	  research,	  a	  baseline	  index	  of	  cognition	  would	  enable	  investigation	  of	  
differences	  in	  forgetting	  as	  related	  to	  overall	  cognitive	  or	  memory	  ability.	  	  	  
	  
The	  present	  results	  suggest	  that	  it	  may	  be	  valuable	  to	  move	  beyond	  viewing	  
‘forgetting’	  as	  a	  reason	  for	  non-­‐adherence	  and	  towards	  a	  focus	  on	  which	  situations	  
are	  more	  or	  less	  likely	  to	  be	  associated	  with	  forgetting.	  	  Perhaps	  the	  use	  of	  specific	  
	   129	  
strategies	  in	  particular	  situations	  is	  especially	  adaptive,	  such	  as	  the	  common	  method	  
of	  writing	  down	  reminders.	  	  In	  other	  situations	  there	  may	  be	  obstacles	  to	  using	  usual	  
reminders,	  which	  could	  interfere	  with	  the	  adherence	  process.	  	  This	  highlights	  an	  
important	  clinical	  implication	  (discussed	  further	  in	  a	  later	  section):	  a	  greater	  
understanding	  of	  situational	  factors	  implicated	  in	  non-­‐adherence	  would	  help	  
clinicians	  and	  young	  people	  to	  plan	  in	  advance	  strategies	  to	  manage	  such	  situations.	  
Behavioural	  situational	  variables	  
There	  were	  significant	  differences	  between	  episode	  in	  routine,	  location	  at	  the	  time	  
of	  medication	  and	  day	  of	  the	  week.	  	  Participants’	  adherent	  episodes	  were	  more	  
likely	  to	  occur	  at	  home	  and	  non-­‐adherent	  episodes	  elsewhere,	  than	  the	  opposite	  
pattern.	  	  Participants	  were	  more	  likely	  to	  be	  adherent	  on	  a	  weekday	  (Monday	  to	  
Thursday)	  and	  non-­‐adherent	  at	  the	  weekend	  (Friday	  to	  Sunday)	  than	  the	  reverse.	  	  
Participants	  were	  more	  likely	  to	  be	  non-­‐adherent	  if	  their	  routine	  was	  different	  to	  
usual	  and	  adherent	  when	  their	  daily	  routine	  was	  normal.	  	  Being	  away	  from	  home	  
and	  having	  a	  change	  in	  routine	  are	  often-­‐cited	  reasons	  for	  non-­‐adherence	  in	  
between-­‐participant	  studies	  	  (Buchanan	  et	  al.,	  2012;	  Murphy	  et	  al.,	  2003;	  Rudy,	  
Murphy,	  Harris,	  Muenz,	  &	  Ellen,	  2009).	  	  The	  findings	  of	  the	  present	  study	  are	  in	  
keeping	  with	  this	  literature,	  and	  with	  the	  within-­‐participants	  differences	  found	  in	  
Vosper,	  et	  al,	  (2013)	  in	  explaining	  the	  variation	  within	  individuals	  rather	  than	  
between	  individuals.	  
	  
The	  differences	  between	  episodes	  on	  behavioural	  variables	  suggest	  it	  may	  have	  been	  
more	  difficult	  to	  adhere	  in	  particular	  contexts.	  If	  a	  young	  person’s	  daily	  routine	  was	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disrupted,	  it	  might	  follow	  that	  their	  medication	  routine	  was	  similarly	  disrupted.	  	  
Having	  a	  medication	  routine	  is	  associated	  with	  greater	  adherence	  in	  global	  
adherence	  studies	  	  (Genberg,	  Lee,	  Rogers,	  &	  Wilson,	  2014).	  	  It	  is	  possible	  that	  
different	  daily	  activity	  interferes	  with	  the	  planning	  and	  cueing	  of	  an	  adherent	  event.	  	  
Similarly,	  the	  weekend	  may	  be	  linked	  to	  an	  increase	  in	  social	  activities,	  which	  in	  turn	  
might	  lead	  to	  a	  forgotten	  dose.	  	  	  
	  
It	  is	  possible	  that	  the	  psychological	  variables	  found	  to	  vary	  between	  episode	  
(behavioural	  skills	  and	  positive	  affect,	  in	  particular)	  may	  mediate	  the	  relationship	  
between	  behavioural	  situation	  and	  adherence.	  	  This	  would	  suggest,	  for	  example,	  
that	  young	  people	  might	  feel	  more	  confident	  in	  particular	  contexts,	  which	  would	  
then	  affect	  their	  adherence.	  	  Unfortunately,	  this	  could	  not	  be	  adequately	  tested	  in	  
the	  current	  study	  due	  to	  the	  small	  sample	  and	  insufficient	  power	  for	  multivariate	  
analysis.	  	  	  
Additional	  factors	  
Unwanted	  adverse	  effects	  are	  considerable	  barriers	  to	  global	  adherence	  amongst	  
the	  PHIV+	  population,	  as	  investigated	  in	  between-­‐subjects	  research	  (e.g.	  Macdonell,	  
Naar-­‐King,	  Murphy,	  Parsons,	  &	  Huszti,	  2011).	  Participants’	  actual	  experience	  of	  such	  
effects	  was	  not	  investigated	  in	  the	  current	  study.	  	  Rather,	  the	  focus	  was	  on	  the	  
anticipation	  of	  and	  perceived	  abilities	  in	  managing	  possible	  side	  effects	  at	  the	  time	  
the	  ART	  dose	  was	  due	  (as	  the	  medication	  would	  not	  yet	  have	  been,	  so	  would	  not	  
have	  caused	  any	  unwanted	  effect).	  	  This	  anticipation	  was	  measured	  as	  part	  of	  the	  
personal	  motivation	  subscale	  and	  subjective	  confidence	  in	  managing	  side	  effect	  was	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measured	  as	  part	  of	  the	  behavioural	  skills	  subscale	  (item:	  “I	  was	  confident	  I	  could	  
manage	  any	  side	  effects”).	  	  
	  
The	  complexity	  of	  the	  medication	  regimen	  was	  not	  included	  in	  the	  episodic	  
questionnaire,	  as	  this	  was	  unlikely	  to	  change	  situationally	  over	  the	  course	  of	  the	  
four-­‐week	  study	  period.	  	  This	  information	  was	  extracted	  from	  the	  AALPHI	  baseline	  
data.	  With	  the	  exception	  of	  one	  young	  person	  who	  was	  taking	  a	  twice-­‐daily	  regimen,	  
all	  participants	  in	  the	  current	  sample	  reported	  once-­‐daily	  ART	  regimens.	  	  There	  is	  a	  
suggestion	  in	  the	  literature	  that	  increased	  treatment	  burden	  and	  complexity	  is	  likely	  
to	  be	  associated	  with	  global	  non-­‐adherence	  and	  lower	  pill	  burden	  is	  related	  to	  
increased	  overall	  adherence	  	  (Nachega	  et	  al.,	  2014).	  	  However,	  the	  findings	  from	  this	  
study	  suggest	  that	  other	  contextual	  factors	  (such	  as	  those	  already	  described	  above)	  
must	  contribute	  to	  episodic	  non-­‐adherence	  in	  this	  group,	  beyond	  the	  impact	  of	  
treatment	  burden,	  as	  the	  treatment	  regimen	  was	  mostly	  the	  same	  for	  each	  person.	  
	  
The	  difference	  in	  alcohol	  and	  substance	  use	  between	  adherent	  and	  non-­‐adherent	  
episodes	  was	  not	  analysed	  here	  due	  to	  such	  small	  numbers	  of	  participants	  who	  
reported	  using	  either	  alcohol	  or	  other	  substances.	  	  Participants	  may	  have	  
deliberately	  chosen	  to	  report	  on	  particular	  adherent	  and	  non-­‐adherent	  episodes	  
when	  they	  were	  not	  using	  alcohol	  or	  illicit	  substances,	  due	  to	  concerns	  about	  
researcher	  judgement.	  	  Alternatively,	  this	  could	  be	  related	  to	  low	  baseline	  levels	  of	  
reported	  alcohol	  use	  (18	  people	  answered	  “never”,	  in	  response	  to	  how	  often	  do	  you	  
drink	  alcohol	  at	  enrolment	  to	  AALPHI),	  in	  which	  case	  there	  would	  be	  little	  to	  no	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expected	  variation	  between	  episodes.	  Overall	  rates	  of	  alcohol	  use	  in	  this	  sample	  
were	  consistent	  with	  the	  AALPHI	  population	  and	  lower	  than	  HIV-­‐exposed	  but	  not	  
infected	  controls.	  	  	  
	  
It	  could	  be	  inferred	  from	  the	  current	  findings	  that	  alcohol	  use	  may	  be	  less	  important	  
in	  episodic	  adherence	  within-­‐individuals	  compared	  to	  the	  findings	  in	  global	  
adherence	  studies	  (e.g.	  Hosek,	  Harper,	  &	  Domanico,	  2005).	  	  Kiene	  and	  Subramanian	  
investigated	  the	  association	  of	  alcohol	  use	  and	  unprotected	  sex	  using	  an	  event	  level	  
design	  (Kiene	  &	  Subramanian,	  2013).	  	  The	  authors	  cited	  between-­‐group,	  global	  
studies	  of	  alcohol	  and	  condom	  use,	  which	  describe	  increase	  in	  unprotected	  sex	  with	  
increased	  use	  of	  alcohol	  (Kalichman,	  Simbayi,	  Jooste,	  &	  Cain,	  2007).	  	  At	  the	  event	  
level,	  however,	  these	  associations	  are	  not	  found;	  in	  some	  situations,	  the	  opposite	  
effect	  occurs.	  	  This	  highlights	  the	  utility	  of	  event-­‐level	  designs	  for	  inferring	  
relationships	  in	  particular	  contexts.	  	  Although	  it	  was	  not	  possible	  to	  carry	  out	  
inferential	  analysis	  of	  difference	  on	  the	  alcohol	  use	  data	  in	  the	  current	  study,	  the	  
levels	  of	  use	  were	  descriptively	  low	  across	  both	  episodes.	  	  Further	  analysis	  on	  a	  
larger	  dataset	  would	  be	  required	  to	  fully	  describe	  the	  relationship	  between	  episodic	  
adherence	  and	  alcohol	  use.	  	  The	  findings	  of	  the	  current	  study	  may,	  however,	  indicate	  
a	  possible	  differential	  relationship	  between	  use	  of	  alcohol	  and	  adherence	  at	  the	  
event	  level	  compared	  to	  findings	  at	  the	  global	  level.	  	  It	  would	  be	  of	  interest	  to	  focus	  
on	  this	  association	  in	  future	  research.	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There	  were	  very	  low	  rates	  of	  onward	  disclosure	  in	  the	  current	  sample,	  with	  38%	  of	  
the	  sample	  having	  not	  disclosed	  their	  status	  to	  any	  other	  person	  outside	  of	  their	  
family	  and	  72%	  having	  disclosed	  to	  two	  other	  people	  or	  fewer.	  	  In	  qualitative	  
reports,	  there	  has	  been	  suggestion	  of	  PHIV+	  young	  people	  deliberately	  not	  taking	  
prescribed	  ART	  in	  an	  effort	  to	  maintain	  a	  level	  of	  secrecy	  around	  their	  diagnosis	  	  
(Denison	  et	  al.,	  2015).	  	  An	  association	  between	  onward	  disclosure	  and	  less	  hiding	  of	  
medication	  and	  higher	  CD4+	  counts	  has	  also	  been	  found	  in	  PHIV+	  	  (Calabrese	  et	  al.,	  
2012).	  	  There	  was	  no	  significant	  between	  episode	  relationship	  between	  adherence	  
and	  whom	  the	  young	  person	  was	  with	  in	  this	  study,	  although	  there	  was	  a	  small	  to	  
medium	  effect	  size.	  	  Due	  to	  the	  small	  sample	  size,	  responses	  were	  grouped	  into	  
‘alone’	  versus	  ‘not	  alone’.	  	  Moreover,	  it	  was	  not	  possible	  to	  investigate	  differences	  
between	  exactly	  who	  was	  around	  at	  the	  time	  of	  the	  ART	  dose.	  	  There	  may	  be	  
differences	  in	  situational	  adherence	  depending	  on	  whether	  the	  accompanying	  
person	  was	  aware	  or	  not	  aware	  of	  the	  PHIV+	  participant’s	  status.	  	  This	  was	  not	  part	  
of	  the	  current	  questionnaire,	  but	  would	  be	  of	  interest	  to	  measure	  in	  future	  studies.	  	  	  	  	  
	  
In	  the	  baseline	  AALPHI	  data	  from	  the	  current	  participants,	  41%	  of	  young	  people	  
rated	  their	  adherence	  as	  ‘excellent’.	  	  Given	  the	  criterion	  of	  at	  least	  one	  missed	  dose	  
over	  the	  previous	  two	  months,	  the	  present	  sample	  could	  also	  be	  categorised	  as	  
‘inconsistent	  adherers’.	  	  This	  may	  not	  necessarily	  fit	  with	  a	  subjective	  rating	  of	  
‘excellent’	  adherence:	  these	  young	  people	  may	  have	  overestimated	  their	  level	  of	  
adherence	  at	  AALPHI	  baseline.	  	  Alternatively,	  the	  perception	  of	  what	  ‘excellent’	  
adherence	  means	  for	  the	  individuals	  in	  this	  sample	  may	  have	  allowed	  for	  occasional	  
	   134	  
missed	  doses.	  	  The	  present	  study	  suggests	  that	  there	  are	  contextual	  factors	  related	  
to	  adherence	  that	  vary	  according	  to	  situation,	  which	  may	  be	  applicable	  to	  PHIV+	  
young	  people	  categorised	  even	  as	  ‘excellent’	  adherers.	  	  	  
Limitations	  
No	  validated	  situational	  measures	  were	  available	  to	  measure	  adherence	  in	  this	  
population	  (or	  any	  others).	  	  The	  reliability	  and	  validity	  of	  the	  measures	  and	  scales	  
should	  be	  approached	  with	  caution.	  	  However,	  the	  scales	  to	  measure	  the	  IMB	  
constructs	  developed	  for	  this	  study	  were	  adapted	  from	  an	  existing	  tool	  
(LifeWindows)	  in	  consultation	  with	  a	  lead	  author	  of	  this	  measure	  and	  of	  the	  theories	  
from	  which	  it	  was	  derived	  (Amico,	  personal	  communication;	  Amico,	  2011;	  Fisher,	  
Fisher,	  Amico,	  &	  Harman,	  2006).	  	  In	  addition,	  a	  piloting	  phase	  took	  place	  to	  explore	  
the	  meaningfulness,	  applicability	  and	  comprehensiveness	  of	  the	  items	  to	  a	  focus	  
group	  of	  young	  people.	  	  These	  young	  people	  also	  commented	  on	  the	  wording	  of	  the	  
scales	  to	  ensure,	  relevance,	  clarity	  and	  appropriateness	  for	  a	  situational	  context.	  	  
During	  this	  phase,	  the	  wording	  of	  a	  number	  of	  items	  was	  amended	  and	  some	  items	  
added.	  	  There	  was	  a	  free	  text	  section	  of	  the	  questionnaire	  for	  additional	  comments	  
about	  salient	  factors	  in	  relation	  to	  the	  adherent	  or	  non-­‐adherent	  day	  from	  which	  no	  
extra	  themes	  arose.	  	  Therefore,	  although	  the	  measures	  were	  not	  validated,	  steps	  
were	  taken	  to	  ensure	  the	  questionnaire	  used	  was	  well	  constructed.	  	  For	  example,	  
item-­‐total	  correlations	  and	  whether	  dropping	  items	  resulted	  in	  increased	  reliability	  
were	  examined.	  	  The	  motivation	  subscale	  was	  adapted	  as	  a	  result	  of	  this	  process.	  	  
The	  good	  internal	  reliability	  of	  the	  scales	  for	  each	  episode	  and	  the	  significant	  effects	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identified	  in	  spite	  of	  a	  small	  sample	  size	  suggests	  the	  measurement	  of	  the	  constructs	  
was	  acceptable.	  
	  
It	  was	  not	  the	  focus	  of	  the	  present	  study,	  nor	  was	  it	  possible	  to	  establish,	  a	  valid,	  
descriptive	  level	  of	  anxiety	  and	  depressive	  symptoms	  in	  the	  current	  sample.	  
Although	  all	  participants	  completed	  the	  Hospital	  Anxiety	  and	  Depression	  Scale	  
(HADS)	  	  (Zigmond	  &	  Snaith,	  1983)	  as	  part	  of	  their	  inclusion	  in	  the	  AALPHI	  study	  there	  
was	  a	  considerable	  delay	  between	  completing	  this	  measure	  and	  the	  enrolment	  to	  
this	  study.	  	  It	  was	  possible	  that	  young	  people	  completed	  the	  HADS	  up	  to	  12	  months	  
or	  greater	  prior	  to	  the	  present	  study.	  	  Studies	  of	  test-­‐retest	  reliability	  in	  adolescents	  
demonstrate	  adequate	  reliability	  over	  periods	  of	  only	  two	  weeks	  (e.g.	  White,	  Leach,	  
Sims,	  &	  Atkinson,	  1999).	  	  Indeed,	  the	  HADS	  is	  a	  measure	  designed	  to	  assess	  levels	  of	  
clinical	  anxiety	  or	  depression	  symptoms	  at	  baseline	  and	  to	  measure	  change	  over	  
time.	  	  Therefore,	  it	  is	  not	  possible	  to	  assert	  that	  the	  HADS	  scores	  would	  be	  reliable;	  
there	  was	  no	  accurate	  characterisation	  of	  the	  level	  of	  clinical	  mood	  symptoms	  in	  the	  
sample	  and	  therefore	  no	  description	  of	  the	  global	  state	  of	  mood	  in	  these	  young	  
people.	  	  There	  was	  a	  single	  indicator	  of	  significant	  mental	  health	  morbidity	  from	  the	  
AALPHI	  baseline	  data:	  whether	  the	  young	  person	  had	  ever	  been	  referred	  to	  CAMHS.	  	  
To	  the	  extent	  that	  a	  history	  of	  CAMHS	  referral	  indicates	  psychiatric	  issues,	  it	  would	  
be	  possible	  to	  say	  the	  current	  sample	  were	  not	  from	  a	  clinical	  mental	  health	  
population.	  	  However,	  this	  is	  a	  very	  crude	  measure	  on	  which	  to	  base	  an	  assumption	  
of	  the	  absence	  of	  mental	  ill	  health.	  	  Therefore,	  in	  a	  further	  study	  greater	  
consideration	  could	  be	  given	  to	  characterising	  the	  mental	  health	  of	  the	  sample.	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There	  may	  be	  differences	  in	  psychological	  contextual	  factors	  between	  adherent	  and	  
non-­‐adherent	  episodes	  in	  participants	  with	  a	  history	  of	  current	  or	  previous	  mental	  
health	  disorder.	  	  	  	  
	  
The	  participants	  in	  the	  current	  study	  were	  a	  subsample	  of	  the	  AALPHI	  cohort	  study.	  	  
Participants	  were	  between	  age	  13	  and	  22,	  which	  is	  in	  keeping	  with	  previous	  studies	  
of	  adolescents;	  the	  mean	  gap	  between	  puberty	  and	  adulthood	  (measured	  by	  social	  
and	  financial	  independence)	  is	  twelve	  years	  in	  the	  UK	  	  (Viner,	  2012).	  	  However,	  it	  is	  
possible	  that	  different	  contextual	  factors	  may	  be	  applicable	  to	  13	  year	  olds	  and	  22	  
year	  olds	  as	  they	  may	  be	  at	  different	  developmental	  stages.	  	  For	  example,	  it	  might	  be	  
expected	  for	  almost	  all	  13	  year	  olds	  to	  be	  attending	  school	  and	  living	  with	  a	  care-­‐
giver;	  at	  22,	  one	  might	  be	  living	  independently	  and	  have	  a	  job.	  	  With	  a	  larger	  sample,	  
it	  would	  be	  possible	  to	  analyse	  possible	  differences	  in	  adherence-­‐associated	  
contextual	  factors	  between	  age	  groups	  and	  subsequently	  control	  for	  age	  in	  
multivariate	  analysis.	  
	  
There	  were	  significant	  statistical	  issues	  in	  the	  conditional	  logistic	  regression	  analysis,	  
most	  likely	  due	  to	  a	  lack	  of	  variability	  in	  categorical	  data	  caused	  by	  too	  few	  
participants.	  	  This	  was	  not	  wholly	  unexpected;	  the	  study	  was	  powered	  for	  bivariate	  
analysis.	  	  A	  larger	  sample	  may	  have	  enabled	  more	  detailed	  multivariate	  analysis	  of	  
the	  relationships	  between	  the	  significant	  episodic	  variables.	  	  With	  more	  cases	  per	  
factor,	  models	  are	  less	  influenced	  by	  leverage	  and	  residuals	  of	  particular	  individual	  
outliers.	  	  More	  participants	  may	  also	  have	  enabled	  more	  detailed	  analysis	  of	  the	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categorical	  variables.	  	  Categorical	  data	  were	  grouped	  due	  to	  small	  numbers	  of	  cases	  
per	  cell,	  although	  this	  was	  still	  not	  sufficient	  to	  support	  the	  conditional	  logistic	  
regression	  models	  for	  day	  and	  location.	  	  With	  a	  greater	  number	  of	  data,	  these	  
variables	  could	  have	  been	  analysed	  without	  the	  necessary	  grouping.	  	  	  
	  
The	  small	  sample	  may	  also	  have	  compromised	  generalizability	  to	  the	  wider	  AALPHI	  
cohort.	  	  However,	  this	  project	  recruited	  from	  multiple	  centres	  and	  employed	  a	  
systematic	  sampling	  strategy	  whereby	  every	  young	  person	  who	  was	  eligible	  at	  the	  
selected	  centres	  was	  approached	  and	  offered	  the	  opportunity	  to	  participate.	  	  The	  
response	  rate	  was	  good	  (81%)	  and	  demographic	  data	  indicate	  similar	  characteristics	  
to	  the	  overall	  CHIPS	  cohort	  and	  specific	  AALPHI	  cohort,	  therefore	  issues	  with	  
generalizability	  may	  be	  minimal.	  
	  
Asking	  participants	  to	  answer	  the	  questions	  about	  a	  particular	  episode	  of	  non-­‐
adherence	  within	  the	  last	  two	  months	  possibly	  served	  to	  limit	  erroneous	  recall	  of	  
specific	  details.	  	  However,	  there	  was	  no	  record	  of	  exactly	  how	  long	  ago	  the	  non-­‐
adherent	  episode	  and	  adherent	  episode	  took	  place.	  	  In	  a	  similar	  project,	  the	  mean	  
number	  of	  days	  ago	  for	  the	  non-­‐adherent	  episode	  was	  10	  days;	  for	  adherent	  
episode,	  1.3	  days	  ago	  	  (Vosper	  et	  al.,	  2013).	  	  It	  is	  possibly	  there	  was	  a	  similar	  time	  
lapse	  from	  episode	  to	  questionnaire	  completion	  in	  this	  study.	  	  	  
	  
Although	  most	  participants	  agreed	  to	  take	  part	  in	  the	  prospective	  component	  to	  the	  
study,	  attrition	  rate	  was	  high	  and	  only	  four	  participants	  completed	  the	  questionnaire	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prospectively	  for	  both	  adherent	  and	  non-­‐adherent	  episodes;	  two	  more	  participants	  
completed	  the	  adherent	  episode	  only.	  	  It	  is	  possible	  that	  these	  two	  participants	  did	  
not	  have	  a	  further	  non-­‐adherent	  episode	  in	  the	  four	  weeks	  following	  enrolment	  to	  
the	  study	  and	  therefore	  could	  not	  fully	  participate	  in	  both	  prospective	  
questionnaires.	  	  The	  SMS	  reminders	  were	  designed	  to	  promote	  the	  ease	  of	  
completing	  the	  questionnaire,	  but	  a	  number	  of	  steps	  were	  required	  in	  order	  for	  this	  
to	  happen:	  the	  prospective	  questionnaire	  was	  only	  available	  online.	  	  Participants	  
would	  have	  required	  access	  to	  the	  internet	  at	  the	  time	  of	  the	  SMS	  reminder	  to	  
complete	  the	  questionnaire	  straight	  away,	  although	  could	  have	  completed	  it	  at	  a	  
later	  point.	  	  However,	  if	  there	  was	  a	  delay	  from	  the	  SMS	  reminder	  to	  being	  able	  to	  
access	  the	  questionnaire,	  this	  allowed	  a	  greater	  margin	  for	  forgetting	  to	  complete	  
the	  questionnaire.	  	  SMS	  reminders	  were	  reduced	  from	  daily	  to	  three-­‐daily	  as	  initial	  
participants	  opted	  out	  of	  the	  reminders	  without	  completing	  the	  questionnaire.	  	  It	  
may	  have	  been	  better	  to	  keep	  the	  daily	  SMS	  reminders	  in	  order	  to	  promote	  the	  
second	  part	  of	  the	  project.	  	  However,	  high	  drop	  out	  rates	  for	  prospective	  studies	  are	  
well	  documented,	  therefore	  it	  could	  be	  that	  more	  participants	  recruits	  were	  needed	  
initially	  to	  account	  for	  high	  attrition	  (although	  this	  could	  have	  led	  to	  bias).	  	  
Alternatively,	  a	  larger	  financial	  reimbursement	  	  or	  more	  direct	  prompting	  may	  have	  
improved	  the	  response	  rate	  for	  the	  prospective	  questionnaires.	  
Strengths	  
In	  spite	  of	  the	  weaknesses	  cited	  above,	  there	  were	  a	  number	  of	  strengths	  of	  this	  
project.	  	  The	  novel	  design	  enabled	  the	  investigation	  of	  situational	  factors,	  an	  
alternative	  and	  potentially	  complementary	  perspective	  to	  studies	  of	  global.	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Temporal	  variation	  and	  the	  dynamic	  nature	  of	  the	  variables	  under	  investigation	  
enabled	  a	  stronger	  association	  with	  the	  adherence	  behaviours	  to	  be	  implied,	  
although	  causation	  cannot	  be	  established.	  	  	  
	  
Using	  scales	  to	  investigate	  psychological	  constructs	  is	  a	  more	  valid	  method	  of	  
measurement	  compared	  to	  survey	  responses.	  	  Previous	  studies	  (e.g.	  Macdonell	  et	  
al.,	  2011)	  have	  required	  participants	  to	  select	  which	  of	  a	  list	  of	  factors	  were	  relevant	  
to	  their	  adherence	  or	  non-­‐adherence	  using	  dichotomous,	  forced	  choice	  ‘yes’	  or	  ‘no’.	  	  
This	  method	  overlooks	  subtle	  quantitative	  differences	  in	  the	  degree	  to	  which	  a	  
factor	  may	  or	  may	  not	  be	  relevant.	  	  Psychological	  variables	  measured	  with	  multi-­‐
item	  scales	  increases	  validity,	  reliability	  and	  enables	  grouping	  of	  related	  constructs	  
for	  analysis	  by	  subscale.	  	  The	  categorical	  measurements	  in	  the	  present	  study	  were	  
analysed	  separately.	  
	  
This	  research	  used	  elements	  of	  the	  Day	  Reconstruction	  Method	  	  (Kahneman,	  
Krueger,	  Schkade,	  Schwarz,	  &	  Stone,	  2004)	  to	  scaffold	  participants’	  accurate	  
remembering	  of	  the	  adherent	  and	  non-­‐adherent	  episodes.	  	  The	  behavioural	  
situational	  questions	  were	  presented	  at	  the	  start	  of	  the	  questionnaire	  to	  orient	  
participants	  to	  the	  particular	  time	  and	  place	  of	  the	  adherent	  or	  non-­‐adherent	  event	  
and	  reduce	  recall	  bias.	  	  Research	  participants	  who	  give	  self-­‐reported	  accounts	  about	  
various	  psychological	  factors	  in	  any	  cross-­‐sectional	  study	  are	  required	  to	  form	  some	  
retrospective	  judgement.	  	  For	  example,	  many	  standardised	  and	  widely	  used	  
measures	  of	  mood,	  such	  as	  PHQ-­‐9	  (Kroenke,	  Spitzer,	  &	  Williams,	  2001)	  and	  GAD-­‐7	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(Spitzer	  &	  Kroenke,	  2006),	  require	  participants	  to	  rate	  their	  emotional	  state	  over	  the	  
past	  two	  weeks.	  	  To	  ask	  participants	  to	  reflect	  on	  their	  feelings	  and	  mood	  at	  the	  time	  
of	  a	  particular	  episode	  could	  be	  considered	  superior	  to	  other	  standard	  approaches	  
that	  ask	  for	  participant	  responses	  about	  a	  longer	  time	  frame.	  	  Additional	  steps	  were	  
taken	  to	  manage	  any	  potential	  recall	  bias,	  by	  asking	  the	  same	  questions	  across	  both	  
episodes.	  	  	  
	  
Investigation	  of	  situational	  variation	  within	  individuals	  has	  potential	  to	  inform	  clinical	  
assessment	  and	  intervention	  for	  promoting	  adherence.	  	  Knowledge	  of	  the	  factors	  
that	  vary	  over	  time	  or	  by	  situation	  rather	  than	  studying	  ‘good	  adherers’	  versus	  ‘bad	  
adherers’	  could	  lead	  to	  the	  development	  of	  realistic,	  practical	  strategies	  to	  improve	  
adherence	  or	  minimise	  non-­‐adherence.	  	  This	  will	  be	  discussed	  in	  further	  detail	  below	  
(see	  ‘Clinical	  Implications’).	  
	  
Theoretical	  Implications	  
The	  results	  from	  the	  study	  demonstrate	  good	  reliability	  of	  the	  IMB	  constructs	  as	  
measured	  situationally.	  	  The	  IMB	  model	  was	  not	  designed	  for	  use	  in	  within-­‐
participants	  comparison	  studies	  and	  has	  not	  been	  tested	  in	  this	  way.	  	  Some	  of	  the	  
key	  relationships	  highlighted	  in	  the	  model,	  particularly	  the	  association	  between	  
adherence	  behavioural	  skills	  and	  positive	  affect,	  were	  supported	  in	  this	  study.	  	  This	  
suggests	  a	  robustness	  of	  some	  aspect	  of	  the	  IMB	  theoretical	  model.	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Most	  health	  behaviour	  theories	  and	  intervention	  models	  highlight	  importance	  of	  
motivation,	  but	  do	  not	  explain	  how	  motivation	  is	  enacted.	  	  Insufficient	  power	  for	  the	  
analysis	  in	  the	  present	  study	  prevents	  reliable	  conclusions	  from	  being	  drawn	  
regarding	  the	  exact	  influence	  of	  motivation	  on	  episodic	  adherence.	  	  However,	  the	  
difference	  in	  effect	  sizes	  may	  indicate	  a	  differential	  influence	  of	  social	  and	  personal	  
motivation	  between	  adherent	  and	  non-­‐adherent	  events,	  with	  the	  latter	  not	  
significantly	  implicated.	  	  Secondly,	  the	  IMB	  model’s	  key	  emphasis	  on	  behavioural	  
skills,	  or	  the	  closely	  related	  construct	  of	  self-­‐efficacy,	  in	  carrying	  out	  a	  behaviour,	  
was	  also	  demonstrated	  as	  key	  in	  the	  current	  study.	  	  There	  was	  a	  very	  large	  effect	  of	  
behavioural	  skills	  between	  episodes	  of	  adherence.	  	  In	  relation	  to	  health-­‐behaviour	  
theory,	  this	  suggests	  the	  importance	  of	  constructs	  relating	  to	  self-­‐efficacy	  as	  a	  crucial	  
determinant	  of	  episodic	  adherence,	  rather	  than	  a	  focus	  on	  motivational	  constructs,	  
which	  had	  little	  relationship	  with	  adherence	  in	  the	  current	  findings.	  
	  
The	  IMB	  model,	  like	  many	  theories	  of	  health	  behaviour,	  neglects	  the	  influence	  of	  
contextual	  factors	  such	  as	  those	  under	  investigation	  here.	  	  The	  current	  findings	  may	  
suggest	  a	  significant	  impact	  of	  situational	  variables	  on	  episodic	  adherence	  that	  
cannot	  be	  adequately	  explained	  by	  the	  IMB	  model.	  	  Other	  frameworks,	  including	  
Social	  Action	  Theory	  	  (Ewart,	  1991),	  describe	  mechanisms	  by	  which	  social	  and	  
environmental	  structures	  influence	  health	  behaviours.	  	  It	  may	  be	  that	  such	  
frameworks	  are	  beneficial	  in	  describing	  the	  event-­‐level	  differences	  in	  adherence	  
behaviour.	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Clinical	  Implications	  
It	  may	  be	  of	  clinical	  importance	  to	  focus	  on	  the	  situational	  factors	  related	  to	  specific	  
episodes	  of	  adherence	  and	  non-­‐adherence	  to	  enable	  idiosyncratic	  assessment	  of	  
barriers	  and	  promotion	  of	  facilitators	  of	  adherence.	  	  This	  novel	  within-­‐subjects	  
approach	  may	  be	  especially	  useful	  in	  developing	  and	  improving	  adherence	  
assessments	  and	  interventions.	  	  Rather	  than	  distinguishing	  between	  generally	  good	  
and	  poor	  adherers,	  this	  design	  highlights	  the	  resources	  within	  an	  individual.	  	  
Understanding	  the	  situational	  relationship	  between	  adherent	  and	  non-­‐adherent	  
episodes	  could	  be	  useful	  for	  implementing	  more	  successful	  interventions.	  	  The	  
identification	  of	  an	  individual’s	  resources	  to	  help	  overcome	  barriers	  is	  central	  to	  a	  
number	  of	  psychological	  interventions,	  including	  those	  used	  to	  promote	  ART	  
adherence,	  such	  as	  Motivational	  Interviewing	  	  (Mbuagbaw	  et	  al.,	  2015;	  Mbuagbaw,	  
Ye,	  &	  Thabane,	  2012)and	  cognitive-­‐behavioural	  techniques	  	  (Wagner,	  et	  al,	  2006).	  	  	  	  
	  
This	  study	  highlights	  behavioural	  skills	  as	  potentially	  critical	  for	  episodic	  ART	  
adherence,	  suggesting	  that	  key	  areas	  for	  intervention	  could	  be:	  improving	  
confidence	  to	  overcome	  barriers,	  promoting	  abilities	  in	  acquiring	  personal	  and	  social	  
support,	  incorporating	  ART	  into	  daily	  life,	  self-­‐cueing	  and	  self-­‐reinforcement	  to	  
adhere	  to	  ART	  	  (Fisher	  et	  al.,	  2006).	  	  The	  difference	  in	  the	  behavioural	  skills	  construct	  
between	  variables	  could	  suggest	  that	  confidence	  to	  overcome	  barriers	  to	  adherence	  
is	  both	  important	  and	  alterable.	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Arrivillaga	  and	  colleagues	  reviewed	  adherence	  promotion	  interventions	  for	  
adolescents	  that	  focused	  on	  managing	  the	  factors	  associated	  with	  adherence	  	  
(Arrivillaga,	  Martucci,	  Hoyos,	  &	  Arango,	  2013).	  	  Of	  ten	  published	  studies,	  the	  
interventions	  involved:	  skills	  and	  knowledge	  education,	  social	  support	  and	  
motivational	  interviewing.	  	  The	  most	  recent	  motivational	  interviewing	  	  (MI)	  
programmes	  to	  promote	  adherence	  in	  young	  people	  are	  computer	  based	  and	  
delivered	  online.	  	  A	  pilot	  study	  of	  two	  sessions	  of	  MI	  focused	  on	  a	  young	  person’s	  
perception	  of	  the	  importance	  of	  ART	  and	  their	  confidence	  in	  adhering	  	  (Outlaw	  et	  al.,	  
2013).	  	  Ten	  young	  people,	  age	  18-­‐24,	  were	  enrolled,	  targeted	  adherence-­‐related	  goal	  
setting	  and	  planning,	  drawing	  on	  past	  successes	  and	  personal	  strengths.	  	  There	  was	  
no	  adherence	  outcome	  measure	  in	  this	  pilot,	  however	  100%	  of	  the	  sample	  improved	  
in	  their	  perceptions	  of	  how	  important	  adherence	  was	  for	  them;	  80%	  of	  the	  sample	  
improved	  on	  subjective	  confidence.	  	  This	  intervention	  would	  be	  supported	  by	  the	  
findings	  and	  the	  approach	  of	  the	  current	  study,	  which	  highlights	  the	  importance	  of	  
perceived	  confidence	  in	  abilities	  to	  adhere	  and	  on	  facilitators	  of	  previous	  adherent	  
episodes.	  	  	  
	  
Blame	  is	  targeted	  in	  compassion-­‐focused	  or	  cognitive-­‐behavioural	  interventions,	  
some	  of	  which	  have	  been	  applied	  to	  ART	  adherence	  behaviours	  but	  have	  not	  been	  
adequately	  tested	  for	  effectiveness.	  	  However,	  if	  blame	  is	  a	  significant	  contextual	  
barrier	  associated	  with	  non-­‐adherence,	  this	  would	  support	  the	  development	  of	  
additional	  interventions	  based	  on	  these	  approaches.	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The	  findings	  presented	  here	  underline	  a	  particular	  difference	  of	  situational	  mood	  
between	  episodes	  of	  adherence	  and	  non-­‐adherence.	  Assessments	  of	  barriers	  to	  and	  
facilitators	  of	  adherence	  could	  focus	  on	  contextual	  variations	  in	  mood	  and	  
confidence.	  	  A	  greater	  understanding	  of	  these	  fluctuations	  would	  help	  health	  care	  
professionals	  to	  identify	  which	  changes	  in	  mood	  are	  related	  to	  non-­‐adherence	  with	  a	  
particular	  individual.	  	  Normalising	  fluctuations	  in	  affect	  may	  help	  to	  engage	  with	  an	  
intervention	  focused	  on	  idiosyncratic	  non-­‐adherence	  patterns	  and	  planning	  for	  
situations	  with	  a	  greater	  risk	  of	  non-­‐adherence.	  	  Advanced	  planning	  may	  take	  the	  
form	  of	  problem-­‐solving	  strategies	  	  (Gross	  et	  al.,	  2013)	  or	  implementation	  intentions	  	  
(Brandstätter	  et	  al.,	  2001;	  Schweiger	  Gallo	  &	  Gollwitzer,	  2007;	  Sheeran	  et	  al.,	  2005).	  
	  
The	  findings	  of	  this	  study	  also	  have	  implications	  for	  indirect	  adherence	  interventions,	  
or	  strategies	  that	  can	  be	  used	  amongst	  healthcare	  professionals.	  	  Although	  
guidelines	  consistently	  recommend	  assessment	  of	  readiness	  to	  adhere	  to	  a	  
(potentially	  lifelong)	  ART	  regimen	  and	  barriers	  that	  may	  impede	  this,	  there	  is	  no	  
specific	  guidance	  on	  how	  to	  go	  about	  this.	  	  The	  current	  study	  suggests	  particular	  
areas	  for	  targeted	  assessment,	  including	  potential	  facilitators.	  	  The	  situational	  
differences	  found	  in	  this	  study	  highlights	  the	  importance	  of	  detailed	  questioning	  
about	  context.	  It	  might	  be	  important	  to	  ask	  about	  changes	  in	  both	  practical	  and	  
emotional	  circumstances	  that	  have	  previously	  accompanied	  both	  adherent	  and	  non-­‐
adherent	  episodes.	  	  The	  findings	  from	  the	  present	  study	  highlight	  day	  of	  the	  week,	  
location	  and	  disruption	  to	  routine	  as	  particular	  areas	  of	  focus	  to	  assess	  barriers	  to	  
non-­‐adherence	  and	  facilitators	  of	  adherence.	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Further	  Research	  
The	  prime	  implication	  for	  developing	  this	  research	  would	  be	  to	  recruit	  a	  larger	  
sample	  size.	  	  Primarily,	  this	  would	  support	  multivariate	  analysis	  and	  enable	  the	  
situational	  variables	  to	  be	  included	  in	  a	  conditional	  logistic	  regression	  model,	  to	  
explore	  the	  significant	  psychological	  relationships	  when	  controlling	  for	  behavioural	  
situation.	  	  This	  would	  also	  facilitate	  additional	  analysis	  of	  factors	  such	  as	  age,	  gender,	  
and	  type	  of	  medication	  as	  related	  to	  the	  significant	  variables	  between	  episodes.	  	  A	  
larger	  number	  of	  participants	  would	  also	  increase	  the	  cell	  sizes	  for	  the	  categorical	  
variables,	  which	  would	  remove	  the	  data-­‐grouping	  requirement	  (e.g.	  grouping	  into	  
‘alone’	  and	  ‘not	  alone’)	  and	  enable	  the	  analysis	  of	  each	  variable	  individually	  (e.g.	  
‘alone’,	  ‘with	  family’,	  ‘with	  friend’,	  ‘with	  partner’,	  etc).	  	  
	  
It	  may	  be	  of	  interest	  to	  expand	  the	  data	  collection	  to	  include	  more	  than	  one	  
adherent	  and	  non-­‐adherent	  episode.	  	  The	  responses	  given	  in	  reference	  to	  particular	  
episodes	  in	  the	  current	  study	  may	  not	  be	  representative	  of	  general	  adherent	  or	  non-­‐
adherent	  events	  for	  the	  sample.	  	  A	  greater	  number	  of	  specific	  episodes	  would	  allow	  
for	  comparisons	  across	  multiple	  contexts.	  	  An	  episodic	  design	  allows	  one	  to	  take	  a	  
longitudinal	  approach.	  	  This	  would	  also	  allow	  for	  comparisons	  within	  as	  well	  as	  
between	  individuals	  over	  a	  longer	  period.	  
	  
In	  focusing	  on	  situational	  variation,	  this	  study	  was	  not	  intended	  to	  investigate	  the	  
neurocognitive	  correlates	  of	  adherence;	  participants’	  cognitive	  abilities	  would	  
almost	  certainly	  remained	  static	  over	  the	  course	  of	  this	  investigation.	  	  However,	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given	  what	  is	  known	  about	  the	  possible	  cognitive	  deficits	  in	  PHIV+	  young	  people	  and	  
the	  implication	  of	  various	  cognitive	  processes,	  particularly	  executive	  function	  	  
(Nichols	  et	  al.,	  2012),	  working	  memory	  (Laughton	  et	  al.,	  2013)	  and	  prospective	  
memory	  (Zogg,	  Woods,	  Sauceda,	  Wiebe,	  &	  Simoni,	  2011),	  in	  medication	  adherence,	  
it	  would	  be	  of	  interest	  to	  investigate	  whether	  there	  is	  any	  impact	  of	  cognition	  on	  the	  
situational	  factors	  found	  to	  be	  associated	  with	  episodic	  adherence	  when	  controlling	  
for	  cognitive	  ability.	  	  	  
	  
The	  length	  of	  the	  prospective	  questionnaire	  may	  have	  been	  off-­‐putting	  for	  some	  
participants.	  	  Completion	  time	  was	  approximately	  10-­‐15	  minutes	  per	  episode,	  not	  
including	  getting	  to	  the	  website.	  	  Although	  this	  was	  an	  acceptable	  time	  in	  clinics	  and	  
for	  a	  retrospective	  report,	  it	  may	  have	  been	  more	  difficult	  to	  schedule	  outside	  of	  the	  
initial	  study	  session.	  	  Previous	  studies	  using	  EMA	  methods	  have	  found	  asking	  
questions	  about	  affect	  and	  self-­‐efficacy	  using	  a	  single	  question	  to	  be	  acceptable	  in	  
their	  reliability	  and	  validity	  when	  data	  is	  collected	  repeatedly	  over	  several	  time	  
points.	  	  An	  alternative	  approach	  to	  the	  prospective	  questionnaire	  could	  be	  to	  
prompt	  participants	  to	  complete	  fewer	  questions	  and	  over	  shorter	  intervals	  and	  on	  
more	  occasions.	  
	  
The	  response	  rate	  to	  the	  prospective	  component	  of	  the	  study	  may	  also	  be	  improved	  
using	  smartphone	  app	  technology,	  for	  example.	  	  Runyan	  and	  colleagues	  (2013)	  
developed	  a	  specific	  ecological	  momentary	  assessment	  app,	  which	  conveniently	  
prompted	  participants	  to	  rate	  a	  particular	  aspect	  of	  their	  behaviour	  at	  random	  or	  at	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time	  intervals	  determined	  by	  the	  researchers.	  	  Although	  this	  methodology	  would	  
require	  participants	  to	  possess	  a	  smartphone,	  there	  would	  be	  considerable	  benefits	  
for	  data	  collection,	  particularly	  regarding	  the	  flexibility	  for	  both	  investigators	  and	  
participants.	  	  In	  addition,	  this	  technology	  has	  the	  potential	  for	  Ecological	  Momentary	  
Intervention	  (EMI)	  approaches	  to	  be	  trialled.	  	  That	  is,	  even	  in	  individuals	  not	  
expressly	  seeking	  change,	  or,	  in	  the	  case	  of	  PHIV+	  ART	  adherence,	  not	  expressly	  
seeking	  to	  improve	  their	  medication	  taking,	  a	  set	  of	  timely,	  changeable	  cues	  could	  be	  
sent	  via	  the	  app,	  relating	  to	  the	  particular	  individual	  context.	  	  This	  approach	  was	  
successful	  in	  first	  year	  undergraduates	  who	  became	  more	  self-­‐aware	  regarding	  
productive	  use	  of	  time	  through	  the	  EMA	  monitoring	  	  (Runyan	  et	  al.,	  2013).	  	  The	  
students	  were	  sent	  notifications	  to	  complete	  a	  short	  survey	  between	  five	  and	  seven	  
times	  per	  day	  at	  random	  intervals	  (within	  waking	  hours).	  	  This	  repeated	  
measurements	  allowed	  the	  authors	  to	  compare	  how	  much	  variation	  there	  was	  
within-­‐participants	  in	  how	  they	  spent	  their	  time	  over	  the	  week	  and	  test	  for	  possible	  
differences	  day-­‐to-­‐day.	  	  Users	  reported	  an	  increase	  in	  self-­‐awareness	  in	  how	  their	  
time	  was	  spent	  over	  the	  study	  period	  as	  they	  became	  accustomed	  to	  using	  the	  app.	  	  
Qualitative	  feedback	  from	  this	  pilot	  suggested	  that	  an	  increase	  in	  self-­‐awareness	  
prompted	  participants	  to	  alter	  their	  behaviour.	  	  In	  the	  case	  of	  PHIV+	  youth,	  using	  a	  
similar	  app	  to	  monitor	  the	  contextual	  factors	  under	  investigation	  in	  the	  present	  
study	  may	  lead	  to	  greater	  awareness	  of	  patterns	  of	  behaviour	  in	  relation	  to	  episodic	  
adherence	  and	  non-­‐adherence	  and	  may	  prompt	  some	  users	  to	  change	  their	  routines	  
accordingly.	  	  A	  more	  structured	  EMI	  approach	  has	  been	  trialled	  in	  patients	  with	  
Borderline	  Personality	  Disorder	  with	  comorbid	  substance	  misuse	  problems.	  	  In	  this	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case,	  the	  app	  has	  been	  used	  as	  a	  Dialectical	  Behaviour	  Therapy	  coach	  (Rizvi,	  Dimeff,	  
Skutch,	  Carroll,	  &	  Linehan,	  2011).	  	  There	  are	  possible	  applications	  of	  this	  method	  to	  
adolescents’	  adherence	  interventions,	  whereby	  EMI	  apps	  could	  be	  used	  for	  in	  vivo	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NRES Committee South Central - Berkshire B 
Whitefriars 







29 May 2014 
 
Ms Amy L Hawkins 






Dear Ms Hawkins  
 
Study title: A within-subjects investigation of episodic antiretroviral 
medication adherence in adolescents with perinatally 
infected HIV 
REC reference: 14/SC/1019 
IRAS project ID: 154311 
 
The Proportionate Review Sub-Committee of the NRES Committee South Central - 




The Sub-Committee would be content to give a favourable ethical opinion of the research, 
subject to clarification of the following issues and/or the following changes being made to 
the documentation for study participants: 
 
1. Changes to the Participants Information sheet:  
a. Add  the  following  statement  “The  study  has  been  given  a  favourable  opinion  
by  the  Berkshire  B  Research  Ethics  Committee”.   
b. Submit  separate  PIS’s  for  12- 15 year olds, 16-18 year olds and 18 years 
and over.  
c. Simplify the language in the PIS for the 12-15 age group (e.g. Clinical 
Psychology doctorate course).   
 
2. Confirm why some of the answers in the ITEM questionnaire are in red and whether 
this might affect the responses.   
 
3. Confirm that parental / carer consent will be sought for children 12- 15.  
 
4. Update either the protocol or PIS to ensure the time that the SMS text will be 
stopped is consistent (the protocol states that SMS text will be stopped after 1 
month but the PIS states SMS will stop after 4 weeks and this needs to be 
consistent).  
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When submitting your response, please send the revised documentation underlining or 
otherwise highlighting the changes you have made and giving revised version numbers and 
dates. 
 
Authority to consider your response and to confirm the final opinion on behalf of the 
Committee has been delegated to the Chair . 
 
Please contact Stephanie Macpherson, 0117 342 1331 if you need any further clarification 
or would find it helpful to discuss the changes required with the lead reviewer. 
 





The documents reviewed were: 
 
 Document   Version   Date   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only)  
1  02 September 2013  
IRAS Checklist XML [Checklist_23052014]    23 May 2014  
Non-validated questionnaire  0.2  19 May 2014  
Participant consent form  1.2  19 May 2014  
Participant information sheet (PIS) [12-15 with Pics]  1.2  19 May 2014  
Participant information sheet (PIS) [16-21]  1.2  19 May 2014  
REC Application Form [REC_Form_23052014]    23 May 2014  
Research protocol or project proposal [RHUL major project 
proposal]  
1.0  28 March 2014  
Summary CV for Chief Investigator (CI) [Amy Hawkins]    05 February 2014  
Summary CV for supervisor (student research) [Dr Michael 
Evangeli]  
  17 February 2014  
 
Membership of the Committee 
 
The members of the Committee who were present at the meeting are listed on the attached 
sheet. 
  
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 







	   168	  
	  
14/SC/1019 Page 3 





Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to: Dr Michael Evangeli, Royal Holloway University of London 
michael.evangeli@rhul.ac.uk 
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NRES Committee South Central - Berkshire B 
 
Attendance at PRS Sub-Committee of the REC meeting on 29 May 2014 
 
  
Committee Members:  
 
Name   Profession   Present    Notes   
Mr Michael Arnott  Consultant Research 
Services  
Yes     
Mr Yash  Patel  Research Support 
Associate  
Yes     
Dr John Sheridan (chair) Consultant Toxicologist 
and Chemist  
Yes     
 
 
Also in attendance: 
Name  Position (or reason for attending)  











NRES Committee South Central - Berkshire B 
Whitefriars 





Telephone: 0117 342 1331 
27 June 2014 
 
Ms Amy L Hawkins 
Clinical Psychology Department 






Dear Ms Hawkins 
 
Study title: A within-subjects investigation of episodic antiretroviral 
medication adherence in adolescents with perinatally 
infected HIV 
REC reference: 14/SC/1019 
IRAS project ID: 154311 
 
Thank you for your letter of 27 June 2014, responding to the Proportionate Review  
Sub-Committee’s  request  for  changes  to  the  documentation  for  the  above  study. 
 
The revised documentation has been reviewed and approved by the sub-committee. 
 
We plan to publish your research summary wording for the above study on the NRES website, 
together with your contact details, unless you expressly withhold permission to do so.  
Publication will be no earlier than three months from the date of this favourable opinion letter.  
Should you wish to provide a substitute contact point, require further information, or wish to 
withhold permission to publish, please contact the REC Manager Miss Stephanie MacPherson, 
nrescommittee.southcentral-berkshireb@nhs.net. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
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Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management  permission  (“R&D  approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.  
 
Where  a  NHS  organisation’s  role  in  the  study  is  limited  to  identifying  and  referring  potential  
participants  to  research  sites  (“participant  identification  centre”),  guidance  should  be  sought  
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations.  
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database within 6 weeks of recruitment of the first participant (for 
medical device studies, within the timeline determined by the current registration and publication 
trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact Catherine Blewett 
(catherineblewett@nhs.net), the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
“Conditions  of  the  favourable  opinion”  above). 
 
 





The documents reviewed and approved by the Committee are: 
 
Document   Version   Date   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only)  
1  02 September 2013  
IRAS Checklist XML [Checklist_23052014]    23 May 2014  
Non-validated questionnaire [Questionnaire (Tracked Copy)]  0.2  10 June 2014  
Participant consent form [Young Person (13-15 Year Olds) Assent 
Form (Tracked Copy)]  
1.2  10 June 2014  
Participant consent form [Parental Consent Form (Tracked Copy)]  1.2  10 June 2014  
Participant information sheet (PIS) [16-18 Year Olds (Tracked 
Copy)]  
1.1  03 June 2014  
Participant information sheet (PIS) [18-21 Year Olds (Tracked 
Copy)]  
1.1  03 June 2014  
Participant information sheet (PIS) [13-15 Year Olds (Tracked 
Copy)]  
1.4  14 June 2014  
REC Application Form [REC_Form_23052014]    23 May 2014  
Research protocol or project proposal [(Tracked Copy)]  1.2  10 June 2014  
Response to Request for Further Information    14 June 2014  
Summary CV for Chief Investigator (CI) [Amy Hawkins]    05 February 2014  
Summary CV for supervisor (student research) [Dr Michael 
Evangeli]  
  17 February 2014  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 




The  attached  document  “After  ethical  review  – guidance  for  researchers”  gives  detailed  
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 








You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance  
 
We  are  pleased  to  welcome  researchers  and  R  &  D  staff  at  our  NRES  committee  members’  
training days – see details at http://www.hra.nhs.uk/hra-training/  
 
14/SC/1019   Please quote this number on all correspondence 
 
 









Enclosures:    “After  ethical  review  – guidance  for  researchers”  [SL-AR2] 
 











NRES Committee South Central - Berkshire B 
Whitefriars 





Tel: 0117 342 1387 
 
10 February 2015 
 
Ms Amy L Hawkins 






Dear Ms Hawkins 
 
Study title: A within-subjects investigation of episodic antiretroviral 
medication adherence in adolescents with perinatally 
infected HIV 
REC reference: 14/SC/1019 
Amendment number: 1 
Amendment date: 09 February 2015 
IRAS project ID: 154311 
 




The members of the Committee taking part in the review gave a favourable ethical opinion 





The documents reviewed and approved at the meeting were: 
 
Document   Version   Date   
Notice of Substantial Amendment (non-CTIMP)  1  09 February 2015  
 
Membership of the Committee 
 










All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
We  are  pleased  to  welcome  researchers  and  R  &  D  staff  at  our  NRES  committee  members’  
training days – see details at http://www.hra.nhs.uk/hra-training/  
 











Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to:   Kirsty Hedditch, King's College Hospital NHS Foundation Trust 
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NRES Committee South Central - Berkshire B 
 
Attendance at Sub-Committee of the REC meeting on 13 February 2015 
 
  
Committee Members:  
 
Name   Profession   Present    Notes   
Mr Mike Arnott  Research Consultant  Yes     
Dr John B Sheridan (Chair) Consultant Toxicologist 
and Chemist  
Yes     
  
Also in attendance:  
 
Name   Position (or reason for attending)   
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Research and Development Department     
Trust Headquarters, 1st Floor, Room 137 





T: 0161 604 5233 
 
Dr. Steve Woby – Director of R&D                                                                                                                                                                                                   
Steve.Woby@pat.nhs.uk                                                                                                                                                                                                                                                      
 




                  
Charlotte Lever – R&D Quality & Performance Manager
    Charlotte.Lever@pat.nhs.uk  
 
    Zoe Drinkwater – Research & Development Coordinator 
   Zoe.Drinkwater@pat.nhs.uk  
 
   Claire Carty – Research & Development Administrator 
   Claire.carty@pat.nhs.uk  
 
 
    
Dr Paddy McMaster - Consultant in Paediatric Infectious Diseases 
Limbert House 
North Manchester General Hospital 
Delaunays Road, Crumpsall 
Manchester M8 5RB 
 
09 April 2015 
  
Dear Dr McMaster, 
 





CSP study ID: N/A (NON NIHR) 
Project Title:  A within subjects investigation of episodic antiretroviral medication 
adherence in adolescents with perinatally infected HIV 
Short Title: Episodic medication adherence in PHIV+ adolescents (PHIV) 
Ethics Reference:  14/SC/1019 
Sponsor: Royal Holloway University of London 
Site:  NMGH 
Recruitment start date: 09.04.2015 
Recruitment end date: 31.07.2015 
Number of participants 
to be recruited/ 
obtained at site: 
12 for the duration of the study 
  
 
Thank you for providing the Research & Development (R&D) department with your research project 
information.  The above study was considered by The Pennine Acute Hospitals NHS Trust in line with 
the Research Governance Framework where based on the information provided the impact of the 
 









study on the Trust’s resources was reviewed. I am pleased to inform you that the study has received 
Trust R&D approval. 
 
Following verification of relevant Regulatory approval from The National Research Ethics Service, the 
following documents as listed on the ethics approval letter have been approved by R&D: 
                                         
IRAS amendment form listing Pennine as a site  
Signed SSI form for The Pennine Acute Hospitals NHS Trust 
Ethics approval letters dated 10.02.3015, 27.06.2014 
Protocol (Version 1.2) dated 10.06.14 
Any other documents listed on Ethics letter dated 27.06.2014 
Email from Katie Doyle to Dr McMaster dated 31.03.15 enclosing protocol V 1.2 and SSI form. Dr 
McMaster confirmed receipt and feasibility by signing the front page of the SSI. 
Signed & dated CVs for those listed on the SSI form 
GCP certificates for Dr McMaster and Katie Rowson 
  
If there are any substantial amendments to the protocol, including the number of patients to be 
recruited from The Pennine Acute Hospitals NHS Trust, you must obtain a favourable opinion from: 
 
- The National Research Ethics Service 
- The Pennine Acute Hospitals NHS Trust (please note that all amendment documentation as 
approved by The Research Ethics Committee (REC) must be submitted to the R&D 
department) 
 
On completion of the study you are required to submit a ‘Declaration of End of Study’ form to the main 
REC, which should also be copied and forwarded to the R&D Department at the above address.  
http://www.nres.npsa.nhs.uk/applications/after-ethical-review/endofstudy/ 
 
As part of research governance the R&D department is expected to monitor the progress of registered 
projects.  Therefore, on-going projects may be subject to random inspection.  Your research must be 
conducted in compliance with the NHS Research Governance Framework for Health & Social Care. 
http://www.dh.gov.uk/en/Researchanddevelopment/A-Z/Researchgovernance/DH_4002112  
 
It is a condition of NHS R&D approval that patient recruitment data should be forwarded on a regular 
basis.  Therefore, project reports must be submitted annually to the main REC and copied to the R&D 
office until the end of the study. 
http://www.nres.npsa.nhs.uk/applications/after-ethical-review/annual-progress-reports/ 
 
In addition to your obligations to the study organisers and the REC, the R&D Department must be 
informed of any governance issues related to the research. 
 
Failure to comply with any of the above may result in withdrawal of approval for the project and the 






Dr. Steve Woby 
Director of Research & Development    
  
cc:  Katie Rowson (Research Nurse) - katie.rowson@pat.nhs.uk 
               Amy Hawkins (Trainee Clinical Psychologist) - amy.hawkins.2012@live.rhul.ac.uk  
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Dr	  Katia	  Prime	  
Consultant	  in	  HIV	  and	  Sexual	  Health	  
St	  George's	  Hospital	  NHS	  Trust	  
Courtyard	  Clinic,	  Department	  of	  GUM	  




Dear	  Dr	  Katia	  Prime,	  
	  
PROJECT	  TITLE	   A	  within	  subjects	  investigation	  of	  episodic	  
antiretroviral	  medication	  adherence	  in	  adolescents	  
with	  perinatally	  infected	  HIV	  
	  
REC	  Reference	   14/SC/1019	  
JREO	  Reference	   14.0168	  
CSP	  Reference	  (if	  applicable)	   N/A	  
Sponsor	   Royal	  Holloway	  University	  of	  London	  
Principal	  Investigator	  (PI):	   Dr	  Katia	  Prime	  
	  
Notification	  of	  St	  George’s	  Healthcare	  NHS	  Trust	  host	  site	  permission	  	  
	  
Permission	   for	   the	   above	   research	   has	   been	   granted	   on	   the	   basis	   described	   in	   the	  
application	   form,	   protocol	   and	   supporting	   documentation.	   	   The	   documents	   reviewed	   and	  
approved	  were	  those	  specified	  in	  the	  ethics	  approval	  letter	  dated	  27/06/2014.	  The	  protocol	  
version	  approved	  is	  version	  v1.2	  dated	  10/06/2014	  
	  
Permission	  is	  granted	  on	  the	  understanding	  that	  the	  study	  is	  conducted	  in	  accordance	  with	  
the	  Research	  Governance	  Framework,	  and	  NHS	  Trust	  policies.	  	  Permission	  is	  only	  granted	  for	  
the	  activities	  for	  which	  a	  favourable	  opinion	  has	  been	  given	  by	  the	  REC.	  	  The	  permission	  may	  
be	   invalidated	   in	   the	   event	   that	   the	   terms	   and	   conditions	   of	   any	   research	   contract	   or	  
agreement	  change	  significantly	  and	  while	  the	  new	  contract/agreement	  is	  negotiated.	  	  
	  
The	   research	   sponsor,	   the	   Chief	   Investigator,	   or	   the	   local	   Principal	   Investigator,	  may	   take	  
appropriate	   urgent	   safety	   measures	   in	   order	   to	   protect	   research	   participants	   against	   any	  
immediate	  hazard	  to	  their	  health	  or	  safety.	  	  The	  JREO	  should	  be	  notified	  that	  such	  measures	  
have	  been	  taken.	  	  The	  notification	  should	  also	  include	  the	  reasons	  why	  the	  measures	  were	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taken	   and	   the	  plan	   for	   further	   action.	   	   The	   JREO	   should	   be	  notified	  within	   the	   same	   time	  
frame	  of	  notifying	  the	  REC.	  
	  
All	   amendments	   to	   this	   study	   (including	   changes	   to	   the	   local	   research	   team)	   need	   to	   be	  
submitted	  in	  accordance	  with	  the	  guidance	  on	  IRAS.	  	  In	  addition	  any	  changes	  to	  the	  status	  of	  
a	  study	  should	  be	  notified	  to	  the	  JREO.	  
	  
Please	   note	   that	   the	   JREO	   is	   required	   to	  monitor	   research	   to	   ensure	   compliance	  with	   the	  
Research	  Governance	  Framework	  and	  other	  legal	  and	  regulatory	  requirements.	  
	  
Any	   intellectual	   property	   that	   is	   identified	   should	  be	  discussed	  with	   the	   JREO	  prior	   to	   any	  
disclosure	   of	   this	   information	   by	   publication	   or	   presentations	   to	   ensure	   that	   all	   rights	   are	  
protected.	  
	  
At	  study	  closure,	  the	  JREO	  together	  with	  the	  approving	  ethics	  committee	  should	  be	  notified	  
that	  the	  study	  is	  closed.	  	  Study	  findings	  should	  be	  disseminated	  as	  identified	  in	  the	  original	  
ethics	   application	   (including	   participants	   where	   appropriate).	   	   Study	   files	   should	   be	  
appropriately	  archived.	  
	  
Please	   contact	   the	   JREO	   if	   you	   require	  any	   further	  guidance	  or	   information	  on	  any	  matter	  






On	  behalf	  of	  SGUL/SGHT	  















Dr Emily Cheserem 
King's College Hospital 





The Research Office 
Kings College Hospital NHS Foundation Trust  
First Floor 161 Denmark Hill,  
London, SE5 8EF 
 
Direct tel: 020 3299 1980  






Dear Dr Cheserem, 
 
Study Title: A within subjects investigation of episodic antiretroviral medication adherence in 
adolescents with perinatally infected HIV  
Ethics ref: 14/SC/1019 
Sponsor:  Royal Holloway University of London 
Location: Denmark Hill 
Study duration: 6 Months 
Target Recruitment: 15 Participants 
Protocol Version: version 1.2 dated 10/06/14 
  
On behalf of King’s  College  Hospital  NHS  Foundation  Trust, I am pleased to inform you that your 
project is approved and you may proceed. 
The study has been registered as KCH14-173. Please quote this reference in any communications 
with the Research Office regarding your project.  
All approved documents are listed at the end of this letter. Please ensure that any amendments to 
the documents or changes to the study team are notified to the office.  
Investigator Responsibilities: 
 You are expected to recruit to time and target. A condition of the approval is to notify the 
Research Office of the date of first recruitment at the above email address. 
 The approval is conditional on the project being conducted as described within the 
application. The project must follow the agreed protocol and be conducted in accordance 
with all Trust Policies and Procedures - especially those relating to research and data 
management. 
 You must notify the office of all changes to the project, such as amendment to protocol and 
changes in study team. An end of study report and copies of the yearly REC report should be 
submitted to R&D.  
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V3 Sept 2014 
 You are responsible for ensuring that good research governance, conduct and practice, are 
maintained throughout the duration of the study.  
 The Trust maintains oversight of all active projects and you may be subject to review and 
audit at any point by internal or external bodies. 
 If the project is a clinical trial under the European Union (EU) Clinical Trials Directive the EU 
legislation must be complied with.  
 
If appropriate it is recommended that you register with the Current Controlled Trials website;  
http://isrctn.org/ 
 
The Research office will support you throughout the duration of your project. Please contact us at 
the address above if and when you require further information or guidance.  
 





Abdul Babalola  
Research Governance Coordinator 
 
cc. Chief Investigator: Amy Hawkins, Royal Holloway University of London, 
Amy.Hawkins.2012@live.rhul.ac.uk> 
 
cc. Sponsor: Andy Macleod, Royal Holloway University of London, a.macleod@rhul.ac.uk 
 
 
List of Approved Documents 
 
Title Version Date 
Participant information sheet -
13-15 Year Olds 
1.4 14/06/14 
Participant information sheet -
18-21 Year Olds 
1.1 3/06/14 
Participant information sheet -
16-18 Year Olds 
1.1 3/06/14 
Participant consent form -
Young Person (13-15 Year Olds) 
Assent Form 
1.2 10/6/14 
Participant consent form -
Parental Consent Form 
1.2 10/06/14 
Questionnaire 1.6 24/10/14 
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The LifeWindows Information-- Motivation -- Behavioral Skills  
ART Adherence Questionnaire (LW-IMB-AAQ) 
ITEMS 
Note: Each LW-IMB-AAQ item represents a barrier primarily falling within the I (Information), M (Motivation), or B 
(Behavioral Skills) constructs. When used with the LifeWindows ART adherence intervention software program, a 
‘critical zone’ is superimposed for a range of response options for each item (reflected here as shaded and in red text). 
Responses within the critical zone are interpreted as signaling the presence of a deficit or potential deficit that then 
triggers the offering of intervention activities specifically developed to address the barrier reflected in the content of the 
item. 
 
I1 I know how each of my current HIV medications is supposed to be taken (for example 
whether or not my current medications can be taken with food, herbal supplements, or 
other prescription medications). 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I2 I know what to do if I miss a dose of any of my HIV medications (for example, whether or 
not to take the pill(s) later). 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I3 Skipping a few of my HIV medications from time to time would not really hurt my health. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I4 I know what the possible side effects of each of my HIV medications are. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I5 As long as I am feeling healthy, missing my HIV medications from time to time is OK. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I6 I understand how each of my HIV medications works in my body to fight HIV. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
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I7 If I don’t take my HIV medications as prescribed, these kinds of medications may not work 
for me in the future. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I8 I believe that if I take my HIV medications as prescribed, I will live longer. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
I9  I know how my HIV medications interact with alcohol and street drugs. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M1 I am worried that other people might realize that I am HIV+ if they see me taking my HIV 
medications. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M2 I get frustrated taking my HIV medications because I have to plan my life around them. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M3 I don’t like taking my HIV medications because they remind me that I am HIV+. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M4 I feel that my healthcare provider takes my needs into account when making 
recommendations about which HIV medications to take. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M5 Most people who are important to me who know I’m HIV positive support me in taking my 
HIV medications. 










I strongly Agree No one that I 
care about knows 
I am positive 
 
M6 My healthcare provider doesn’t give me enough support when it comes to taking my 
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medications as prescribed. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M7 It frustrates me to think that I will have to take these HIV medications every day for the 
rest of my life. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M8 I am worried that the HIV medications I have been prescribed will hurt my health. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M9 It upsets me that the HIV medications I have been prescribed can affect the way I look. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
M10 It upsets me that the HIV medications I have been prescribed can cause side effects. 
                                   
I strongly disagree I somewhat 
disagree 
I neither agree nor 
disagree 
I somewhat agree I strongly agree 
 
B1 There are times when it is hard for me to take my HIV medications when I drink alcohol or 
use street drugs. 










I strongly agree I don’t drink 
alcohol or use 
street drugs 
 
B2 How hard or easy is it for you to stay informed about HIV treatment? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B3 How hard or easy is it for you to get the support you need from others for taking your HIV 
medications (for example, from friends, family, doctor, or pharmacist)? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
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B4 How hard or easy is it for you to get your HIV medication refills on time? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B5 How hard or easy is it for you to take your HIV medications when you are wrapped up in 
what you are doing? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B6 How hard or easy is it for you to manage the side effects of your HIV medications? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B7 How hard or easy is it for you to remember to take your HIV medications? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B8 How hard or easy is it for you to take your HIV medications because the pills are hard to 
swallow, taste bad, or make you sick to your stomach? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B9 How hard or easy is it for you to make your HIV medications part of your daily life? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B10 How hard or easy is it for you to take your HIV medications when your usual routine 
changes (for example, when you travel or when you go out with your friends)? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B11 How hard or easy is it for you to take your HIV medications when you do not feel good 
emotionally (for example, when you are depressed, sad, angry, or stressed out)? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
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B12 How hard or easy is it for you to take your HIV medications when you feel good physically 
and don’t have any symptoms of your HIV disease?  
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
 
B13 How hard or easy is it for you to take your HIV medications when you do NOT feel good 
physically?  
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 
B14 How hard or easy is it for you to talk to your health care provider about your HIV 
medications? 
                                   
Very hard Hard Sometimes hard, 
sometimes easy 
Easy Very easy 
 




	   	   	   	   	   	   	  
	   	  
Information	  Sheet	  for	  Participants	  (age	  13-­‐15)	  	  
v1.4	  14.06.14	  
	  
Research	  title:	  Antiretroviral	  Medication	  Adherence	  in	  Young	  People	  with	  Perinatal	  
HIV	  
	  
We	  are	  asking	  you	  to	  take	  part	  in	  a	  research	  project	  to	  find	  out	  more	  
about	  how	  young	  people	  take	  their	  HIV	  medicine	  	  
Before	  you	  decide	  if	  you	  want	  to	  join	  in,	  it	  is	  important	  you	  understand	  
why	  the	  research	  is	  being	  done	  and	  what	  it	  will	  involve	  for	  you.	  	  Please	  
read	  this	  leaflet	  carefully,	  think	  about	  it,	  and	  talk	  to	  your	  family,	  friends,	  
or	  a	  member	  of	  your	  clinical	  team	  if	  you	  want	  to.	  
	  
Why	  are	  we	  doing	  this	  research?	  
Some	  young	  people	  who	  were	  born	  with	  HIV	  have	  to	  take	  pills	  or	  medicines	  every	  
day	  to	  keep	  healthy.	  	  We	  know	  that	  sometimes	  this	  might	  be	  easier	  to	  do	  than	  at	  
other	  times.	  	  There	  might	  be	  some	  times	  when	  you	  don’t	  take	  your	  medicine	  for	  
some	  reason.	  	  We	  are	  interested	  in	  the	  reasons	  why	  you	  do	  and	  why	  you	  don’t	  take	  
your	  medicine.	  We	  hope	  that	  by	  asking	  young	  people	  about	  specific	  times	  when	  they	  
do	  or	  don’t	  take	  their	  medicine	  we	  will	  have	  a	  better	  idea	  of	  what	  the	  reasons	  for	  
taking	  or	  not	  taking	  it	  might	  be.	  	  	  
	  
This	  project	  is	  part	  of	  the	  training	  course	  for	  qualifying	  as	  a	  Clinical	  Psychologist	  at	  
Royal	  Holloway	  University	  of	  London.	  	  
	  
Who	  is	  invited	  to	  take	  part?	  
This	  research	  is	  open	  to	  young	  people	  aged	  13-­‐21	  who	  were	  born	  with	  HIV.	  	  To	  take	  
part,	  you	  must	  have	  missed	  taking	  your	  medicines	  at	  least	  once	  in	  the	  last	  two	  
months.	  	  If	  you	  have	  taken	  all	  of	  your	  medicines	  (this	  means	  every	  time	  you	  should	  
have)	  for	  the	  last	  two	  months,	  you	  won’t	  be	  able	  to	  take	  part.	  	  	  
	  
Do	  I	  have	  to	  take	  part?	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No,	  it	  is	  up	  to	  you.	  	  If	  you	  are	  interested,	  we	  will	  ask	  you	  to	  fill	  out	  a	  form	  that	  
says	  you	  agree	  to	  take	  part.	  	  	  If	  you	  change	  your	  mind,	  you	  are	  free	  to	  stop	  taking	  
part	  without	  giving	  a	  reason	  at	  any	  point	  during	  the	  study.	  	  It	  will	  not	  affect	  the	  
care	  you	  get	  at	  your	  HIV	  clinic	  if	  you	  decide	  to	  drop	  out	  of	  the	  study	  or	  don’t	  
want	  to	  take	  part.	  	  	  
	  
What	  will	  I	  be	  asked	  to	  do?	  
There	  are	  2	  parts	  to	  the	  study:	  
Part	  1	  	  
We	  will	  ask	  you	  to	  remember	  a	  time	  in	  the	  last	  two	  months	  when	  you	  did	  take	  your	  
medicine	  and	  ask	  you	  to	  answer	  some	  questions	  about	  it.	  	  Then	  we	  will	  ask	  you	  
about	  a	  time	  when	  you	  did	  not	  take	  your	  medicine	  and	  ask	  you	  to	  answer	  some	  
questions	  about	  it.	  	  The	  questions	  will	  be	  about	  how	  you	  were	  feeling,	  what	  you	  
were	  thinking	  and	  what	  was	  going	  on	  at	  the	  time.	  	  You	  can	  fill-­‐in	  these	  questions	  on	  
paper	  or	  online,	  whichever	  you	  prefer.	  	  You	  will	  receive	  a	  £10	  voucher	  for	  taking	  part	  
in	  this	  section	  of	  the	  project.	  
Part	  2	  
If	  you	  agree,	  we	  will	  send	  you	  text	  messages	  every	  day	  for	  four	  weeks	  to	  remind	  you	  
to	  complete	  the	  questionnaires	  again	  for	  a	  time	  when	  you	  do	  and	  a	  time	  if	  you	  don’t	  
take	  your	  medicine.	  	  	  
These	  questionnaires	  will	  be	  online.	  	  You	  won’t	  get	  any	  more	  text	  messages	  after	  the	  
four	  weeks	  is	  up	  or	  after	  you	  have	  answered	  the	  questions	  for	  both	  the	  time	  that	  
you	  did	  and	  the	  time	  you	  did	  not	  take	  your	  medicine.	  	  If	  you	  decide	  to	  take	  part	  in	  
this	  section	  of	  the	  project,	  you	  will	  be	  entered	  into	  a	  prize	  draw	  to	  receive	  an	  extra	  
£50	  of	  vouchers.	  	  	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
There	  might	  not	  be	  any	  direct	  benefit	  to	  you	  straightaway.	  	  But	  if	  we	  can	  understand	  
what	  makes	  it	  easier	  or	  more	  difficult	  for	  young	  people	  to	  take	  their	  medicine,	  we	  
might	  be	  able	  to	  help	  other	  people	  like	  you	  to	  manage	  their	  medicine	  better	  in	  the	  
future.	  	  	  
	  
Will	  anyone	  else	  know	  I’m	  doing	  this?	  
We	  will	  keep	  your	  information	  private	  and	  store	  it	  securely.	  	  This	  means	  only	  the	  
research	  team	  will	  be	  able	  to	  access	  it.	  	  Your	  name	  won’t	  be	  kept	  with	  any	  of	  your	  
questionnaires;	  we	  will	  only	  be	  able	  to	  identify	  you	  through	  a	  unique	  code.	  We	  will	  
not	  tell	  your	  healthcare	  team	  any	  of	  the	  answers	  to	  the	  questionnaires	  that	  you	  fill	  
in.	  	  
	  
What	  happens	  if	  I	  don’t	  want	  to	  carry	  on	  with	  the	  study?	  
You	  can	  leave	  the	  study	  at	  any	  time.	  	  If	  you	  decide	  you	  don’t	  want	  to	  take	  part	  any	  
more,	  we	  will	  not	  use	  any	  of	  the	  answers	  you	  have	  given	  us	  on	  the	  questionnaires,	  
delete	  any	  information	  that	  could	  identify	  you	  and	  not	  contact	  you	  again.	  
	  
What	  if	  there	  is	  a	  problem?	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Contact	  details	  
The	  main	  person	  to	  contact	  for	  this	  project	  is	  Amy	  Hawkins,	  Trainee	  Clinical	  Psychologist,	  	  
at	  the	  Department	  of	  Clinical	  Psychology,	  Royal	  Holloway	  University	  of	  London	  (RHUL).	  	  
You	  can	  get	  in	  touch	  in	  the	  following	  ways	  if	  you	  have	  any	  questions	  about	  the	  research	  at	  
any	  time.	  
	  
Email:	  	  amy.hawkins.2012@live.rhul.ac.uk	  	  
Phone:	  01784	  414012	  (this	  is	  an	  answering	  machine	  –	  please	  say	  your	  message	  is	  for	  Amy	  
Hawkins,	  leave	  your	  contact	  details	  and	  a	  brief	  message	  and	  I	  will	  call	  you	  back)	  
Address:	  	  Dept.	  of	  Clinical	  Psychology,	  RHUL,	  Egham	  Hill,	  Egham,	  Surrey,	  TW20	  0EX.	  	  	  
If	  you	  are	  worried	  about	  any	  part	  of	  the	  project,	  you	  should	  ask	  to	  speak	  to	  the	  main	  
researcher,	  Amy	  Hawkins,	  who	  will	  do	  her	  best	  to	  help	  you.	  	  Her	  contact	  details	  are	  
below.	  	  	  You	  can	  also	  contact	  Kate	  Sturgeon,	  AALPHI	  Research	  Nurse,	  on	  
07500975776.	  	  If	  you	  get	  upset	  by	  any	  of	  the	  questions	  you	  can	  also	  get	  help	  from	  
Amy	  or	  Kate.	  
	  
What	  happens	  after	  the	  research	  project	  stops?	  
We	  will	  let	  you	  know	  what	  we	  find	  out	  from	  the	  project	  after	  it	  is	  finished.	  	  We	  will	  
leave	  a	  leaflet	  in	  your	  clinic	  for	  you	  to	  read	  and	  there	  will	  be	  a	  summary	  in	  the	  
AALPHI	  newsletter.	  	  	  
	  
We	  hope	  to	  publish	  the	  results	  in	  an	  academic	  journal,	  so	  other	  researchers	  can	  
know	  about	  our	  findings.	  	  We	  might	  also	  want	  to	  present	  the	  results	  at	  
conferences	  so	  that	  we	  can	  help	  clinicians	  to	  help	  other	  young	  people	  with	  
taking	  their	  medication.	  	  You	  won’t	  be	  identified	  in	  any	  reports	  or	  articles.	  	  	  
	  
Who	  has	  reviewed	  this	  study?	  
Before	  any	  research	  goes	  ahead,	  it	  has	  to	  be	  checked	  by	  a	  Research	  Ethics	  
Committee.	  	  They	  make	  sure	  that	  the	  research	  is	  safe	  and	  fair.	  	  The	  study	  has	  been	  
given	  a	  favourable	  opinion	  by	  Berkshire	  B	  Research	  Ethics	  Committee,	  checked	  by	  
NHS	  Research	  &	  Development	  and	  Royal	  Holloway	  Departmental	  Ethics	  Committee.	  	  	  
	  
	  
Thank	  you	  for	  reading	  this.	  	  Please	  ask	  any	  questions	  if	  you	  need	  to.	  
	  
	  









	   	   	   	   	   	   	  
	   	  
Information	  Sheet	  for	  Participants	  (age	  16-­‐18)	  
v1.1	  03.06.14	  
	  
Research	  title:	  Antiretroviral	  Medication	  Adherence	  in	  Young	  People	  with	  
Perinatally-­‐Infected	  HIV	  
	  
We	  are	  asking	  you	  to	  take	  part	  in	  a	  research	  project	  to	  find	  out	  more	  about	  how	  
young	  people	  take	  their	  medication.	  	  	  
Before	  you	  decide	  if	  you	  want	  to	  participate,	  it	  is	  important	  you	  understand	  why	  the	  
research	  is	  being	  done	  and	  what	  it	  will	  involve.	  	  Please	  consider	  this	  leaflet	  carefully	  
and	  talk	  to	  your	  family,	  friends,	  doctor	  or	  nurse	  if	  you	  want	  to.	  
	  
Why	  are	  we	  doing	  this	  research?	  
Young	  people	  who	  were	  born	  with	  HIV	  have	  to	  take	  medication	  every	  day	  to	  keep	  
healthy.	  	  We	  know	  that	  sometimes	  this	  might	  be	  easier	  to	  do	  than	  other	  times.	  	  
There	  might	  be	  some	  times	  when	  you	  don’t	  take	  your	  medication	  for	  some	  reason.	  	  
We	  are	  interested	  in	  what	  influences	  whether	  you	  do	  or	  do	  not	  take	  your	  medication	  
by	  asking	  you	  about	  actual	  times	  recently	  when	  you	  did	  or	  did	  not	  take	  it.	  	  We	  hope	  
that	  by	  asking	  young	  people	  about	  specific	  times	  when	  they	  do	  or	  don’t	  take	  their	  
medication	  we	  will	  have	  a	  better	  idea	  of	  what	  the	  reasons	  for	  taking	  or	  not	  taking	  it	  
might	  be.	  
	  
This	  project	  is	  being	  carried	  out	  as	  part	  of	  a	  Clinical	  Psychology	  doctorate	  course	  at	  
Royal	  Holloway	  University	  of	  London.	  
	  
Who	  is	  invited	  to	  take	  part?	  
This	  research	  is	  open	  to	  young	  people	  age	  12-­‐21	  who	  were	  born	  with	  HIV.	  	  To	  take	  
part,	  there	  must	  have	  been	  a	  time	  in	  the	  last	  two	  months	  when	  you	  did	  not	  take	  
your	  medication.	  	  If	  you	  have	  taken	  your	  medication	  every	  day	  for	  the	  last	  two	  
months,	  you	  won’t	  be	  able	  to	  take	  part.	  	  	  
	  
Do	  I	  have	  to	  take	  part?	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No,	  it	  is	  up	  to	  you.	  	  If	  you	  are	  interested,	  we	  will	  ask	  you	  to	  complete	  a	  form	  that	  
says	  you	  agree	  to	  take	  part.	  	  If	  you	  change	  your	  mind,	  you	  are	  free	  to	  stop	  taking	  
part	  without	  giving	  a	  reason	  at	  any	  point	  during	  the	  research.	  	  Your	  healthcare	  will	  
not	  be	  affected	  in	  any	  way	  if	  you	  decide	  to	  withdraw	  from	  the	  study.	  	  	  
	  
What	  will	  I	  be	  asked	  to	  do?	  
There	  are	  2	  parts	  to	  the	  study:	  
Part	  1	  	  
We	  will	  ask	  you	  to	  remember	  a	  time	  in	  the	  last	  two	  months	  when	  you	  did	  take	  your	  
medication	  and	  a	  time	  when	  you	  did	  not	  take	  your	  medication	  	  .	  	  We	  will	  ask	  you	  to	  
answer	  questions	  about	  each	  of	  these	  times.	  	  The	  questions	  will	  be	  about	  how	  you	  
were	  feeling,	  what	  you	  were	  thinking	  and	  what	  was	  going	  on	  at	  the	  time,	  for	  
example.	  	  You	  can	  fill-­‐in	  these	  questions	  on	  paper	  or	  online,	  whichever	  you	  prefer.	  	  
You	  will	  receive	  a	  £10	  voucher	  for	  taking	  part	  in	  this	  section	  of	  the	  project.	  
Part	  2	  
If	  you	  agree,	  we	  will	  also	  ask	  you	  to	  answer	  the	  same	  questions	  for	  one	  further	  time	  
that	  you	  did	  and	  one	  further	  time	  that	  you	  did	  not	  take	  your	  medication	  	  in	  the	  four	  
weeks	  after	  you	  sign	  up	  to	  the	  study.	  	  We	  will	  send	  you	  text	  messages	  to	  remind	  you	  
to	  do	  this	  every	  day	  until	  you	  have	  answered	  the	  questions	  for	  one	  time	  that	  you	  did	  
and	  one	  time	  that	  you	  did	  not	  take	  your	  medication.	  	  These	  questionnaires	  will	  be	  
online.	  	  You	  won’t	  get	  any	  more	  text	  messages	  after	  the	  four	  weeks	  is	  up	  or	  after	  you	  
have	  answered	  the	  questions	  for	  both	  the	  time	  that	  you	  did	  and	  the	  time	  you	  did	  
not	  take	  your	  medication	  (whichever	  is	  the	  soonest).	  	  If	  you	  decide	  to	  take	  part	  in	  
this	  section	  of	  the	  project,	  you	  will	  be	  entered	  into	  a	  prize	  draw	  to	  receive	  an	  extra	  
£50	  of	  vouchers.	  	  	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
There	  might	  not	  be	  any	  direct	  benefit	  to	  you	  straightaway.	  	  But	  if	  we	  can	  understand	  
what	  makes	  it	  easier	  or	  more	  difficult	  for	  young	  people	  to	  take	  their	  medication,	  we	  
might	  be	  able	  to	  help	  other	  people	  like	  you	  to	  manage	  in	  the	  future.	  	  	  
	  
Will	  anyone	  else	  know	  I’m	  doing	  this?	  
We	  will	  keep	  your	  information	  in	  confidence	  and	  store	  it	  securely	  on	  an	  encrypted	  
memory	  stick.	  	  This	  means	  only	  the	  research	  team	  will	  be	  able	  to	  access	  it.	  	  Your	  
name	  won’t	  be	  kept	  with	  any	  of	  your	  questionnaires;	  we	  will	  only	  be	  able	  to	  identify	  
you	  through	  a	  unique	  user	  code.	  We	  might	  tell	  your	  healthcare	  team	  that	  you	  are	  
taking	  part,	  but	  we	  will	  not	  tell	  them	  any	  of	  the	  answers	  to	  the	  questionnaires	  that	  
you	  fill	  in.	  	  
	  
What	  happens	  if	  I	  don’t	  want	  to	  carry	  on	  with	  the	  study?	  
If	  you	  decide	  you	  don’t	  want	  to	  take	  part	  any	  more,	  we	  will	  not	  use	  any	  of	  the	  
answers	  you	  give	  us	  on	  the	  questionnaires	  and	  delete	  any	  information	  that	  could	  
identify	  you.	  
	  
What	  if	  there	  is	  a	  problem?	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Contact	  details	  
The	  main	  person	  to	  contact	  for	  this	  project	  is	  Amy	  Hawkins,	  Trainee	  Clinical	  Psychologist,	  	  
at	  the	  Department	  of	  Clinical	  Psychology,	  Royal	  Holloway	  University	  of	  London	  (RHUL).	  	  
You	  can	  get	  in	  touch	  in	  the	  following	  ways	  if	  you	  have	  any	  questions	  about	  the	  research	  at	  
any	  time.	  
	  
Email:	  	  amy.hawkins.2012@live.rhul.ac.uk	  	  
Phone:	  01784	  414012	  (this	  is	  an	  answering	  machine	  –	  please	  say	  your	  message	  is	  for	  Amy	  
Hawkins,	  leave	  your	  contact	  details	  and	  a	  brief	  message	  and	  I	  will	  call	  you	  back)	  
Address:	  	  Dept.	  of	  Clinical	  Psychology,	  RHUL,	  Egham	  Hill,	  Egham,	  Surrey,	  TW20	  0EX.	  	  	  
If	  you	  have	  a	  concern	  about	  any	  part	  of	  the	  project,	  or	  in	  the	  unlikely	  event	  that	  you	  
become	  upset	  or	  distressed	  by	  the	  questions,	  you	  should	  ask	  to	  speak	  to	  the	  main	  
researcher,	  Amy	  Hawkins,	  who	  will	  do	  her	  best	  to	  help	  you.	  	  Her	  contact	  details	  are	  
below.	  	  	  You	  can	  also	  contact	  Kate	  Sturgeon,	  AALPHI	  Research	  Nurse,	  on	  020	  7670	  
4862.	  
	  
What	  happens	  after	  the	  research	  project	  stops?	  
We	  will	  let	  you	  know	  what	  we	  find	  out	  from	  the	  project	  after	  it	  is	  finished.	  	  We	  will	  
send	  you	  a	  leaflet	  for	  you	  to	  read	  and	  there	  will	  be	  a	  summary	  in	  the	  AALPHI	  
newsletter.	  	  	  
	  
We	  hope	  to	  publish	  the	  results	  in	  an	  academic	  journal,	  so	  other	  researchers	  can	  
know	  about	  our	  findings.	  	  We	  might	  also	  want	  to	  present	  the	  results	  at	  conferences	  
so	  that	  we	  can	  help	  clinicians	  to	  help	  other	  young	  people	  with	  taking	  their	  
medication.	  	  You	  won’t	  be	  identified	  in	  any	  reports	  or	  articles.	  	  	  
	  
Who	  has	  reviewed	  this	  study?	  
Before	  any	  research	  goes	  ahead,	  it	  has	  to	  be	  checked	  by	  a	  Research	  Ethics	  
Committee.	  	  They	  make	  sure	  that	  the	  research	  is	  safe	  and	  fair.	  	  This	  project	  has	  been	  
given	  a	  favourable	  opinion	  by	  Berkshire	  B	  Ethics	  Committee,	  and	  checked	  by	  NHS	  
Research	  &	  Development	  and	  Royal	  Holloway	  Departmental	  Ethics	  Committee.	  	  	  
	  
	  




There	  will	  be	  a	  form	  for	  you	  to	  fill	  in	  if	  you	  want	  to	  take	  part.	  	  	  
	  
	  





	   	   	   	   	   	   	  
	   	  
Information	  Sheet	  for	  Participants	  (age	  18-­‐21)	  
v1.1	  03.06.14	  
	  
Research	  title:	  Antiretroviral	  Medication	  Adherence	  in	  Young	  People	  with	  
Perinatally-­‐Infected	  HIV	  
	  
We	  invite	  you	  to	  take	  part	  in	  a	  research	  project	  investigating	  how	  young	  people	  take	  
their	  medication.	  	  	  
Before	  deciding	  if	  you	  want	  to	  participate,	  it	  is	  important	  you	  understand	  why	  the	  
research	  is	  being	  done	  and	  what	  it	  will	  involve.	  	  Please	  consider	  this	  leaflet	  carefully	  
and	  talk	  to	  your	  family,	  friends,	  doctor	  or	  nurse	  if	  you	  want	  to.	  
	  
Why	  are	  we	  doing	  this	  research?	  
Young	  people	  who	  were	  born	  with	  HIV	  often	  have	  to	  take	  daily	  medication	  to	  stay	  
healthy.	  	  We	  know	  that	  sometimes	  this	  might	  be	  easier	  to	  do	  than	  other	  times.	  	  
There	  might	  be	  some	  times	  when	  you	  don’t	  take	  your	  medication	  for	  some	  reason.	  	  
We	  are	  interested	  in	  what	  influences	  whether	  you	  do	  or	  do	  not	  take	  your	  medication	  
by	  asking	  you	  about	  actual	  times	  recently	  when	  you	  did	  or	  did	  not	  take	  it.	  	  We	  hope	  
that	  by	  asking	  young	  people	  about	  specific	  times	  when	  they	  do	  or	  don’t	  take	  their	  
medication	  we	  will	  have	  a	  better	  idea	  of	  what	  the	  reasons	  for	  taking	  or	  not	  taking	  it	  
might	  be.	  
	  
This	  project	  is	  being	  carried	  out	  as	  part	  of	  a	  Clinical	  Psychology	  doctorate	  course	  at	  
Royal	  Holloway	  University	  of	  London.	  
	  
Who	  is	  invited	  to	  take	  part?	  
This	  research	  is	  open	  to	  young	  people	  age	  12-­‐21	  who	  were	  born	  with	  HIV.	  	  To	  take	  
part,	  there	  must	  have	  been	  a	  time	  in	  the	  last	  two	  months	  when	  you	  did	  not	  take	  
your	  medication.	  	  If	  you	  have	  taken	  your	  medication	  every	  day	  for	  the	  last	  two	  
months,	  you	  won’t	  be	  able	  to	  take	  part.	  	  	  
	  
Do	  I	  have	  to	  take	  part?	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No,	  it	  is	  up	  to	  you.	  	  If	  you	  are	  interested,	  we	  will	  ask	  you	  to	  complete	  a	  form	  that	  
says	  you	  agree	  to	  take	  part.	  	  If	  you	  change	  your	  mind,	  you	  are	  free	  to	  stop	  taking	  
part	  without	  giving	  a	  reason	  at	  any	  point	  during	  the	  research.	  	  Your	  healthcare	  will	  
not	  be	  affected	  in	  any	  way	  if	  you	  decide	  to	  withdraw	  from	  the	  study.	  	  	  
	  
What	  will	  I	  be	  asked	  to	  do?	  
There	  are	  2	  parts	  to	  the	  study:	  
Part	  1	  	  
We	  will	  ask	  you	  to	  remember	  a	  time	  in	  the	  last	  two	  months	  when	  you	  did	  take	  your	  
medication	  and	  a	  time	  when	  you	  did	  not	  take	  your	  medication.	  	  We	  will	  ask	  you	  to	  
answer	  questions	  about	  each	  of	  these	  times.	  	  The	  questions	  will	  be	  about	  how	  you	  
were	  feeling,	  what	  you	  were	  thinking	  and	  what	  was	  going	  on	  at	  the	  time,	  for	  
example.	  	  You	  can	  fill-­‐in	  these	  questions	  on	  paper	  or	  online,	  whichever	  you	  prefer.	  	  
You	  will	  receive	  a	  £10	  voucher	  for	  taking	  part	  in	  this	  section	  of	  the	  project.	  
Part	  2	  
If	  you	  agree,	  we	  will	  also	  ask	  you	  to	  answer	  the	  same	  questions	  for	  one	  further	  time	  
that	  you	  did	  and	  one	  further	  time	  that	  you	  did	  not	  take	  your	  medication	  in	  the	  four	  
weeks	  after	  you	  sign	  up	  to	  the	  study.	  	  We	  will	  send	  you	  text	  messages	  to	  remind	  you	  
to	  do	  this	  every	  day	  until	  you	  have	  answered	  the	  questions	  for	  one	  time	  that	  you	  did	  
and	  one	  time	  that	  you	  did	  not	  take	  your	  medication.	  	  These	  questionnaires	  will	  be	  
online.	  	  You	  won’t	  get	  any	  more	  text	  messages	  after	  the	  four	  weeks	  is	  up	  or	  after	  you	  
have	  answered	  the	  questions	  for	  both	  the	  time	  that	  you	  did	  and	  the	  time	  you	  did	  
not	  take	  your	  medication	  (whichever	  is	  the	  soonest).	  	  If	  you	  decide	  to	  take	  part	  in	  
this	  section	  of	  the	  project,	  you	  will	  be	  entered	  into	  a	  prize	  draw	  to	  receive	  an	  extra	  
£50	  of	  vouchers.	  	  	  
	  
What	  are	  the	  possible	  benefits	  of	  taking	  part?	  
There	  might	  not	  be	  any	  direct	  benefit	  to	  you	  straightaway.	  	  But	  if	  we	  can	  understand	  
what	  makes	  it	  easier	  or	  more	  difficult	  for	  young	  people	  to	  take	  their	  medication,	  we	  
might	  be	  able	  to	  help	  other	  people	  like	  you	  to	  manage	  in	  the	  future.	  	  	  
	  
Will	  anyone	  else	  know	  I’m	  doing	  this?	  
We	  will	  keep	  your	  information	  in	  confidence	  and	  store	  it	  securely	  on	  an	  encrypted	  
memory	  stick.	  	  Only	  the	  research	  team	  will	  be	  able	  to	  access	  it.	  	  Your	  name	  won’t	  be	  
kept	  with	  any	  of	  your	  questionnaires;	  we	  will	  only	  be	  able	  to	  identify	  you	  through	  a	  
unique	  user	  code.	  We	  might	  tell	  your	  healthcare	  team	  that	  you	  are	  taking	  part,	  but	  
we	  will	  not	  tell	  them	  any	  of	  the	  specific	  answers	  to	  the	  questionnaires	  that	  you	  fill	  in.	  	  
	  
What	  happens	  if	  I	  don’t	  want	  to	  carry	  on	  with	  the	  study?	  
If	  you	  decide	  you	  don’t	  want	  to	  take	  part	  any	  more,	  we	  will	  not	  use	  any	  of	  the	  
answers	  you	  give	  us	  on	  the	  questionnaires	  and	  delete	  any	  information	  that	  could	  
identify	  you.	  
	  
What	  if	  there	  is	  a	  problem?	  
If	  you	  have	  a	  concern	  about	  any	  part	  of	  the	  project,	  or	  in	  the	  unlikely	  event	  that	  you	  
become	  upset	  or	  distressed	  by	  the	  questions,	  you	  should	  ask	  to	  speak	  to	  the	  main	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Contact	  details	  
The	  main	  person	  to	  contact	  for	  this	  project	  is	  Amy	  Hawkins,	  Trainee	  Clinical	  Psychologist,	  	  
at	  the	  Department	  of	  Clinical	  Psychology,	  Royal	  Holloway	  University	  of	  London	  (RHUL).	  	  
You	  can	  get	  in	  touch	  in	  the	  following	  ways	  if	  you	  have	  any	  questions	  about	  the	  research	  at	  
any	  time.	  
	  
Email:	  	  amy.hawkins.2012@live.rhul.ac.uk	  	  
Phone:	  01784	  414012	  (this	  is	  an	  answering	  machine	  –	  please	  say	  your	  message	  is	  for	  Amy	  
Hawkins,	  leave	  your	  contact	  details	  and	  a	  brief	  message	  and	  I	  will	  call	  you	  back)	  
Address:	  	  Dept.	  of	  Clinical	  Psychology,	  RHUL,	  Egham	  Hill,	  Egham,	  Surrey,	  TW20	  0EX.	  	  	  
researcher,	  Amy	  Hawkins,	  who	  will	  do	  her	  best	  to	  help	  you.	  	  Her	  contact	  details	  are	  
below.	  	  	  You	  can	  also	  contact	  Kate	  Sturgeon,	  AALPHI	  Research	  Nurse,	  on	  020	  7670	  
4862.	  
	  
What	  happens	  after	  the	  research	  project	  stops?	  
We	  will	  let	  you	  know	  what	  we	  find	  out	  from	  the	  project	  after	  it	  is	  finished.	  	  We	  will	  
send	  you	  a	  leaflet	  for	  you	  to	  read	  and	  there	  will	  be	  a	  summary	  in	  the	  AALPHI	  
newsletter.	  	  	  
	  
We	  hope	  to	  publish	  the	  results	  in	  an	  academic	  journal,	  so	  other	  researchers	  can	  
know	  about	  our	  findings.	  	  We	  might	  also	  want	  to	  present	  the	  results	  at	  conferences	  
so	  that	  we	  can	  help	  clinicians	  to	  help	  other	  young	  people	  with	  taking	  their	  
medication.	  	  You	  won’t	  be	  identified	  in	  any	  reports	  or	  articles.	  	  	  
	  
Who	  has	  reviewed	  this	  study?	  
Before	  any	  research	  goes	  ahead,	  it	  has	  to	  be	  checked	  by	  a	  Research	  Ethics	  
Committee.	  	  The	  study	  has	  been	  given	  a	  favourable	  opinion	  by	  Berkshire	  B	  Research	  
Ethics	  Committee,	  checked	  by	  NHS	  Research	  &	  Development	  and	  Royal	  Holloway	  
Departmental	  Ethics	  Committee.	  	  	  
	  
	  






There	  will	  be	  a	  form	  for	  you	  to	  fill	  in	  if	  you	  want	  to	  take	  part.	  	  	  
	  
	  




Consent	  Form	  	  
Version	  1.1	  10.03.14	  
	  
Title	  of	  project:	  Medication	  adherence	  in	  young	  people	  with	  perinatally-­‐infected	  
HIV	  
	  




1.	  	  I	  confirm	  that	  I	  have	  read	  and	  understood	  the	  information	  sheet	  for	  the	  
above	  study.	  	  I	  have	  had	  the	  opportunity	  to	  consider	  the	  information	  and	  ask	  
questions.	  	  Any	  questions	  have	  been	  answered	  to	  my	  satisfaction.	  
	  
2.	  	  I	  understand	  that	  my	  participation	  is	  voluntary	  and	  I	  am	  free	  to	  withdraw	  at	  any	  
time	  (without	  giving	  a	  reason,	  without	  my	  healthcare	  being	  affected).	  
	  
3.	  	  I	  understand	  that	  relevant	  sections	  of	  my	  medical	  notes	  and	  data	  collected	  by	  this	  
study	  may	  be	  looked	  at	  researchers	  from	  Royal	  Holloway	  and	  AALPHI,	  from	  
regulatory	  authorities	  or	  from	  the	  NHS	  Trust.	  	  I	  give	  permission	  for	  these	  individuals	  
to	  have	  access	  to	  this	  information.	  	  	  
	  
4.	  	  I	  agree	  that	  my	  GP	  can	  be	  informed	  of	  my	  participation	  in	  this	  study.	  	  
	  
5.	  	  I	  agree	  to	  take	  part	  in	  the	  above	  study.	  
	  
	  













Please	  tick	  the	  
box	  if	  you	  
agree	  






RHUL	  ART	  Situational	  Adherence	  Questionnaire	  	  
v1.6	  (24/10/14)	  
	  
Think	  about	  the	  time	  when	  you	  did	  take	  your	  medication.	  	  Please	  





What	  day	  of	  the	  week	  was	  it	  (when	  you	  did	  take	  your	  medication)?	  
…………………………………….	  
	  
Was	  there	  someone	  there	  to	  remind	  you	  to	  take	  the	  medication	  at	  the	  time?	  
(when	  you	  did	  take	  your	  medication)	  (please	  circle)	  
	  
	   	   	   	   YES	   	   	   	   	   NO	  
	  
Please	  tick	  which	  one	  applied	  to	  you	  at	  the	  time	  (when	  you	  did	  take	  your	  
medication):	  
	  
My	  day	  was	  the	  same	  as	  normal	   	   	   	   	   	   ☐	  
My	  day	  was	  different	  to	  normal	  because	  of	  something	  unexpected	   ☐	   	  
My	  day	  was	  different	  to	  normal	  because	  I	  had	  made	  plans	   	   ☐	  
Other	   	   	   	   	   	   	   	   	   	   ☐	  
	  
Where	  were	  you?	  (when	  you	  did	  take	  your	  medication)	  (please	  tick)	  
Home	  ☐	   A	  friend’s	  house	  	   ☐	   Partner’s	  house	   ☐	   	  
A	  public	  place	  (e.g.,	  work,	  college	  )	  ☐	   A	  family	  member’s	  house	  	   ☐	  
	  
Who	  were	  you	  with?	  (when	  it	  was	  time	  to	  take	  your	  medication	  and	  you	  did	  
take	  it)	  (please	  tick)	  
Alone	  ☐	   With	  a	  friend	  	  ☐	   With	  a	  partner	   ☐	   With	  family	   ☐
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With	  an	  acquaintance	   ☐	   With	  a	  work	  colleague	   ☐	  
	  
Were	  you	  using	  alcohol	  or	  taking	  street	  drugs	  (e.g.	  cannabis,	  ecstasy)	  around	  
the	  time	  you	  were	  due	  to	  take	  your	  medicines?	  (please	  circle)	  	  	   	   YES
	   	   	   	   	   NO	  
	  
	  
	   1	  Strongly	  
disagree	  
2	  Disagree	   3	  Neither	  
agree	  or	  
disagree	  
4	  Agree	   5	  Strongly	  
agree	  
I	  knew	  the	  correct	  
way	  to	  take	  my	  
medicines	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  knew	  how	  taking	  
the	  medication	  
could	  make	  me	  feel	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  understood	  how	  
my	  medicines	  would	  
work	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  understood	  what	  
medication	  to	  take	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  thought	  other	  
people	  would	  notice	  
I	  was	  taking	  my	  
medication,	  which	  
concerned	  me	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  thought	  I	  had	  to	  
plan	  my	  life	  around	  
my	  medicine,	  which	  
frustrated	  me	   ¢	   ¢	   ¢	   ¢	   ¢	  
The	  medicines	  
reminded	  me	  I	  was	  
HIV+,	  which	  
bothered	  me	   ¢	   ¢	   ¢	   ¢	   ¢	  
People	  around	  me	  
























I	  thought	  that	  I	  
would	  have	  to	  take	  
these	  medicines	  
every	  day	  for	  the	   ¢	   ¢	   ¢	   ¢	   ¢	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rest	  of	  my	  life,	  
which	  I	  did	  not	  like	  
I	  thought	  the	  
medication	  was	  not	  
working,	  which	  
bothered	  me	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  thought	  my	  
medication	  was	  
helping	   ¢	   ¢	   ¢	   ¢	   ¢	  
	  
	  


















I	  thought	  my	  
medication	  would	  
cause	  side	  effects	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  was	  bothered	  by	  
the	  size,	  taste	  or	  
amount	  of	  
medication	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  had	  easy	  access	  to	  
my	  medicines	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  was	  confident	  I	  
could	  find	  the	  time	  
to	  take	  my	  
medication	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  was	  confident	  I	  
could	  manage	  any	  	  
side	  effects	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  was	  confident	  that	  
I	  could	  	  remember	  












I	  was	  confident	  I	  
could	  manage	  the	  
size	  of	  the	  pills	  or	  
the	  taste	  of	  the	  
medicine	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  confident	  that	  I	  
could	  fit	  my	  
medicines	  around	  
what	  I	  was	  doing	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  confident	  I	  
could	  take	  my	   ¢	   ¢	   ¢	   ¢	   ¢	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medicines	  correctly	  
I	  felt	  confident	  I	  
could	  take	  my	  
medicines	  even	  if	  
other	  people	  were	  
around	  	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  confident	  I	  
could	  ask	  for	  help	  to	  
take	  my	  medication	  
if	  I	  needed	  to	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  confident	  I	  
could	  take	  my	  
medicines	  however	  I	  
was	  feeling	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  ill	   ¢	   ¢	   ¢	   ¢	   ¢	  
Taking	  the	  
medicines	  was	  my	  




How	  did	  you	  feel	  when	  it	  was	  time	  to	  take	  your	  medication?	  
	   1	  Very	  
slightly	  





Proud	   ¢	   ¢	   ¢	   ¢	   ¢	  
Happy	   ¢	   ¢	   ¢	   ¢	   ¢	  
Scared	   ¢	   ¢	   ¢	   ¢	   ¢	  
Lively	   ¢	   ¢	   ¢	   ¢	   ¢	  
Afraid	   ¢	   ¢	   ¢	   ¢	   ¢	  
Miserable	   ¢	   ¢	   ¢	   ¢	   ¢	  
Joyful	   ¢	   ¢	   ¢	   ¢	   ¢	  
Mad	   ¢	   ¢	   ¢	   ¢	   ¢	  
Sad	   ¢	   ¢	   ¢	   ¢	   ¢	  
Cheerful	   ¢	   ¢	   ¢	   ¢	   ¢	  
Blamed	   ¢	   ¢	   ¢	   ¢	   ¢	  
Weak	   ¢	   ¢	   ¢	   ¢	   ¢	  
Helpless	   ¢	   ¢	   ¢	   ¢	   ¢	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Out	  of	  control	   ¢	   ¢	   ¢	   ¢	   ¢	  
Calm	   ¢	   ¢	   ¢	   ¢	   ¢	  
At	  ease	   ¢	   ¢	   ¢	   ¢	   ¢	  
Content	   ¢	   ¢	   ¢	   ¢	   ¢	  





RHUL	  ART	  Situational	  Adherence	  Questionnaire	  	  
v1.6(24/10/14)	  
	  
Think	  about	  the	  time	  when	  you	  did	  not	  take	  your	  medication.	  	  Please	  





What	  day	  of	  the	  week	  was	  it	  (when	  you	  did	  not	  take	  your	  medication)?	  
…………………………………….	  
	  
Was	  there	  someone	  there	  to	  remind	  you	  to	  take	  the	  medication	  at	  the	  time?	  	  
(when	  you	  did	  not	  take	  your	  medication)	  (please	  circle)	  
	  
	   	   	   	   YES	   	   	   	   	   NO	  
	  
Please	  tick	  which	  one	  applied	  to	  you	  at	  the	  time	  (when	  you	  did	  not	  take	  your	  
medication):	  
	  
My	  day	  was	  the	  same	  as	  normal	   	   	   	   	   	   ☐	  
My	  day	  was	  different	  to	  normal	  because	  of	  something	  unexpected	   ☐	   	  
My	  day	  was	  different	  to	  normal	  because	  I	  had	  made	  plans	   	   ☐	  
Other	   	   	   	   	   	   	   	   	   	   ☐	  
	  
Where	  were	  you?	  (when	  it	  was	  time	  to	  take	  your	  medication	  and	  you	  did	  not	  
take	  it)	  (please	  tick)	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Home	  ☐	   A	  friend’s	  house	  	   ☐	   Partner’s	  house	   ☐	   	  
A	  public	  place	  (e.g.,	  work,	  college	  )	  ☐	   A	  family	  member’s	  house	  	   ☐	  
	  
Who	  were	  you	  with?	  (when	  you	  did	  not	  take	  your	  medication)	  
Alone	  ☐	   With	  a	  friend	  	  ☐	   With	  a	  partner	   ☐	   With	  family	   ☐
	   	  
With	  an	  acquaintance	   ☐	   With	  a	  work	  colleague	   ☐	  
	  
Were	  you	  using	  alcohol	  or	  taking	  street	  drugs	  (e.g.	  cannabis,	  ecstasy)	  around	  
the	  time	  you	  were	  due	  to	  take	  your	  medicines?	  (please	  circle)	  	  	   	   YES
	   	   	   	   	   NO	  
	  
	  
	   1	  Strongly	  
disagree	  
2	  Disagree	   3	  Neither	  
agree	  or	  
disagree	  
4	  Agree	   5	  Strongly	  
agree	  
I	  knew	  the	  correct	  
way	  to	  take	  my	  
medicines	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  knew	  how	  taking	  
the	  medication	  
could	  make	  me	  feel	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  understood	  how	  
my	  medicines	  would	  
work	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  understood	  what	  
medication	  to	  take	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  thought	  other	  
people	  would	  notice	  
I	  was	  taking	  my	  
medication,	  which	  
concerned	  me	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  thought	  I	  had	  to	  
plan	  my	  life	  around	  
my	  medicine,	  which	  
frustrated	  me	   ¢	   ¢	   ¢	   ¢	   ¢	  
The	  medicines	  
reminded	  me	  I	  was	  
HIV+,	  which	  
bothered	  me	   ¢	   ¢	   ¢	   ¢	   ¢	  
People	  around	  me	  

























I	  thought	  that	  I	  
would	  have	  to	  take	  
these	  medicines	  
every	  day	  for	  the	  
rest	  of	  my	  life,	  
which	  I	  did	  not	  like	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  thought	  the	  
medication	  was	  not	  
working,	  which	  
bothered	  me	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  thought	  my	  
medication	  was	  
helping	   ¢	   ¢	   ¢	   ¢	   ¢	  
	  
	  


















I	  thought	  my	  
medication	  would	  
cause	  side	  effects	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  was	  bothered	  by	  
the	  size,	  taste	  or	  
amount	  of	  
medication	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  had	  easy	  access	  to	  
my	  medicines	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  was	  confident	  I	  
could	  find	  the	  time	  
to	  take	  my	  
medication	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  was	  confident	  I	  
could	  manage	  any	  	  
side	  effects	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  was	  confident	  that	  
I	  could	  	  remember	  












I	  was	  confident	  I	  
could	  manage	  the	  
size	  of	  the	  pills	  or	  
the	  taste	  of	  the	   ¢	   ¢	   ¢	   ¢	   ¢	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medicine	  
I	  felt	  confident	  that	  I	  
could	  fit	  my	  
medicines	  around	  
what	  I	  was	  doing	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  confident	  I	  
could	  take	  my	  
medicines	  correctly	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  confident	  I	  
could	  take	  my	  
medicines	  even	  if	  
other	  people	  were	  
around	  	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  confident	  I	  
could	  ask	  for	  help	  to	  
take	  my	  medication	  
if	  I	  needed	  to	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  confident	  I	  
could	  take	  my	  
medicines	  however	  I	  
was	  feeling	   ¢	   ¢	   ¢	   ¢	   ¢	  
I	  felt	  ill	   ¢	   ¢	   ¢	   ¢	   ¢	  




How	  did	  you	  feel	  when	  it	  was	  time	  to	  take	  your	  medication?	  
	   1	  Very	  
slightly	  





Proud	   ¢	   ¢	   ¢	   ¢	   ¢	  
Happy	   ¢	   ¢	   ¢	   ¢	   ¢	  
Scared	   ¢	   ¢	   ¢	   ¢	   ¢	  
Lively	   ¢	   ¢	   ¢	   ¢	   ¢	  
Afraid	   ¢	   ¢	   ¢	   ¢	   ¢	  
Miserable	   ¢	   ¢	   ¢	   ¢	   ¢	  
Joyful	   ¢	   ¢	   ¢	   ¢	   ¢	  
Mad	   ¢	   ¢	   ¢	   ¢	   ¢	  
Sad	   ¢	   ¢	   ¢	   ¢	   ¢	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Cheerful	   ¢	   ¢	   ¢	   ¢	   ¢	  
Blamed	   ¢	   ¢	   ¢	   ¢	   ¢	  
Weak	   ¢	   ¢	   ¢	   ¢	   ¢	  
Helpless	   ¢	   ¢	   ¢	   ¢	   ¢	  
Out	  of	  control	   ¢	   ¢	   ¢	   ¢	   ¢	  
Calm	   ¢	   ¢	   ¢	   ¢	   ¢	  
At	  ease	   ¢	   ¢	   ¢	   ¢	   ¢	  
Content	   ¢	   ¢	   ¢	   ¢	   ¢	  
Satisfied	   ¢	   ¢	   ¢	   ¢	   ¢	  
	  
Do	  you	  have	  a	  medication	  regime?	  (please	  circle)	  
	   	   	   	   YES	   	   	   	   	   NO	  
	  
Was	  there	  anything	  else	  important	  about	  the	  day	  you	  missed	  your	  
medication?	  E.g.	  you	  were	  told	  not	  to	  take	  it	  by	  your	  doctor	  that	  day	  
…………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………	  
	  
